

EMORY UNIVERSITY SCHOOL OF MEDICINE

Revised: 8/11/26

1. **Name:** Laurence S. Sperling, MD, FACC, FACP, FAHA, MASPC
2. **Current Emory Office Address:** The Emory Clinic
Center for Heart Disease Prevention
57 Executive Park
Atlanta, Georgia 30324
Telephone: (404)778-2722
Fax: (404)325-2796
3. **E-mail Address:** lsperli@emory.edu
4. **Citizenship:** U.S.
5. **Current Titles and Affiliations:**
 - a. **Academic appointments:**
 1. **Primary appointments:**
2009-present Professor of Medicine, Division of Cardiology
Emory University School of Medicine
2018-present Endowed Katz Professor in Preventive Cardiology
 2. **Joint (Secondary) Appointment:**
2014-present Professor of Global Health
Hubert Department of Global Health
Rollins School of Public Health at Emory University
 3. **Visiting Professorship:**
2016-2017 National Heart and Lung Institute
The Faculty of Medicine at Imperial College, London, UK
 - b. **Clinical appointments:**
1997-present Founder of the Center for Heart Disease Prevention,
Emory Healthcare
1997-2019 Director of the Center for Heart Disease Prevention,
Emory Healthcare
2019-present Founder and Director of Emory Cardiovascular Prevention
Network
 - c. **Other administrative appointments:**

1997-2014	Founder and Director of the HeartWise Risk Reduction Program
1999-2011	Associate Director, Cardiovascular Disease Fellowship Program at Emory
2003-present	Founder and Co-Director of LDL Apheresis Program, Emory University Hospital
2021-present	Founded Evinacumab Infusion Program, Emory University Hospital
2007-2019	Appointed by the Dean as Society Advisor for Medical Student Education – Emory University School of Medicine
2011-2018	Appointed by the Dean to Emory Center for Experiential Learning Advisory Group (ExCEL advisory group for medical education)
2019-2024	Million Hearts Executive Director, Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Center for Medicare and Medicaid Services (Intergovernmental Personnel Act Agreement / Expert Consultant)
2024-2025	Chief Medical Officer, The Family Heart Foundation

6. **Previous Academic and Professional Appointments:**

1994-1997	Coordinator of House Physicians, Wesley Woods Hospital, Atlanta, GA
1994-1995	Substitute Physician, Occupational Health Clinic, Center for Disease Control, Atlanta, GA
1997-2004	Assistant Professor of Medicine, Division of Cardiology, Emory University
2004-2009	Associate Professor of Medicine, Division of Cardiology, Emory University
2000-2006	Medical Director, <i>Staying Aloft</i> Cardiovascular Risk Program for Delta pilots
2000-2007	Medical Director, <i>Intervent Atlanta</i>
2003-2004	Appointment to the Research Participation Program at the Centers for Disease Control and Prevention, National Immunization Program administered by the Oak Ridge Institute for Science and Education - related to investigation of cardiovascular complications of smallpox vaccine
2019-2024	Executive Director, CDC-CMS Million Hearts Initiative

7. **Licensures/Boards:**

Medical License Georgia, 1990

8. **Specialty Boards:**

1992	Diplomate of American Board of Internal Medicine
1998	Diplomate of ABIM (Cardiovascular Disease)
2008	Recertification in ABIM CV Disease

2018 Recertification in ABIM CV Disease

9. **Education:**

1985 Emory College, Atlanta, GA
BA, Psychology
1989 Emory University School of Medicine
MD, Medicine

10. **Postgraduate Training:**

1989-1990 Intern in Medicine
Emory University
Juha Kokko, MD, PhD
1990-1992 Resident in Medicine
Emory University
Juha Kokko, MD, PhD
1992-1993 Chief Resident in Medicine
Emory University Hospital J
Juha Kokko, MD, PhD
1993-1995 Vascular Biology Research
Emory University Fellow
Marschall Runge, MD, PhD
Patrick Delafontaine, MD
1995-1997 Clinical Cardiology Fellow
Emory University
R. Wayne Alexander, MD, PhD
1997 Coronary EBCT Certification
LifeTech, Nashville, TN
Tracy Callister, MD
2008 Graduate of the Woodruff Leadership Academy
Emory Healthcare (mentor: Dean Tom Lawley)
2016 Cognitively-Based Compassion Training
(through Emory-Tibet Partnership)
Geshe Lobsang Tenzin Negi, PhD
2019 Cognitively-Based Compassion Training Intensive
Drepung Loseling Monastery,
Geshe Lobsang Tenzin Negi, PhD

11. **Committee Memberships:**

a. **National and International:**

2003 Leaders of Emerging Science of Lipid Management, Co-
Chair of Mid-Atlantic Working Group
2003-2006 Appointed to the American College of Cardiology (ACC)
Education Strategic Directions Committee (Working Group
on Live Programs)

2006-2010	Member of the AHA Clinical Council in Cardiology (Membership/ Communications committee Council on Clinical Cardiology)
2008-present	ACC Strategic Directions Committee focusing on the convergence of Type 2 Diabetes and Cardiovascular Disease
2009-2012	ACC Prevention of Cardiovascular Disease Committee
2009-2010	Elected to the Sudden Cardiac Arrest Foundation Board of Directors
2011	American Board of Internal Medicine Practice Improvement Module Expert panel for Preventive Cardiology
2012-	Treasurer of the American Society of Preventive Cardiology
2012-	Chair of the American College of Cardiology Foundation Cardiometabolic working group
2012-	Chair of the National Cardiometabolic Quality Care Alliance (American College of Cardiology, American Association of Clinical Endocrinologists, National Minority Quality Forum)
2013-2014	member of American Heart Association's Genomics & Translational Biology Epi & Observational Epi-Clinical (GTOE-CL) Peer Review Committee
2013	Invited founding member of The Familial Hypercholesterolemia Consortium working group
2013	Invited participant in the Global CVD Prevention Leadership meeting/group (Rome, Italy)
2013-2014	President-Elect, American Society for Preventive Cardiology
2013	Steering committee member, Familial Hypercholesterolemia Summit
2014-	Representative on the International Council of Cardiovascular Prevention and Rehabilitation (ICCPR)
2014-	Member of the Diabetes Collaborative Registry Research and Publications Subcommittee of The American College of Cardiology's National Cardiovascular Data Registry (NCDR)
2014-2016	President, American Society for Preventive Cardiology
2014-	ASPC Liaison to the Leadership Committee of the American Heart Association's Epidemiology & Prevention Council
2013-	Delegate of the World Heart Federation Global Alliance for CVD Prevention in Clinical Practice, Leadership committee
2014-	Founding member of CROSS-Europe CV Collaboration
2014-2016	Member of the American College of Cardiology's Population Health Policy and Health Promotion Committee
2015-	Member of the AHA Predictors of CVD committee, Cardiovascular Genome-Phenome Study

2016-	Appointed to 2 nd term as member of ACC Population Health Policy and Health Promotions Committee
2015-	Member scientific executive committee, Chairman, section of Preventive Cardiology, International Academy of Cardiology
2016-	Member of the Alliance for Patient Access, Physicians Cardiovascular Disease working group
2016-2018	Immediate Past-President American Society for Preventive Cardiology
2016	Invited participant, American College of Cardiology LDL: Address the Risk Think Tank
2016	Invited participant, Familial Hypercholesterolemia Global Summit, Dallas, TX
2017-	Invited member of the Writing Group for the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol
2017	Co-Chair of ACC Diabetes and Cardiovascular Risk Roundtable, Heart House, Washington, D.C.
2017	Member of Steering Committee- Familial Hypercholesterolemia Global Summit
2016-2018	American Society for Preventive Cardiology a. Chair of Nominating & Awards Committee b. Chair Congress Abstract Review Committee c. Chair Past Presidents Advisory Committee
2018	Chair of the World Heart Federation Writing Group- Roadmap for the Prevention of CVD in People with Diabetes
2018	Co-Chair of the ACC Diabetes and Cardiovascular Risk Roundtable 2, Heart House, Washington, D.C.
2019	Member of Steering Committee, 7 th Familial Hypercholesterolemia Global Summit
2019-	Chair of the Million Hearts Cardiac Rehabilitation Collaborative
2019-	Member of United States Tobacco Control Steering Committee under the U.S. Surgeon General
2020-	Special Advisor to the World Heart Federation Global COVID-19 Study
2020-	Special Advisor to the World Heart Federation Use Heart for Cardiovascular Disease and Diabetes Project
2020	American Society for Preventive Cardiology, Chair Early Career Abstract Award Committee
2020	Invited Participant, ACC Virtual Roundtable in LDL-C Lowering Therapies: The Changing Lipid Landscape
2020	CDC Subject Matter Expert, Strategies to Update NHANES Cholesterol Measurements
2020	Invited Expert Working Group member, CMS Measure 22 / 317: Screening for High Blood Pressure and Follow-up Documented

2020	Invited Expert Working Group member, CMS Measure 347 / 438: Statin therapy for the Prevention and Treatment of Cardiovascular Disease
2020	National Association of Community Health Centers (NACHC) Preventing Heart Attacks and Strokes (PHAS) Steering Committee
2020	Member of Detection and Treatment Group, American Heart Association National PAD Action Plan, Activating Health Care Systems
2020	Chair, National Million Hearts Cardiac Rehabilitation Think Tank; Advancing New Care Models
2020	Member, American College of Cardiology Applied Health Innovation Consortium; Virtual Summit
2020	Reviewer / Counsel to the Surgeon General's Call to Action to Control Hypertension
2020	Chair, Federal Hypertension Control Leadership Council (AHRQ, CDC, CMS, FDA, HRSA, IHS, NHLBI, NINDS, ODPHP, OMH, ONC, OWH, OSG)
2020	Member of the Familial Hypercholesterolemia Surveillance Collaborative Group
2021	Faculty for American College of Cardiology Cardiovascular Overview and Board Prep 2021
2021	Co-Chair, Million Hearts Cardiac Rehabilitation Innovation Model Test Work Group
2021	Invited participant, NHLBI Stakeholder Meeting, Prevention of CVD in Patients with Psoriasis and Psoriatic Arthritis (CP3 Study): Bridging the Evidence to Practice Gap
2021	Invited member American Society for Preventive Cardiology Writing Group: Core Components, Key Attributes, and Effective Models of Clinical Preventive Cardiology Programs
2021	American College of Cardiology Fellow in Training Mentor
2021	Clinical Advisor, National Association of Community Health Centers Million Hearts Preventing Heart Attacks and Strokes in Primary Care
2022	Key Opinion Leader, World Heart Vision 2030, World Heart Federation
2022	Steering Committee Member, INTERASPIRE, International Survey of Secondary Prevention of Coronary Heart Disease in Six WHO Regions
2022	Advisor, Centers for Medicare and Medicaid QIO 13 th Scope of Work, Chronic Disease Management, Hypertension, Diabetes, CKD Work Group
2022	Planning committee member, CDC Office of Genomics and Precision Public Health Panel Discussion on Implementing Precision and Equitable Public Health Cascade Testing for Genetic Disorders

2022	Invited participant, Health Policy Partnership CVD Thought Leadership Forum
2022	Invited NIH RECOVER Post-Acute Sequelae COVID (PASC) Intervention Prioritization Panel (PIPP) sub-committee on Rehabilitation
2022	member AHA Writing Group, Lipoprotein Apheresis- Utility, Outcomes, and Implementation in Clinical Practice
2022	Invited participant, National Forum on Heart Disease and Stroke Prevention LDL-C Quality Measure Roundtable
2022	contributor to Health Policy Partnership, The Heart of Society: Why addressing CVD is critical to achieving wider societal goals
2022	Chair, AHA Scientific Statement on Lipoprotein Apheresis
2022	Member, International Federation on Aging Advisory Committee (WHF representative) on Adult Vaccination Education Program
2021-	Faculty Advisor for World Heart Federation Emerging Leaders Program. Team Project-Exploring the Feasibility of Integrating Diabetes Screening into May Measurement Month (MMM, led by the International Society of Hypertension)
2023-	SME / Consultant for Emory Clinical Immunization Safety Assessment (CISA)Team to the CDC
2023	Senior faculty lead, Emory site for National FIND-FH Initiative Collaborative Learning Network
2024	Co-Chair of World Heart Federation Forum on Multimorbidity and Integrated Care Program Advisory Group
2024	Cardiovascular advisor- CDC CRUSH (Combination Regimen for Shortening TB Treatment)TB Study
2024	Co-Chair, 10 th Annual Family Heart Foundation Summit
2024	Invited Participant, ACC Heart House Virtual Roundtable, From Pressure to Problems: Navigating the Impact of Hypertension on Cardiovascular Disease
2024	Invited participant CDC OHE/ OMH John R. Lewis Undergraduate Public Health Scholars speed mentoring event
2024	Co-Chair of the LEAD (Leveraging Evidence AND Data) for Pediatric Cholesterol Screening committee
2024	Vice-Chair, American Heart Association Scientific Statement- Pragmatic Detection of Coronary Artery Calcium on Chest Computed Tomography
2024	Advisor, ACC Rural Cardiovascular Health Initiative
2024	Co-PI, FIND Lp(a) Initiative
2025	member, ACC/ AHA 2026 Cholesterol Guideline Peer Review committee
2025	Invited participant, NCQA Chronic Kidney Disease Roundtable Convening

2025	Planning Committee, ACC Heart House Roundtable, Advanced Cardiovascular Risk Detection for the Critical Decades; PRIME-Heart Initiative (Predictive Risk-Informed Middle-Age Excellence in Cardiovascular Care)
2026	Participant, ACC Healthy Cities Virtual Summit
2026	CDC-NIH / NHLBI CVD Testing Work Group to Update Performance Criteria for Lipids
2026	External Advisory Board member for UCI Center for Global Cardiometabolic Health and Nutrition (CGCHN)
2026	Participant, ACC Heart House Roundtable, Sequenced CV Interventions for Lifetime Benefit: Primary Prevention Across the CKM Spectrum
2026-	Advisor, World Youth Heart Federation
2026	Advisor, AHA Science to Science meeting; Influenza Prevention in CV Care

b. Regional and State:

1999	Member of Georgia Association of Cardiopulmonary Rehabilitation, (Board of Directors and Vice President)
2001-present	Member of Southeast Lipid Association
2003-2005	Member of the Georgia Department of Human Resources Tobacco Use Prevention Physician Advisory Board
2011-present	Member of the Advisory Board for the Georgia Coalition to Combat Cardiometabolic Syndrome
2020-	Member, Medical Association of Georgia
2025	Honorary Co-Chair, CDC Atlanta Hypertension Initiative Roundtable

c. Institutional:

1992-1993	Emory University Hospital Resuscitation Committee
1994-present	Associate Member, Emory Medical School Admissions Committee
1999-2001	Member, Intern Applicant Committee, Department of Medicine
1999-2001	Member, Committee to Re-evaluate Teaching Programs, Department of Medicine
1999-2001	Chairman, Physician Retention Committee, Emory Cardiology
2000-2006	Member, Emory Heart Center Board
2000-2006	Co-Chairman, Education and Community Outreach Committee, Emory Heart Center
2000-2015	Member, Cardiology Physician Compensation Committee, Emory Clinic
2007-present	Member, Emory Cardiology Clinical Operations Committee
2007-2013	Member, Dean's Electives subcommittee

2007-present	Member, Foundations of Medicine Steering Committee (Healthy Human Subcommittee)
2008-present	Member, Heart and Vascular Center Program Team
2008-present	Member, Internal Medicine Leadership Group on Quality and Patient Safety
2009-2011	Appointed to EVP's WHSC Healthcare Benefactor Program
2009-2011	Appointed to Dr. EVP's WHSC Culture Transformation Group
2009-present	Appointed to Internal Medicine School of Medicine Mentoring Program: mentees- Dr. Allen Dollar Dr. Jefferson Baer Dr. Bryan Wells Dr. Ijeoma Isiadinso
2009-present	Appointed to Department of Internal Medicine Ambassador program
2010-present	member of My Emory Healthcare Development Support team
2010	member of the Search committee for the Director of Physical Therapy for Emory University
2012-2013	Emory Univ. School of Medicine Dean's CME Advisory Committee
2013	member of the search committee to recruit experts in global health and physical activity to The Hubert Dept. of global Health in the Rollins School of Public Health
2013	co-chair of the search committee to recruit Director of the Physician's Assistant Program
2013-	Member of the Emory University School of Medicine Progress and Promotions committee
2014	invited member of the Emory Healthcare Mobile Cardiac Screening Oversight / Advisory committee
2014	member of the Curricular Content Committee of the Liaison Committee on Medical Education for Emory Univ. School of Medicine
2014	Member of the Emory Healthcare Telemedicine steering committee
2015-	Invited member of the Executive Education committee for the Department of Medicine
2015	faculty advisor for Hispanic Health Fair Cardiovascular Risk Assessment
2016	member of Emory Healthcare Clinical Network Strategy Local subcommittee
2016	member of the Emory Healthcare Diabetes Collaborative Care/ Population Health Strategy committee
2017	member of GME Consortium of Champions, Well Being sub-committee
2018	member of Cardiology Clinical Leadership Committee

2018-	Emory Pharmacy Health Plan- Strategy Expert Consultant
2019-	Faculty volunteer, Emory College Phi Eta Sigma Honor Society Scholarship night
2019	member of Circle of Advisors for Emory Healthcare System Strategy Care Transformation Initiative
2019	faculty lead for Emory Innovation Hub, Sharecare partnership
2019	faculty member, Emory Innovation Hub, Somalogics relationship
2020	Search Committee member, Chief Wellness Officer, Emory Healthcare
2020-	Advisory Board, Emory Food Studies and Ethics Program
2020-	Member, Emory School of Medicine Alumni Board (Service on Nominating Committee)
2021-	NIH (Emory Site) All of Us Trial Clinical Champion
2021-	CHOA / EHC GENI (GI, Endocrinology, and Nutrition Innovation) Steering Committee
2022	Founder of Emory Healthcare Evinacumab Infusion Program for People Living with Homozygous Familial Hypercholesterolemia
2023	Chair, Ad-hoc Emory School of Medicine Committee to review student grade appeal

12. **Consultantships:**

2003-2004	Appointment to the Research Participation Program at the Centers for Disease Control and Prevention, National Immunization Program administered by the Oak Ridge Institute for Science and Education related to investigation of cardiovascular complications of smallpox vaccine
2008-present	Cardiovascular Consultant for the European Malaria Vaccine Initiative
2009-present	Appointed consultant to National Vaccine Adverse Event Program
2011-present	Consultant to U.S. News and World Report on diets and health; "Best Diets"
2021-	Consultant to CDC CISA (Clinical Immunization Safety Assessment) Program reviewing possible COVID vaccination-related myocarditis and pericarditis
2021-	Host, Medscape / WebMD InDiscussion Podcast Series on Dyslipidemia
2023-	Subject Matter Expert / Clinical Consultant to Emory Clinical Immunization Safety Assessment (CISA) Team to the CDC

13. **Editorships and Editorial Boards:**

2007-present	Member of Editorial Board for Clinical Cardiology
2007-present	Section Editor (Prevention), Current Treatment options in Cardiovascular Medicine

2009	Co-Editor of American College of Cardiology's Diabetes Self-Assessment Program
2015-	Member of the Editorial Board for Cardiovascular Endocrinology and Metabolism
2015-2016	Associate Editor Journal of Clinical Lipidology
2016-	Member of the Editorial Board for Clinical Lipidology
2020-	Member of the Editorial Board for American Journal of Preventive Cardiology
2020-	Section Editor, Current Cardiology Reports, Global Cardiovascular Health
2020-	Associate Editor, American Journal of Preventive Cardiology
2021-	Guest Associate Editor, JACC Asia
2023-	Guest Associate Editor, JACC
2025-	Associate Editor, Journal of Clinical Lipidology
2026	Guest Editor, JACC Advances

14. Manuscript reviewer:

1999-present	Reviewer for ABIM Cardiovascular Disease Exam
2001-present	invited reviewer for <i>Annals of Epidemiology</i>
2001-present	invited reviewer for <i>Journal of Clinical Outcomes Management</i>
2001-present	invited reviewer for <i>The American Journal of Cardiology</i>
2001-present	invited reviewer for <i>Hypertension</i>
2001-present	invited reviewer for <i>The American Heart Journal</i>
2001-present	invited reviewer for <i>The American Journal of Medicine</i>
2001-present	invited reviewer for <i>The Journal of the American Medical Association</i>
2001-present	invited reviewer for <i>Mayo Clinic Proceedings</i>
2009-present	invited reviewer for <i>Atherosclerosis</i>
2010-present	invited reviewer for <i>Circulation</i>
2004-present	ACC abstract reviewer and session Co-Chair
2012-present	invited reviewer for <i>The European Journal of Preventive Cardiology</i>
2012-present	invited reviewer for <i>The Journal of the American College of Cardiology</i>
2012-present	invited reviewer of <i>Vox Sanguinis</i>
2012	Expert scientific reviewer for The NHLBI Adult CV Risk Factor Reduction Guidelines (Risk Assessment report)
2013-present	AHA Scientific Sessions abstract reviewer
2013-present	invited reviewer for <i>Journal of Clinical Lipidology</i>
2013-present	invited reviewer for <i>Circulation Quality and Outcomes</i>
2014	invited reviewer of the 2 nd WHO Global Status Report on Non-Communicable Diseases (2014)
2016-present	invited reviewer for <i>JACC Imaging</i>
2017-present	invited reviewer for <i>JAMA</i>

2020-present invited reviewer for American Journal of Preventive Cardiology
2020-present invited reviewer for Lancet
2020-present invited reviewer for JAMA Cardiology
2020-present invited reviewer for European Heart Journal
2025-present invited reviewer for New England Journal of Medicine

15. Honors and Awards:

1982 Alpha Epsilon Upsilon
1983 Emory Medical School Early Acceptance (as college sophomore)
1984 Phi Beta Kappa
1984 Robert T. Jones Scholarship Finalist
1985 Dooley's Honorary Bodyguard
1987 Lange Book Award for Academic Excellence (Emory Medical School)
1991 Alpha Omega Alpha
1994 NIH Training Grant in vascular/molecular biology
1995 Bristol-Meyers Squibb Fellow's Abstract Award, American Heart Association
1999 Elected Fellow of the American College of Cardiology
1999 Elected Fellow of the American College of Physicians
2001 American College of Cardiology Harry B. Graf Career Development Award for Heart Disease Prevention
2001 Excellence in Teaching Award at Emory University Hospital presented by graduating Cardiovascular Fellowship Class of 2001
2001 American Heart Association Council on Clinical Cardiology Scholarship for Physical Activity and Public Health
2002 Emory University Attending Teaching Award
2003 Elected as member of Georgia Department of Human Resources Tobacco Use Prevention Physician Advisory Board
2003 Appointed to American College of Cardiology Education Strategic Directions Committee (Working Group on Live Programs)
2004 Mentorship Award for the J. Willis Hurst Internal Medicine Residency Program
2004 Golden Apple Award for Excellence in Teaching at Emory Hospital for the J. Willis Hurst Internal Medicine Residency Program
2006 Selected one of America's "Top Cardiologists", Consumers' Research Council of America
2007 Golden Apple Award for Excellence in Teaching at Emory University Hospital for the J. Willis Hurst Internal Medicine Residency Program
2008 Fellow of Emory Woodruff Leadership Academy
2009 Named as one of Atlanta's Top Doctors by Atlanta Magazine
2009 Golden Apple Award for Excellence in Teaching at EUH for J. Willis Hurst IM Residency Program
2010 Named as one of Atlanta's Top Doctors by Atlanta Magazine
2010 Emory College Class of 1985 Luminary
2010 Emory University School of Medicine Dean's Teaching Award

- 2011 Featured physician on the first interactive web chat in the history of Emory Healthcare
- 2011 Honorary Alumni Athlete at the Emory University Victory Bell Celebration for student athletes.
- 2011 Named as one of Atlanta's Top Doctors by Atlanta Magazine
- 2012 Named as one of Atlanta's Top Doctors by Atlanta Magazine
- 2012 elected to the Department of Medicine Academy of Medical Educators
- 2013 President-elect, American Society for Preventive Cardiology
- 2013 America's Top doctors, U.S. News & World Reports
- 2013 Named as one of Atlanta's Top Doctors by Atlanta Magazine
- 2014 Named as one of Atlanta's Top Doctors by Atlanta Magazine
- 2014 President, American Society for Preventive Cardiology
- 2014 Recognized as 1 of 23 Emory Healthcare physicians to receive > 90th% patient satisfaction scores for all quarters of 2014 at the Inaugural Dean's Emory Medicine Program
- 2015 Emory University, Division of Campus Life CLASS service award, Friends in Faculty Award
- 2015 Nominee for the Emory Department of Medicine Nanette K. Wenger distinguished Service Award
- 2015 Named as one of Atlanta's Top doctors by Atlanta Magazine
- 2015 Golden Apple Award for Excellence in Teaching at Emory University Hospital
- 2016 National Doctor's Day Recognized & Featured Physicians- Emory Medicine
- 2016 Nationwide Gold Provider (Top 10% Patient Satisfaction)
- 2016 Nominee for the Emory Department of Medicine Nanette K. Wenger Distinguished Service Award
- 2016 Named as one of Atlanta's Top Doctors by Atlanta Magazine
- 2016 Invited participant, Making Healthcare Better Series: Cardiovascular Health (White House Sept. 9, 2016)
- 2016 Elected Fellow of the American Society for Preventive Cardiology, Inaugural Fellowship Class
- 2016 Hong Kong Heart Foundation Lecture, 6th Asian Preventive Cardiology Conference
- 2017 Emory Campus Life Executive Roundtable invited speaker- Ethical Leadership in a Global Society: Pressing Concerns, New Possibilities
- 2017 Named as one of Atlanta's Top Doctors by Atlanta Magazine
- 2017 Emory University School of Medicine 2017 Alumni Award of Honor
- 2017 Recognized Educator, Emory Univ. School of Medicine Recognitions Committee
- 2017 Nominee for the Emory Department of Medicine Nanette K. Wenger Distinguished Service Award
- 2017 Emory Department of Medicine Distinction as Master Clinician
- 2017 Cardiovascular Disease Fellowship R. Wayne Alexander Research Mentoring Award
- 2018 endowed Katz Professor in Preventive Cardiology

- 2018 Nominee for the Emory Department of Medicine Nanette K. Wenger Distinguished Service Award
- 2018 Named as one of Atlanta's Top Doctors by Atlanta Magazine
- 2018 Recognized with Inaugural Emory Department of Medicine Laurence Sperling Outstanding Faculty Research Mentor Award
- 2018 Emory University School of Medicine Mentoring Award
- 2019 Nominee for the American College of Cardiology Distinguished Mentor Award
- 2019 Named as one of Atlanta's Top Doctors by Atlanta Magazine
- 2019 Nominee for the Emory Department of Medicine Nanette K. Wenger Distinguished Service Award
- 2020 Named as one of Atlanta's Top Doctors by Atlanta Magazine
- 2020 Member, Emory University School of Medicine Alumni Board
- 2021 Nominee for European Society of Cardiology Geoffrey Rose Lecture on Population Science
- 2021 Named as one of Atlanta's Top Doctors by Atlanta Magazine
- 2021 Emory University School of Medicine Distinction as Master Clinician
- 2021 Emory University School of Medicine Millipub Club, Co-author, 2018 ACC/ AHA/ Multispecialty Cholesterol Guidelines, 2021
- 2021 Wedding Officiant, 2021
- 2022 Right Care Initiative (California) Leadership Award, For Precision Medicine in Heart Attack and Stroke Prevention
- 2023 Elected member, Association of University Cardiologists
- 2023 Named as one of Atlanta's Top Doctors by Atlanta Magazine
- 2023 Nominee for 71st CDC Honor Awards for Excellence in Communications (Group Award), DHDSP Million Hearts Live to the Beat Campaign Team
- 2023 CDC NCCDPHP Center's Director Award for Creative Communications (Group Award), Million Hearts Live to the Beat Campaign
- 2023 PR Week Center for Plain Language, Clearmark Award for Best App (Group Award), Live to the Beat Pulse Check
- 2023 American Society for Preventive Cardiology Joseph Stokes III, MD Pioneer in Prevention Award (and Lecture)
- 2023 Recognized as Inaugural Master of the American Society for Preventive Cardiology
- 2023 CDC Shepard Award, Best original research publication, Assessment category. JAMA publication- Myocarditis Cases Reported After mRNA-based COVID-19 Vaccination. JAMA #1 Most talked about article of 2022
- 2023 Emory Physician Group Practice Diamond Provider, Top 1% Recognition
- 2024 Elected member, Association of University Cardiologists (AUC)
- 2024 World Heart Federation Presidential Medal in Recognition of Commitment to Heart Health
- 2024 National Lipid Association Honorary Lifetime Achievement and Membership Award in Recognition of Extraordinary Expertise and

- Contributions to the Field of Clinical Lipidology, presented at NLA National meeting.
- 2024 Medical Association of Atlanta Aven Cup Award- annually awarded since 1953 to a physician who plays a significant role in civic affairs and community involvement for outstanding contributions to education, medicine, the arts, and government- for leadership in the Atlanta Hypertension Initiative
 - 2024 National Association of Chronic Disease Directors Joseph W. Cullen Excellence Award for Impact in Public Health
 - 2024 National Forum for Heart Disease and Stroke Prevention Heart Healthy and Stroke Free Award- to a individual whose work embodies the recommendations of the National Health Action Plan to Prevent Heart Disease and Stroke
 - 2025 William B. Kannel Memorial Lecture, AHA Epi/ Prevention Conference
 - 2026 Invited Dan May Visiting Professor, Vanderbilt
 - 2026 99th Percentile Patient Satisfaction, Emory Healthcare, Fiscal Year 2025
 - 2026 Doctor Honoris Causa, University of Medicine and Pharmacy, Victor Babes, Timisoara, Romania
 - 2026 Diamond Physician Award winner, top 1% of National Peers for patient-centered care

16. **Society Memberships:**

- 1997-2003 Member of Georgia Association of Cardiopulmonary Rehabilitation, (Board of Directors and Vice President 1999)
- 1997-2003 Member of American Association of Cardiovascular and Pulmonary Rehabilitation
- 1999 Fellow of the American College of Cardiology
- 2000 Fellow of the American College of Physicians
- 2001-present Member of Southeast Lipid Association
- 2001-present Member of AHA Vascular Biology Working Group
- 2001-present Member of AHA Council on Clinical Cardiology
- 2004-present Member of National Lipid Association
- 2007 Fellow of the American Heart Association
- 2011-present Member of the American Society for Preventive Cardiology
- 2012-2013 Treasurer of the American Society of Preventive Cardiology
- 2011-2014 Member of the New York Academy of Sciences
- 2014-2016 President, American Society for Preventive Cardiology
- 2020 Member of International Society for Cardiovascular Disease Prevention

17. **Organization of National or International Conferences:**

ACC abstract reviewer and session Co-Chair since 2004

AHA abstract reviewer since 2007

WHF abstract reviewer since 2014

ESC abstract reviewer since 2013

18. **Research focus:**

Research efforts focused on preventive cardiology. Diets and cardiovascular disease and effects of therapeutic lifestyle change on vascular risk. Risk Assessment and risk assessment tools, subclinical atherosclerosis, cardiometabolic risk, Lp(a), premature coronary disease and novel lipid therapies. Scope of research spans translational to clinical and extends to population/ public / global cardiovascular health.

Faculty member of Emory Clinical Cardiovascular Research Institute (ECCRI)

19. **Grant Support:**

Current Support:

BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) core site at the University of Pittsburgh Medical Center (UPMC). Co principal investigator, BARI 2D study; 10/00-present \$5000

Funded Katz Foundation grant for fellowship for preventive cardiology \$500,000/yr support over 2 years. 1st fellow recruited, 2009; 2nd funded fellowship July 2015.

Funded Katz Foundation grant to support preventive cardiology education development, \$70,000, 2009.

NIH/ NIDDK P30 Diabetes Center Grant (Emory-GA Tech-Morehouse), Georgia Center for Diabetes Translational Research, 2016-

Emory PI, National Familial Hypercholesterolemia Registry, 2017-2020

Emory and Kaiser Permanente Collaborative COVID-19 Study, Co-Investigator, 2020

Previous Support:

NY Department of Health Grant for Cancer Research, Roswell Park Memorial Institute, Buffalo, NY, "Determination of circulating plasminogen activators in the blood of cancer patients as a diagnostic tool." Summer 1983

Molecular/Vascular Biology Research Fellowship in Cardiology, Emory University projects (under the supervision of Dr. Marshall Runge), 1993-1994

1. Thrombin receptor regulation in human microvascular endothelial cells

Plasminogen activators as mediators of endothelial cell migration projects (under the supervision of Dr. Patrick Delafontaine), 1994-1995

1. Cloning and sequencing the porcine insulin-like growth factor-1 receptor

2. Role of IGF-1 in restenosis following overstretch balloon injury of porcine coronary arteries
3. Growth factor mediated IRS-1 signal transduction in rat aortic smooth muscle cells

NIH Training Grant in vascular / molecular biology, \$40,000, 1994

The effects of physiologic doses of estrogen on conduit and resistance artery endothelial cell function and exercise test results in postmenopausal women with defined coronary artery disease (Emory Estrogen Vascular Study with Dr. Nanette Wenger), 1996 – 1997

Grant for evaluation of the role of MRI in the diagnosis of cardiac sarcoidosis, 1997

Sub-investigator, COURAGE (Clinical Outcomes Using Revascularization and Aggressive Drug Evaluation) trial, 1999-2006

Co-principal investigator, Exercise-induced immunomodulation of vaccine responses in elderly humans, University Research Committee Grant, \$29,956, 2000

Premature coronary artery disease: 15 year follow-up in patients under the age of 40 (with Dr. William Weintraub), 2001

Effects of exercise training on endothelial function, nitric oxide, and ecSOD production in human subjects (with Dr. David Harrison), 2001

American College of Cardiology Harry B. Graf Career Development Award for Heart Disease Prevention, \$40,000, 2001

STARR (Strategies to Achieve Risk Reduction)- Emory Hospital-based physician small grant award, \$10,000, 2001

Prime of Our Lives- Multifaceted educational program for post-menopausal women (\$10,000 grant-Pfizer), 2002

Principal investigator for CHESS trial - Comparative HDL Efficacy and Safety Study (Merck), 2003

Co-Investigator of NIH sponsored HF-ACTION Trial (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training), 2005-2008. No funding for investigator – only for other personnel

Astra-Zeneca. Principal Investigator for JUPITER trial (study of Rosuvastatin in the Primary Prevention of Cardiovascular Events among subjects with low LDL and elevated C- Reactive Protein), 2005 – 2008. Funding was for personnel but ultimately no funds were received as no subjects were used in trial.

Internal Advisory Board for NHLBI P01 Program Project Grant- Precision Cardiovascular Phenotyping and Pathophysiological Pathways in the CARRS Cohort (Precision-CARRS)

Mentor for Dr. Danny Eapen, Emory FAME (Fostering the Academic Mission of Emory) Grant, Chasing Cholesterol: Investigating the Utility of a Machine Learning Algorithmic Approach to Flag, Identify, Network, and Deliver (FIND) Patients with Familial Hypercholesterolemia within the Emory Healthcare System, 2021-

20. **Clinical Service Contributions:**

Founder and Director of the Preventive Cardiology section and HeartWise Risk Reduction Program at Emory since 1997

Attending on the Hurst Clinical Cardiology Teaching Service at Emory University Hospital since 1997

Founder and co-Director of the first (only) LDL Apheresis Program in the state of Georgia since 2003

21. **Formal Teaching:**

a. **Medical Student Teaching:**

1992-2006	Clinical Methods Physical Exam and Diagnosis Course
1993-1995	Mentor, Problem-Based Learning Course
1998-2006	Faculty lecture in Clinical Correlations of Medical Biochemistry (M1's)
2007-present	Faculty lecture on Clinical Correlations in Lipids and Atherosclerosis, M1 Cardiology module
1999-2000	Junior Medicine Clerkship Handbook-wrote Cardiology syllabus
2000-2005	Mentor for M1's in Patient-Doctor course
2001	Lecture to M1's on exercise testing/physiology
2002	Faculty lecture in Pathophysiology course (M2's)
2002-present	Course Director for M4 elective in Preventive Cardiology
2002-present	Co-Course Director for Emory Cardiology CME programs ESCAPE and Cardiology for the Primary Care Physician
2007-present	Appointed by Dean to Osler Society Advisor for Medical student education
2007-present	Co-Director of M1 module on Exercise and the Healthy Human
2012	M4 Discovery project mentor/ advisor to Max Weiss, M4
2015	M4 Discovery project mentor/ advisor to Elliot Mahlof, M4

b. **Graduate Program**

Residency program:

1997-present Faculty supervisor for housestaff in Medicine-outpatient preventive Cardiology

1997-present Faculty supervisor for housestaff in Family and Preventive

Medicine-outpatient clinic

1997-present Faculty supervisor for cardiology fellows - outpatient preventive Cardiology

1997-present Faculty supervisor for housestaff in Rehab Medicine-cardiac rehab

b. **Other categories:**

1998-present Faculty supervisor for Physician's Assistant Program

2000-present Faculty supervisor for Family Nurse Practitioner Program

2017 Fall Semester, Emory College Course, HLTH 320, Nutrition and Chronic

Disease Guest Lecturer, Heart Healthy Dietary Patterns: A Recipe for Life

2017 Spring Semester, University Course, Eating Ethics Guest Lecturer- "Heart Healthy Dietary Patterns: A Recipe for Life"

2019 Spring Semester University Course, Eating Ethics Guest Lecturer- "Heart Healthy Dietary Patterns: A Recipe for Life"

2024 Spring Semester University Course, Eating Ethics Guest Lecturer- "Heart Healthy Dietary Patterns: A Recipe for Life"

22. **Supervisory Teaching:**

a. **Post-doctoral fellows directly supervised:**

Joseph I. Miller, III, 2000-2007, currently Director of Preventive Cardiology at Piedmont Hospital

Andrew DeFilippis, 2003-2007, Cardiology Fellow at the John Hopkins Hospital /faculty (Chief) University of Louisville, KY- now at Vanderbilt

Puja Mehta- faculty Emory

Danny Eapen, 2010-2012 faculty Emory Healthcare- now at Baylor

Nima Ghasemzadeh, 2012-2014- faculty GA Heart Institute

Kobi Wilmot- Novant Heart Health, Mooresville, NC

Jia Shen, 2012- 2014 (current faculty at UCSD)

Riaz Patel- faculty Univ College London, Barts NHS Trust

Jonathan Kim- Emory faculty

Salim Hayek- Univ of Michigan; current Chair of Medicine UT Galveston

Heval Mohamed Kelli, 2015-2018- Northside Preventive Cardiology

Pratik Sandesara, 2016- 2018- Emory faculty

Raymundo Quintana- faculty Univ of Colorado

Anurag Mehta, 2018-2019- Director of Preventive Cardiology VCU- Emory faculty

Devinder Dhindsa, 2018-2019- Emory faculty

Brian Cheung, 2021- UCI fellow

Merilyn Varghese, 2021-, AHA Post-doc fellowship; BI Deaconess MC, Harvard-Yale faculty

Alexander Razavi, 2021- Emory fellow

b. **Residency Program**

Jason Cole, 2001-2005, currently faculty at University of South Alabama, Mobile, Alabama

Tamir Baman (student) Univ of Chicago

Kimberly Champney, 2003-2007, currently Preventive Cardiologist at Northside Hospital, Atlanta, Georgia

Danny Sims- Fellowship Director Montefiore, NY

Ben Mackie- faculty USF
 Michel Corban- faculty Mayo Rochester
 Thura Abd, 2008-2011, currently cardiology fellow at John Hopkins
 Vimal Ramjee, 2008-2011, currently cardiology fellow at University of Pennsylvania- faculty Chattanooga, TN
 Ria Nieva, 2008-2011, fellow at The University of Colorado
 Joseph Knapper- fellow Minnesota
 James MacNamara- fellow UTSW
 William Schutz- fellow Northwestern- Emory faculty
 Robert Heinl- Ohio Health
 Nino Isakadze- fellow Hopkins
 Jay Khambati- fellow MGH
 Eric Stahl- Staten Island, NY
 Marc Allard-Ratick- fellow MGH
 Melroy D-Souza- Emory faculty
 Aneesha Thobani- Buffalo, NY
 Tiffany Dong- Cleveland Clinic fellow
 Weston Dicke- Univ of Kentucky fellow
 Ben Hirsh (student)- Director of Preventive Cardiology Northwell
 Christian Faaborg Anderson (student)- fellow MGH
 Jeffery Osei (student SoPH Emory)
 Nicole Guynn- Morehouse fellow
 Scott Eisenberg (Emory student)

23. **Lectureships, Seminar Invitations, and Visiting Professorships:**

02/2001	Visiting Professor, Columbus Medical Center
06/2003	Visiting Professor, University of South Carolina Charleston
09/2006	Visiting Professor, University of South Florida Tampa
10/2006	Visiting Professor, University of North Carolina Chapel Hill School of Medicine
09/2013	Visiting Professor, University of Alberta, Canada
12/ 2013	Visiting Professor, University of California Irvine
09/ 2014	Visiting Professor, Johns Hopkins Medical Center
11/2014	Anandi L. Sharma Visiting Professorship & Simon Dack, M.D. Memorial Lecturer, Mt. Sinai Medical Center, N.Y.
4/ 2015	Visiting Professor, Weill Cornell Medical Center, N.Y.
6/2015	Visiting Professor, Stony Brook Medical Center, N.Y.
6/2015	Visiting Professorship, Lynchburg General Hospital, Centra Heart & Vascular Center, VA
9/2015	Visiting Professorship, Sulpizio Cardiovascular Center, UC San Diego, CA
12/16-1/17	Visiting Professorship, National Heart & Lung Institute of the Faculty of Medicine at Imperial College, London, UK
5/2017	Visiting Professorship, University of Minnesota Lillehei Heart Institute, Minneapolis, MN
6/2017	Visiting Professorship, University of Nebraska Medical Center, Omaha, NE
6/2018	Visiting Professor, 6 th Emory-Tibet Medical Sciences Program,

4/2026

Men-Tsee-Khang Medical School, Dharamsala, India
Dan May Visiting Professor, Vanderbilt University Medical Center,
Nashville, TN

Regional invitations:

1. Cardiology in Primary Care, When to Return to Work and Sex after a Cardiac Event, Atlanta, GA, 1997
2. 20th Annual Georgia Cardiopulmonary Rehab Update, New Frontiers in the Primary Prevention of Coronary Artery Disease, Atlanta, GA, 1998
3. Cardiology in Primary Care, Preparing for Discharge after a Cardiovascular Event, Atlanta, GA 1998
4. Update on Transplantation, Reducing the Risk of Cardiovascular Disease in the Renal Transplant Patient, Savannah, GA, 1999
5. Cardiology in Primary Care, Hyperlipidemia: Current Thoughts and Future Directions, Sea Island, GA, 1999
6. 9th Annual Update in Preventive Medicine, Prevention and Regression of Coronary Artery Disease, Turnersville, GA, 1999
7. Management of Lipoprotein Disorders, Assessment of Coronary Artery Disease, Callaway Gardens, GA, 1999
8. Cardiology in Primary Care, Hyperlipidemia as a Cardiovascular Risk Factor, Atlanta, GA, 1999
9. ACC Visiting Fellowship Program, Cardiovascular Risk Reduction for the Interventional Cardiologist, Atlanta, GA, 1999
10. Emory Updates in Primary Care, Assessment of Coronary Artery Disease, Atlanta, GA, 2000
11. Emory Updates in Primary Care, Prevention of Coronary Artery Disease, Atlanta, GA, 2000
12. Cardiology in Primary Care, Lipid Lowering Agents: Pharmacology and Beyond, Sea Island, GA, 2000
13. Alabama Medical Directors Association Meeting, Hyperlipidemia and Cardiovascular Disease, Sandestin, FL, 2000
14. Georgia Association of Physician Assistant's 25th Annual Conference, Lipids and Cardiovascular Disease, Jekyll Island, GA, 2000
15. Cardiology in Primary Care, Role of Risk Factors in Coronary Atherosclerosis, Atlanta, GA, 2000
16. Visiting Professor for a Day with Emory, Columbus Medical Center, Columbus, GA, 2001
17. Medical Grand Rounds, Northlake Hospital, New Insights into Lipid Therapy, Atlanta, GA, 2001
18. Merck Regional Consultant's Meeting, Inflammation in Atherosclerosis, Charleston, SC, 2001
19. The Bays Medical Society Annual Meeting, New Insights into Lipid Therapy, Panama City Beach, FL, 2001
20. 23rd Annual Georgia Cardiopulmonary Rehabilitation Update, New Insights into Lipid Therapy, Callaway Gardens, GA, 2001
21. Cardiology in Primary Care, A Practical, Office-based Approach to Hypertension, Sea Island, GA, 2001

22. Wellstar Health System Cardiology Symposium, Insights from NCEP ATP III and Closing The Treatment Gap, Marietta, GA, 2001
23. Georgia Academy of Family Practice 53rd Annual Meeting, A Practical Office-Based Approach to Hypertension, Cobb, GA, 2001
24. Emory Updates in Primary Care, New Frontiers in Lipids and Atherosclerosis, Atlanta, GA, 2001
25. EPIC (Emory Practical Intervention course), Real World Approach to Coronary Risk Reduction, Atlanta, GA, 2002
26. Emory Symposium on Coronary Atherosclerosis Prevention (ESCAPE), Inflammatory Markers and Atherosclerosis, (Course Co-Director), Sea Island, GA, 2002
27. Medical Grand Rounds, Emerging Concepts in Lipids and Atherosclerosis, Athens Regional Medical Center, Athens, GA, 2002
28. Coronary Calcium Scoring as a Screening Tool: Subclinical Markers of Atherosclerosis, Spartanburg Regional Medical Center, Spartanburg, SC, 2002
29. Leaders of Emerging Science of Lipid Management Southeast Regional Working Group Meeting, Strategies for Educating Special Populations about Cardiovascular Risk, Naples, FL, 2002
30. Cardiology in Primary Care Meeting, Workshop on Management of Lipid Disorders, (Course Co-Director) Atlanta, GA, 2002
31. 37th American Society of Hospital Pharmacists Meeting, Cholesterol-Lowering Agents and the Implications for Diabetics, Atlanta, GA, 2002
32. DeKalb County School Board meeting, New Frontiers in Heart Disease Prevention, Atlanta, GA, 2002
33. Medical Grand Rounds, New Frontiers in Lipids and Atherosclerosis, St. Vincent's Medical Center, Jacksonville, FL, 2003
34. 24th Annual Georgia Cardiopulmonary Rehabilitation Update, New Frontiers in Heart Disease Prevention, Savannah, GA, 2003
35. Setting the Pace 2003: Emerging Trends for Cardiovascular Nursing, New Frontiers in Heart Disease Prevention, Atlanta, GA, 2003
36. Emory Symposium on Coronary Atherosclerosis Prevention and Education (ESCAPE), Setting the Goals for Lipid Management and the Strategies for Achieving Them (Co-Course Director), Sea Island, GA, 2003
37. Cardiology Grand Rounds, Inflammatory Markers and Atherosclerosis, Medical University of South Carolina, Charleston, SC, 2003
38. Southeast Lipid Association Scientific Forum, How to Run a Successful Lipid Clinic/Preventive Cardiology Center in 2003, Boca Raton, FL, 2003
39. Cardiology in Primary Care, Beyond LDL: What Do We Need to Know about Lipid Lowering? Atlanta, GA, 2003
40. EPIC (Emory Practical Intervention Course) A Real World Approach to Coronary Risk reduction, Atlanta, GA, 2004
41. ESCAPE (Emory Symposium on Coronary Atherosclerosis Prevention and Education), Placing the Recent Lipid Trials in Perspective, Sea Island, GA, 2004
42. ESCAPE (Emory Symposium on Coronary Atherosclerosis Prevention and Education), Exercise/Weight/Diet-How much/How little? (Co-Course Director), Sea Island, GA, 2004
43. 25th Annual Georgia Cardiopulmonary Rehabilitation Meeting, Beyond LDL, Savannah, GA, 2004
44. Cardiology in Primary Care, Lipid Targets and Goals, (Co-Course Director) Atlanta, GA, 2004

45. EPIC 2005, New Approaches to Coronary Risk Reduction, Atlanta, GA, 2005
46. Boca Raton Cardiovascular Summit II. Beyond LDL..., Boca Raton, FL, 2005
47. ESCAPE 2005, Diets and CVD: Assessment of current Evidence, (Co-Course Director), Amelia Island, FL, 2005
48. Cardiology in Primary Care, Beyond LDL..., (Co-Course Director) Atlanta, GA, 2005
49. Georgia Chapter of the American College of Cardiology, Beyond LDL, Reynolds Plantation, GA, 2005
50. CME Symposium-Diagnosis and Treatment of Lipid Disorders. Non-invasive Imaging in the Atherosclerosis. Emory Conference Center, Atlanta, GA, 2006
51. Internal Medicine Update, Diets and CVD: An Evidence-Based Approach, Boca Raton, FL, 2006
52. 10th Annual Day of Cardiology. Diets and CVD. Columbus Medical Center, GA, 2006
53. ESCAPE 2006. LDL: Can We Go Too Low? (Course Director), Amelia Island, FL, 2006
54. Cardiology Grand Rounds/Visiting Professor. Approach to Chronic Angina, University of South Florida, Tampa, 2006
55. Cardiology in Primary Care. What should our goals be for LDL and does it matter how we get there? Atlanta, GA 2006
56. South Miami Heart Center Comprehensive Cardiovascular Conference, Heart Healthy Diet, Coral Gables, FL, 2006
57. Cardiology Grand Rounds/Visiting Professor. Diets and CVD: An Evidence-Based Assessment. UNC Chapel Hill School of Medicine, 2006
58. First Annual Internal Medicine Conference: Heart and Vascular Disease Update. Diets and CVD. Memorial University Medical Center, Savannah, GA, 2007
59. 11th Annual Symposium on The Prevention of Cardiovascular Disease, Heart Health Living: Focus on Diet and Exercise. Coral Gables, FL, 2007
60. 6th Annual Emory ESCAPE meeting. New Approaches to Tobacco Cessation. (Course Director) Amelia Island, FL, 2007
61. 6th Annual Emory ESCAPE meeting. Understanding Omega 3's Amelia Island, FL, 2007
62. 6th Annual Emory ESCAPE meeting. Psychological Influences in Atherosclerosis. Amelia Island, FL, 2007
63. Emory Comprehensive Update in OBGyn. Diets and Obesity: What is the Evidence? Amelia Island, FL, 2007
64. Cardiology in Primary Care, The Role of Sophisticated Lipid Analysis, Atlanta, GA, 2007
65. NLA Comprehensive Cardiometabolic Risk Reduction Program, The Drivers of Cardiometabolic Risk, Atlanta, GA, 2008
66. 7th Annual ESCAPE meeting (Course Director), Does Size Matter? Role of Advanced Lipid Testing, Amelia Island, FL, 2008
67. 7th Annual ESCAPE meeting, Prehypertension: Detection, Evaluation, and Management, Amelia Island, FL, 2008
68. Invited speaker for The Georgia ACP meeting, Cardiovascular Disease Prevention, Savannah, GA, 2009
69. Invited presentation at 36th South Atlantic Cardiovascular Society Meeting, "New Strategies in Lipid Management: Medical and Surgical Implications," Isle of Palms, S.C., 2009
70. Course Director of 8th Annual ESCAPE meeting, Amelia Island, FL [Emory Symposium on Coronary Atherosclerosis Prevention and Education], 2009
Presentation: "Should We Use CRP on Earth or Just on Jupiter?"
Presentation: "Should We Put Statins in the Water?"

71. Cardiology in Primary Care (Course Director)
HDL, hS-CRP, LP(a): Pieces of the Puzzle?
The patient with Recurrent Chest Pain and Normal Angiograms
Atlanta, GA, 2009
72. Course Director of 9th Annual ESCAPE meeting, Amelia Island, FL, 2010
 - a. "Focus on non-HDL Cholesterol: Do the Math"
 - b. "Office-based Risk Assessment: Practical Approach"
73. Cardiology in Primary Care (Course Director), Atlanta, GA, 2010
 - a. Office-based risk assessment: Practical approach
74. EPIC (Emory Practical Intervention Course), Keys to a better, longer life, Atlanta, GA, 2011
75. Course Director of 10th Annual ESCAPE meeting, Amelia Island, FL, 2011
 - a. "Diets and CVD: Is there a recipe for success?"
 - b. "Omega 3 Fatty Acids and CVD: Is something fishy?"
76. Cardiology in Primary Care (Course Director), Atlanta, Ga 2011
 - a. Optimal Lipid Targets (OLT) for the New Era of Cardiovascular Prevention
77. Atlanta Clinical Cardiology Update. Optimal Lipid Targets for the New Era of Cardiovascular Prevention. Atlanta, Ga., 2012
78. Course Director of The 11th Annual ESCAPE meeting, Amelia Island, FL, 2012
 - a. Optimal Lipid Targets (OLT) for the New Era of CV Prevention
 - b. Keys to a Better, Longer Life
79. St. Josephs Hospital Heart and Vascular Institute Grand Rounds, Optimal Lipid Targets for the new Era of Cardiovascular Prevention, Atlanta, GA, 2012
80. St. Joseph's Hospital 6th Annual Women and Heart Disease Conference: Evolving Concepts and New Therapies. Moderator, Stone Mountain, GA, 2012
81. Atlanta Clinical Cardiology Update. Time to Focus on Cardiovascular Health (not Disease). Atlanta, Ga. 2013
82. Internal Medicine Update 2013. Time to Focus on Cardiovascular Health (Not Disease). Boca Raton, FL. 2013
83. Dekalb Hospital Grand Rounds, Optimal Lipid Targets for the New Era of Cardiovascular Prevention, Atlanta, GA. 2013
84. Course Director of The 12th Annual ESCAPE meeting, Amelia Island, FL, 2013
 - a. Increasing Awareness of & Approach to Familial Hypercholesterolemia
 - b. Time to Focus on Cardiovascular Health (Not Disease)
85. Invited speaker, Centers for Disease Control and Prevention, Division of Heart Disease and Stroke Prevention Science Seminar Series, Time to Focus on Cardiovascular Health (Not Disease). Atlanta, GA, 2013
86. Keynote speaker, St. Joseph's Hospital Reward Your Heart Program. Best Diets. Atlanta, GA, 2013
87. 7th Annual St. Joseph's Hospital Women and Heart Disease meeting. Diets and Cardiovascular Disease: An evidence-based assessment. Atlanta, GA, 2013
88. Cardiology in Primary Care. The Heart Healthy Diet. Atlanta, GA. 2013
89. Atlanta Clinical Cardiology Update. Treatment of Blood Cholesterol: New Approaches / New Agents. Atlanta. Ga. 2013
90. Georgia ACC APP Meeting. Treatment of Blood Cholesterol: New Approaches / New Agents. Atlanta. Ga. 2014
91. Georgia Leadership in Worksite Wellness and Cardiometabolic Health. National Cardiometabolic Health Initiatives. Ga. 2014

92. Course Director of the 13th Annual ESCAPE meeting, Amelia Island, FL, 2014
 - a. HIV and Cardiovascular Risk
 - b. Navigating the 2013 ACC/AHA Blood Cholesterol Guidelines
93. South East Lipid Research Conference. Omega 3's and CVD: Is something fishy? Callaway Gardens, GA. 2014
94. Cardiology in Primary Care. Heart Healthy Diet. Atlanta, GA. 2014
95. Heart and Vascular Institute Grand Rounds. Treatment of Blood Cholesterol: New Approaches / New Agents. Emory St. Joseph's Hospital. Atlanta, Ga. 2014
96. Primed Meeting Symposium. Meeting the Challenges of Managing Lipids Beyond LDL-C. Fort Lauderdale, FL. 2015
97. 11th Annual Cardiovascular Symposium at Sarasota Memorial Hospital. Sarasota, FL 2015
 - a. Time to Focus on Cardiovascular Health (not CV Disease)
 - b. The Heart Healthy Diet
98. 34th EPIC SEC (Emory Practical Intervention Course). Guideline-based and Novel Anti-Atherosclerotic Therapies, Atlanta, GA, 2015
99. Course Director for the 14th Annual ESCAPE meeting, Amelia Island, FL, 2015
 - a. Cholesterol goals & Targets: Opportunities for Improvement
 - b. Heart Healthy Diet
100. Cardiology for the Primary Care Physician, Emory Conference Center, 2015
 - a. Heart Healthy Diet
101. Baptist Health South Florida Obesity Symposium, Miami, FL, 2016
 - a. Medical Consequences of Obesity- Metabolic Syndrome & Diabetes
 - b. Obesity, Dyslipidemia, and CVD Risk
 - c. Preventive Cardiology and the future of cardiovascular medicine: Opportunities for Improvement
102. Cardiovascular Center of Sarasota 12th Annual CV Symposium, Sarasota, FL, 2016
 - a. Preventive Cardiology and the future of cardiovascular medicine: Opportunities for Improvement
 - b. New approaches to Understanding Cardiometabolic risk
 - c. Therapeutic Lifestyle Changes for CVD Prevention
103. 7th Annual AnMed Health Cardiovascular Symposium. Anderson, S. Carolina, 2016
 - a. Living Longer and Better
104. Emory Practical Intervention Course Southeastern Consortium (EPIC-SEC), Atlanta, GA, 2016
 - a. Interventional Preventive Cardiology: Perspectives, Pitfalls, and Possibilities
105. Medical Grand Rounds, University of Tennessee College of Medicine Treatment of Blood Cholesterol: New Approach / New Agents. Chattanooga, TN, 2016.
106. Course Director for the 15th Annual ESCAPE meeting, Amelia Island, FL, 2016
 - a. Comprehensive Cardiovascular Risk Reduction in the Metabolic Syndrome and Diabetes
 - b. Treatment of Blood Cholesterol: New Approaches/ New Agents- Promise of PCSK9 Inhibitors
107. Cardiology for the Primary Care Physician, Emory Conference Center, 2016
 - a. The Art of Cardiovascular Risk Assessment
108. 13th Annual Congress on Early Cardiovascular Disease Prevention: Update 2017, Sarasota, FL
 - a. Cardiobesity

- b. Comprehensive Cardiovascular Risk Reduction in the Metabolic Syndrome & Diabetes
 - c. Living Longer & Better
- 109. 8th Annual AnMed Health Cardiovascular Symposium, Anderson, SC, 2017
 - a. The Art of Cardiovascular Risk Assessment
- 110. 14th Annual Boca Raton Regional Hospital Internal Medicine Conference, 2017
 - a. Preventive Cardiology & the Future of Cardiovascular Medicine: Opportunities for Improvement
- 111. Emory Practical Intervention Course Southeastern Consortium (EPIC-SEC), Atlanta, GA, 2017
 - a. Co-Chair for Symposia on The Evolution of Lipid-Lowering Treatments for Reducing the Burden of Atherosclerosis
 - b. Management of Blood Cholesterol 2017: New Approaches / New Agents
- 112. 16th Annual Emory ESCAPE Cardiovascular Prevention meeting, Amelia Island, FL, 2017
 - a. Course Director
 - b. PCSK9 Inhibition: Promise and Possibilities
 - c. Cardiac Rehabilitation and Secondary Prevention: New Care Models for A New World
- 113. 9th Annual AnMed Health Cardiovascular Symposium, Anderson, SC. 2018
 - a. Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement
- 114. Emory Practical Intervention Course Southeastern Consortium (EPIC-SEC), Atlanta, GA, 2018
 - a. Co-Chair Clinical Cardiology Prevention Symposium
 - b. Presentation- "The Era of PCSK9 Inhibition: How Low is Too Low?"
- 115. Course Director, 17th Annual Emory ESCAPE meeting, Amelia Island, FL, 2018
 - a. Non-pharmacologic interventions for Elevated BP
 - b. Roundtable: Diets & CV Prevention
 - c. Transforming the Heart Team approach to comprehensive CV Prevention in Diabetes
 - Transforming the Heart Team approach to comprehensive CV Prevention in Diabetes
- 116. 10th Annual AnMed Health Cardiovascular Symposium, Anderson, SC. 2019
 - a. Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World
- 117. Georgia Chapter ACC Annual Scientific Meeting. Session Moderator- Diabetes and Cardiovascular Disease. Greensboro, Ga. 2018
- 118. Georgia Association of Cardiovascular and Pulmonary Rehabilitation Conference, Marietta, Ga, 2019
 - a. Reconfiguring Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World
- 119. 16th Annual Boca Raton Regional Hospital Internal Medicine Conference, Boca Raton, FL, 2019
 - a. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of ASCVD
- 120. Emory Practical Intervention Course Southeastern Consortium (EPIC-SEC) Clinical CV Update, Atlanta, GA, 2019

- a. Moderator for 2 Sessions: CV Prevention; New Treatments for CAD
- b. Lessons from the 2018 Cholesterol Guidelines
- 121. Course Director, 18th Annual Emory ESCAPE meeting, Amelia Island, FL, 2019
 - a. Statin Safety and Statin-Associated Side Effects
 - b. Approach to CV Risk Assessment: Enhancing and Informing
- 122. Emory Women's Heart Center 13th Annual Women & Heart Disease: Evolving Concepts & New Therapies
 - a. Lessons from the 2018 Cholesterol Guidelines
- 123. Georgia Chapter ACC Annual Scientific Session Meeting. Biomarkers for CV Risk Prediction for the Practicing Cardiologist. Greensboro, GA, 2019
- 124. Emory Practical Intervention Course – Southeastern Consortium- Clinical Cardiovascular Update, 2020
 - a. Moderator for Session- MI, Chest Pain, Ischemia, and Cardiovascular Disease in Women
 - b. New Lipid Agents
- 125. A Minute with Mayor Muryn: Heart Health- Virtual Event with the Mayor of Findlay, Ohio, 2020
- 126. Advancing Million Hearts South Carolina. Virtual Meeting. Million Hearts 2022 Update, 2020
- 127. Advancing Million Hearts Montana. Virtual Meeting. Million Hearts 2022 Update, 2020
 - a. Managing Chronic Conditions in the Midst of COVID-19, Moderator
- 128. 19th Emory ESCAPE meeting (Virtual), Co-Course Director and Moderator, 2021
 - a. The (Post-COVID) Future of Cardiovascular Disease Prevention
- 129. President's Invited Lecture, Southern Thoracic Surgical Association meeting,
 - a. 2021
 - b. Impact of COVID-19 on Cardiovascular Care and Cardiovascular Disease Prevention
- 130. 20th Emory ESCAPE meeting, Co-Course Director and Moderator, Amelia Island, FL, 2022
 - a. Heart Healthy Dietary Patterns: A Recipe for Life
 - b. NAFLD: The Heart of the Matter
- 131. Inaugural Georgia Heart and Vascular Symposium, Braselton, GA, 2022
 - a. The (Post-COVID) Future of CVD Prevention
- 132. 23rd CardioSarasota Congress on Heart Disease Prevention, 2023
 - a. NAFLD: The Heart of the Matter
- 133. Ohio Association of Community Health Centers Diabetes Collaborative, 2023
 - a. Million Hearts 2027: The ABC's of CVD Prevention in Diabetes
- 134. Missouri Department of Health TeleECHO Series to Improve Health, 2023
 - a. Adopting Cholesterol Management / ASCVD Risk Calculator
- 135. 21st Annual Emory ESCAPE Meeting, Co-Course Director and Moderator, 2023
 - a. Influenza Vaccination: An Opportunity for CVD Prevention
 - b. Familial Hypercholesterolemia: A Prototype for Precision Public Health
- 136. Georgia American College of Cardiology, Annual Scientific Meeting, 2023
 - a. Diet for Weight Loss vs. Heart Health?
- 137. City of Philadelphia, Department of Public Health Ambulatory Services / Health Centers Update, 2024
 - a. Lipid Management to Reduce ASCVD Risk: Lessons from the Guidelines/ To
 - b. Infinity and Beyond?

138. Atlanta Inquiry Club (Founded 1931, prior speakers including John Lewis and
 - a. Andrew Young), 2024
 - b. Heart Healthy Dietary Patterns: A Recipe for Life
139. Georgia Heart Institute Cardiovascular Grand Rounds, 2024
 - a. Focus on CKMH to PREVENT CVD
140. Northwell Preventive Cardiology Conference, 2024
 - a. Focus on CKMH to PREVENT CVD
141. CDC DHDSP Lunch and Learn, 2024
 - a. Million Hearts 2027: Aiming for Impact- Improving Cholesterol
 - b. Management
142. 22nd Emory ESCAPE CME meeting, Amelia Island, FL, 2024
 - a. Health, Well-being, Mindfulness, and Movement
 - b. Time-Restricted Eating: A Strategy for CVD Prevention?
 - c. Focus on CKMH to PREVENT CVD
143. 3rd Georgia Heart & Vascular Symposium, Chateau Elan, GA, 2024
 - a. Heart Healthy Dietary Patterns: A Recipe for Life
144. 23rd Emory ESCAPE meeting, Amelia Island, FL, 2025
 - a. Risk Assessment: Foundation for Population Health and Precision Prevention
 - b. Covid-19 Pandemic: Wake-up Call and Accelerator for Cardiac Rehab
 - c. Looking Back and Looking Forward: The Next 23 Years of CVD Prevention
145. Honorary Co-Chair, Atlanta Hypertension Initiative Executive Roundtable, Atlanta, GA, 2025
146. Zuffall Health System Primary Care Grand Rounds, NJ, 2026
 - a. CVD Prevention in Primary Care
147. Emory Neuroscience Symposium, Atlanta, GA, 2026
 - a. Controlling BP is VITAL to ATL
148. Boca Raton Regional Hospital Internal Medicine Symposium, 2026
 - a. The Alphabet Soup of Diabetic Agents for CVD Prevention: The Role of SGLT2-inhibitors and GLP-1 agonists
149. Opening Remarks, Atlanta Hypertension Initiative Spring Convening, 2026
150. 24th Emory ESCAPE meeting, Amelia Island, FL, 2026
 - a. Heart Healthy Dietary Patterns: A Recipe for Life
 - b. Focus on CLMH with the Goal of Prevention

Institutional Invitations:

1. Diagnostic Electrocardiography Conference, EKG of Myocardial Infarction, Emory Conference Center, Atlanta, GA, 1996
2. Family Practice Grand Rounds, New Frontiers in the Primary Prevention of Coronary Artery Disease, Grady Hospital, Atlanta, GA, 1998
3. Grady Hospital, Cardiology Grand Rounds, C-Reactive Protein: A Marker for Cardiovascular Risk?, Atlanta, GA, 2000
4. Medical Grand Rounds, Emory University Hospital, Diabetes and Cardiovascular Disease: New and Unresolved Issues, Atlanta, GA, 2001
5. Medical Grand Rounds, Crawford Long Hospital, New Frontiers in Lipids and Atherosclerosis, Atlanta, GA, 2001
6. Cardiology Grand Rounds, Grady Memorial Hospital, Emerging Concepts in Lipids and Atherosclerosis, Atlanta, GA, 2002

7. Medical Grand Rounds, New Frontiers in Preventive Cardiology, The Atlanta Medical Center, Atlanta, GA, 2002
8. Medical Grand Rounds, Inflammatory Markers and Atherosclerosis, Emory University Hospital, Atlanta, GA, 2003
9. Family and Preventive Medicine Grand Rounds, Beyond LDL, Grady Memorial Hospital, Atlanta, GA, 2004
10. Cardiology Grand Rounds, Low Carbohydrate or Low Fat? (Or Somewhere in between): The Current Evidence. Grady Memorial Hospital, Atlanta, GA 2004
11. Medical Grand Rounds, Beyond LDL. St. Joseph's Hospital, Atlanta, GA, 2004
12. Cardiology Grand Rounds, Cardiac Complications of the Smallpox Vaccine Grady Memorial Hospital, Atlanta, GA, 2005
13. Medical Grand Rounds, Diets and CVD: Assessment of Current Evidence, Hamilton Medical Center, Dalton, GA, 2005
14. Grand Rounds, Emory-Dunwoody Hospital. Diets, Hypertension and CVD: Assessment of Current Evidence, Dunwoody, GA, 2005
15. Emory's Mini-Medical School, The Healthy Heart, Atlanta, GA, 2005
16. Cardiology Grand Rounds, Diets and Cardiovascular Disease: An Evidence-Based Assessment. Grady Memorial Hospital, Atlanta, GA, 2005
17. Medical Grand Rounds at Emory University Hospital, 55 yo F with Progressive Dyspnea on Exertion and Lower Extremity Edema; Discussant, Atlanta, GA, 2006
18. Cardiology Grand Rounds. LDL: Can We Go Too Low? Grady Memorial Hospital, Atlanta, GA, 2006
19. Cardiology Grand Rounds, Grady Memorial Hospital, Prehypertension: Detection, Evaluation, and Management, Atlanta, GA, 2008
20. Presentation at Emory Internal Medicine Board Review: Lipid Disorders, 2008.
21. Presentation at Grady Memorial Hospital Cardiology Grand Rounds, "Primary Prevention of Cardiovascular Disease, 2009
22. Presentation at Emory Center for Lifelong Learning, "Heart Disease Prevention", 2009
23. Presentation, Pathology and Laboratory Medicine Grand Rounds, "Advanced Lipid Testing," EUH, 2009
24. Presentation at Emory Internal Medicine Board Review: Lipid Disorders, 2009
25. Clinical outcomes and Epi Conference, "Surrogate Markers are Necessary for Clinical Practice and Research", 2009
26. Presentation at Emory Internal Medicine Board Review: Lipid Disorders, 2010
27. Cardiology Fellow's Core Conference, Lipid Disorders, 2011
28. Cardiology Fellow's Core Conference, Lipids, Risk Assessment, Cardiac Rehab, 2012
29. Heart and Vascular Grand Rounds, Time to focus on cardiovascular health (not disease), 2013
30. Grady Memorial Cardiology Grand Rounds, Time to focus on cardiovascular health (not disease), 2013
31. Cardiology Fellow's Core Conference. Office-based cardiovascular risk assessment: A perspective on the 2013 AHA/ ACC Prevention Guidelines. 2014
32. The Emory Clinic Primary Care Conference. Office-based cardiovascular risk assessment: A perspective on the 2013 AHA/ ACC Prevention Guidelines. 2014
33. Internal Medicine Housestaff Core Curriculum Conference. Office-based CV Risk Assessment: A perspective on the 2013 AHA/ ACC Prevention Guidelines. 2014

34. Emory Clinical Cardiovascular Research Institute Research conference. Office-based CV Risk Assessment: A Perspective on the 2013 ACC/ AHA Prevention Guidelines. 2014
35. Emory-Pfizer Atrial Fibrillation Seminar: Atrial Fibrillation- Diagnosis & Consequences, 2014
36. Department of Medicine Education Community Orientation. Teaching in the Inpatient Environment. 2014
37. Cardiology Fellow's Core Conference: Treatment of Blood Cholesterol: New Approaches / New Agents, 2015
38. Department of Medicine Education Community Orientation. Teaching in the Inpatient Environment. 2015
39. Emory Specialty Associates for Primary Care Quarterly Best Practice CME lecture/ webinar. Treatment of Blood Cholesterol: New Approaches/ New Agents. 2015
40. 6th Annual Mark Silverman invited lecture. Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement. Grady Memorial Hospital. 2015
41. ACC Cardiosmart Program. Managing Cholesterol. Atlanta, GA. 2015
42. Medical Grand Rounds, Emory University Hospital, Update in Preventive Cardiology, 2016
43. Cardiology Grand Rounds, Emory St. Joseph's Hospital, Preventive Cardiology & the Future of Cardiovascular Medicine: Opportunities for Improvement, 2016.
44. Cardiology Fellow's Core Conference: Lipids and Atherosclerosis. 2016
45. Cardiology Fellow's Core Conference: Cardiovascular Risk Assessment; Comprehensive Risk Reduction in Metabolic Syndrome & Diabetes; Diets and Cardiovascular Disease. 2016
46. Emory Cardiovascular Grand Rounds, Preventive Cardiology & the Future of CV Medicine: Opportunities for Improvement, 2016
47. Emory Department of Medicine, Fellows Educator Development Conference, Teaching in the Inpatient Environment, 2017
48. Emory School of Medicine Society Advisor Grand Rounds, Academic Pursuits as an Extension of Medical Education, 2017
49. Emory University Rollins School of Public Health, Hubert Department of Global Health Seminar, Reconfiguring Cardiac Rehabilitation & Secondary Prevention into a New Care Model for the New World, 2017
50. Cardiology Fellows' Core Conference: Preventive Cardiology, 2017
51. Emory Alumni Association Lifelong Learning Faculty Webinar: Heart Healthy Diets: A Recipe for Life, 2017
52. Emory Univ. School of Medicine Learning to be Better Teachers Conference, "Academic Pursuits as an Extension of Medical Education", 2017
53. Presentation to the Emory Employee Council, Health, Wellness, Mindfulness, and Movement. 2018
54. Presentation to the Office of Clinical Research- Research Matters meeting. Health, Wellness, Mindfulness, and Movement. 2018
55. Guest lecture in Cardiovascular Disease Epidemiology, Rollins School of Public Health, Preventive Cardiology & the Future of CV Medicine, 2018
56. Guest lecture in Chronic Disease Prevention and Control (NCDs), Rollins School of Public Health, Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World, 2018

57. Department of Medicine Mentoring Series: How to Determine your Academic Niche as a Clinician, 2018
58. Guest lecture, Emory College Center for the Study of Human Health, Nutrition and Chronic Disease CHSS-320, Diets and Cardiovascular disease: A Recipe for Life, 2017 and 2018
59. Emory University School of Medicine, Society Advisor Grand Rounds, Health, Well-being, Mindfulness, and Movement. 2018.
60. Emory Monthly Primary Care Forum. The 2018 Cholesterol Guidelines, 2019
61. Emory College Course-Introduction to Predictive Health, predicting Cardiovascular Health and Disease, 2019
62. Guest lecture, Emory Interdisciplinary Studies Course, Eating Ethics, Heart Healthy Dietary Patterns: A Recipe for Life, 2019
63. Invited faculty speaker, Emory Phi Eta Sigma Freshman Honor Society Scholarship night, 2019
64. Guest Lecture, Emory Rollins School of Public Health, Cardiovascular Epidemiology, Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement, 2019
65. Guest lecture, Rollins School of Public Health, Chronic Disease in Global Health, Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World, 2019
66. Emory Rollins School of Public Health Seminar, The Future of Cardiovascular Disease Prevention, 2019
67. Guest lecture, Emory Interdisciplinary Studies Course, Eating Ethics, Heart Healthy Dietary Patterns: A Recipe for Life, 2020
68. Guest lecture, Rollins School of Public Health, Chronic Disease in Global Health, Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World, 2020
69. Guest lecture, Rollins School of Public Health, Cardiovascular Disease Epidemiology, The Future of Cardiovascular Prevention, 2020
70. Emory Cardiology Grand Rounds, The (Post-COVID) Future of Cardiovascular Medicine, 2020
71. Emory Goizueta Alzheimer's Disease Research Center Webinar, The State of Men's Health. Focus on Men's Cardiovascular Health, 2020
72. Emory School of Medicine M1 Class lecture, Integrated Human Physiology Module, Exercise and the Healthy Human; Director SOM Virtual Fun Run Week, 2020
73. Emory-Clifton Rotary Club 3rd Annual Polio & Health Symposium: Overcoming the Challenges of COVID-19 to Achieve a Global Health Legacy. The (Post-COVID) Future of Cardiovascular Disease Prevention, 2020
74. Emory University Emeritus College Luncheon Colloquium, Heart Healthy Dietary Patterns: A Recipe for Life, 2020
75. CDC DHDSP / NCCDPHP Moderated Panel Discussion- Racial Discrimination, Resilience, and Cardiovascular Risk, 2020
76. Conversations with CDC Authors: Social Determinants of Health- Disparities in Influenza Vaccination- Opportunity to Extend Cardiovascular Prevention to Millions of Hearts, 2020
77. Guest lecture, Rollins School of Public Health, Genetic Epidemiology, Familial Hypercholesterolemia: From Gene discovery to Population Health Impact, 2021

78. Guest lecture, Rollins School of Public Health, Cardiovascular Epidemiology 543. The (Post-COVID)Future of CVD Prevention, 2021
79. Emory University Hospital Midtown, Medicine Faculty Peer Mentoring Group, How to Determine Your Academic Niche as a Clinician, 2021
80. CDC DHDSP Science Office: CVD 101- Enduring Video for Staff Orientation, 2021
81. Emory University Alumni Global 60+ Network Series, Cardiovascular Health: Living Longer and Better, 2022
82. Guest lecture, Emory Rollins School of Public Health, Cardiovascular Epidemiology 543. The (Post-COVID) Future of CVD Prevention, 2022
83. Moderator, CDC DHDSP Science Seminar, Trends in Heart Failure-related Mortality in Young Adults in the U.S., 2022
84. Guest lecture, Emory University Interdisciplinary Studies Course, Eating Ethics, Heart Healthy Dietary Patterns: A Recipe for Life, 2024
85. Clinical Correlations in Lipids and Atherosclerosis, M1 Cardiology module, 2024
86. Guest lecture, Rollins School of Public Health, CV Epidemiology 543, The (Post-COVID) Future of CVD Prevention, 2024
87. Emory Department of Medicine Grand Rounds, Focus on CKMH to PREVENT CVD, 2024
88. Emory Univ School of Medicine; Orientation of M1 Students- People who Inspire- Session, 2025
89. Grady Hospital Interdisciplinary Stroke Conference, 2026
 - a. Atlanta Hypertension Initiative: Controlling BP in viTAL to ATL

24. **Invitations to National or International Conferences:**

1. AACVPR 12th Annual National Meeting, New Frontiers in Preventive Cardiology Session, Pathogenesis of Atherosclerosis, Dallas, TX, 1997
2. 12th Annual Kentucky Coalition of Nurse Practitioner Conference, Managing Lipid Disorders, Louisville, KY, 2000
3. Merck Regional Consultant's meeting, Inflammation in Atherosclerosis, Toronto, Canada, 2001
4. Merck Regional Consultant's meeting, New insights into Lipid Therapy, Panama City Beach, FL, 2001
5. Leaders of Emerging Science of Lipid Management Mid-Atlantic Regional Working Group Meeting. Low-Carbohydrate and Mediterranean Diets: Assessment of the Current Evidence, Washington, DC, 2003
6. AACVPR 18th Annual Meeting, The Primary Prevention of Cardiovascular Disease: Focus on the Guidelines, Kansas City, MO, 2003
7. Current Trends in Cardiovascular Disease VIII, Beyond LDL (Keynote Speaker), Spokane, WA, 2004
8. 15th Annual Convention ACC Puerto Rico Chapter, New Frontiers in the Management of Hypertension and Dyslipidemia, San Juan, Puerto Rico, 2004
9. 145th Annual Session for The American Dental Association, Distinguished Speaker Series, Men's Conference. Risk Reduction in Cardiovascular Disease, Orlando, FL, 2004
10. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Cardiac events following smallpox vaccination, Washington, DC, 2004
11. Council of Science Editors Meeting, Readers Speak Out, Atlanta, GA, 2005

12. Johns' Hopkins CME at Sea, workup of Suspected Coronary Disease: Assessment of Cardiovascular Risk; Cholesterol Management; Anticoagulant And Antiplatelet Therapy, Holland America (MASDAM), 2005
13. Nephrology and Transplantation Update 2005 for NKFG, Beyond LDL, Ponte Vedra Beach, FL, 2005
14. LDL Apheresis, Hoxworth Blood Center, University of Cincinnati, 2006
15. 55th Annual ACC meeting. Role of Inflammation and the Immune System in Atherosclerosis, Atlanta, GA, 2006
16. 24th Annual Central American Congress of Cardiology. Primary Prevention and CAD, Havana, Cuba, 2006
17. 39th Annual ACC Foundation New York Cardiovascular Symposium. Diets and Overweight: An Evidence-Based Assessment, New York, NY, 2006
18. 56th Annual American College of Cardiology meeting, Which Diet is Best for Obesity? New Orleans, LA, 2007
19. ACC Pri-med Initiative: Clinical Focus on Cardiovascular Risk, Atlanta, GA, 2008
20. World Congress of Cardiology, Which diet is best for obesity? Buenos Aires, Argentina, 2008
21. SCAI Strategies for Success XVI meeting, The Economics of a Preventive Cardiology Program for your Practice, Cayman Islands, BWI, 2008
22. National AHA meeting, The View from Framingham: The Basis of ATP3 and ATP3.5, New Orleans, LA, 2008
23. Invited speaker for the AHA Quality of Care and Outcomes Research Conference, Surrogate Outcomes in clinical research and Practice, Washington, D.C., 2009
24. Invited speaker for the American Heart Association's spotlight series on Mixed Dyslipidemias, 2009
25. Invited participant 8th Annual Nitroglycerin Symposium, Hamburg, Germany, 2009
26. Meet the Expert Presentation at National American College of Cardiology meeting, "Educational Initiatives of the ACC", Orlando, FL, 2009
27. National Lipid Association meeting, Non-HDL: Do the Math....., Washington, D.C., 2009
28. HIV DART meeting, HIV, Inflammation, and Cardiovascular Disease, Cabo San Lucas, Mexico, 2010
29. 60th American College of Cardiology meeting, Lipid Management in the Elderly, New Orleans, LA, 2011
30. 6th Annual Europrevent meeting, Diets and Cardiovascular Disease: An Evidence-based Assessment, Geneva, Switzerland, 2011
31. 7th American College of Cardiology / Sociedad Espanola de Cardiologia Official Joint Meeting. Dyslipidemia challenges: optimal LDL, HDL, and triglycerides. Washington, D.C., 2011
32. Evolving Challenges in Promoting Cardiovascular Health (sponsored by the New York Academy of Sciences). Optimal Lipid Targets (OLT) for the New Era of Cardiovascular Prevention. Barcelona, Spain, 2011
33. 11th Annual Cardiology Conference at Mohonk. The New York Cardiological Society. Diets and CV Disease: An Evidence-Based Assessment, New Paltz, N.Y., 2012

34. 38th Annual Tutorials in the Tetons Conference. Office-based cardiovascular risk assessment; Optimal Lipid targets in the new era of cardiovascular prevention. Jackson, WY, 2012
35. American Society of Preventive Cardiology Update 2012. Office-based cardiovascular risk assessment; Increasing awareness and approach to the patient with familial hypercholesterolemia. Chicago, Illinois, 2012
36. 51st Romania National Congress of Cardiology. Global Challenges in cardiovascular prevention: The polypill or public health? Sinaia, Romania, 2012
37. 51st Romania National Congress of Cardiology. From the American “dream” to Romanian reality: Focus on cardiovascular prevention. Sinaia, Romania, 2012.
38. 51st Romania National Congress of Cardiology. From prevention to intervention- to be or not to be? Prevention in the U.S. measure for measure. Sinaia, Romania, 2012.
39. 11th Annual Cardiovascular Disease Prevention International Symposium. The optimal diet for cardiovascular health. Miami, FL. 2013
40. 11th Annual Cardiovascular Disease Prevention International Symposium. The role of exercise in cardiovascular disease risk reduction: Does it make a difference? Miami, FL. 2013
41. Invited presenter. Familial Hypercholesterolemia Roundtable. New Orleans, LA. 2013
42. Panelist in session: Managing statin side effects and complications, American College of Cardiology meeting. San Francisco, CA. 2013
43. GE Medical Council Conference. Time to focus on Cardiovascular Health (Not Disease). Atlanta, GA. 2013
44. Europrevent 2013. Optimal Lipid Targets for the New Era of Cardiovascular Prevention. (Poster Judge) Rome, Italy. 2013
45. Inaugural U.S. Familial Hypercholesterolemia Summit. Steering committee member and moderator of opening session. Annapolis, MD. 2013
46. Cardiology Divisional Rounds. Time to focus on cardiovascular health (not Disease). Mazankowski Alberta Heart Institute, Alberta, Canada. 2013
47. 8th Cardiometabolic Health Congress. Moderator of session- Cardiometabolic risk in racial/ethnic minorities: unique aspects and practical solutions. Presentation- Lifestyle Management. Boston, MA. 2013
48. Kansas City Southwest Clinical Society's 91st Annual Clinical Care Conference. Time to focus on cardiovascular health (not disease). Kansas City, KS. 2013
49. Cardiology Grand Rounds, University of California Irvine. Office-based cardiovascular risk assessment: A perspective on the 2013 AHA/ ACC Prevention Guidelines. 2013
50. Preventive Cardiology Seminar. UC Irvine. Time to focus on cardiovascular health (not disease). 2013
51. Preventive Cardiology of Orange County meeting, California chapter of the ACC. Office-based cardiovascular risk assessment: A perspective on the 2013 AHA/ ACC Prevention Guidelines. 2013
52. 50th Research Day-The Heart of Medicine, invited speaker. Ross University School of Medicine. Time to focus on CV Health (not CV Disease). Dominica, WI. 2014
53. 63rd American College of Cardiology meeting, Washington, D.C. 2014

- a. Prevention Intensive: Sorting out Risk Prevention in 2014- Prevention Risk Assessment Tools: Practice Changers
 - b. Co-Chair and moderator of International session- Conquering Healthcare Challenges in the Emerging World
54. World Congress of Cardiology. Melbourne, Australia. 2014
- a. Overview of non-traditional biomarkers in CVD risk assessment
 - b. Co-Chair: Global patterns and health consequences of cardiometabolic risk factors
 - c. Co- Chair: Use of risk factor surveys in health policy development
55. 3rd Annual American Society for Preventive Cardiology Cardiovascular Disease Prevention Conference. Boca Raton, FL. 2014
- a. Familial Hypercholesterolemia: Hidden in Plain Sight-Current and Novel Approaches
 - b. Participant in ACC/ AHA Guideline Dialectic
56. International Academy of Cardiology 19th World Congress on Heart Disease, Boston MA, 2014
- a. Invited member of scientific executive committee
 - b. Co-chair of Plenary session on CVD Prevention and Risk factors
 - c. Time to Focus on CV Health (not CV Disease)
57. European Society of Cardiology Congress, Barcelona Spain, 2014
- a. Familial Hypercholesterolemia: Hidden in Plain Sight; Current Treatment Approaches
 - b. Moderated poster judge: Addressing the challenges of cardiac rehabilitation
 - c. Rapid fire oral abstract session chair: Diabetes under siege
58. Visiting Professor, Johns Hopkins Ciccarone Prevention Center. Baltimore, MD. 2014
- a. Familial Hypercholesterolemia: Hidden in Plain Sight- Diagnosis, Management, and Focus on LDL Apheresis
59. Cardiovascular Disease Prevention Joint meeting with the Moroccan Society of Cardiology: New Guidelines and Global Strategies for Reducing Cardiovascular Risk, El Jadida, Morocco. 2014
- a. Time to Focus on Cardiovascular Health (not Disease)
 - b. Session Chair: Guidelines for Europe and America: Understanding the Differences
 - c. Are Current Guidelines Relevant or Helpful?
60. 25th Great Wall of China- International Cardiovascular Conference. Beijing, China. 2014
- a. 2013 ACC/ AHA Guideline on the Assessment of Cardiovascular Risk
 - b. Session Chair: ASPC @ GW-ICC: New Prevention of Cardiovascular Disease Guidelines
 - c. Overview of the ACC/ AHA Cholesterol Management and JNC-8 Blood Pressure Guidelines

61. 9th Annual Cardiometabolic Health Congress. Boston, MA. 2014
 - a. Session Chair: Confronting Racial and Ethnic Disparities in Cardiometabolic Disease
 - b. Epidemiological Profiles of Racial and Ethnic Disparities in Cardiometabolic Disease
62. Anandi L. Sharma Visiting Professorship & Simon Dack, M.D. Memorial Lecturer, Mt. Sinai Medical Center, New York, N.Y. 2014
 - a. Time to Focus on Cardiovascular Health (Not CV Disease)
 - b. Controversies in Cardiology Session- Cholesterol Goals and Targets: Should we IMPROVE-IT?
63. HIV DART (Frontiers in Drug Development for Antiretroviral Therapies) 2014. Protecting the Heart during HAART. Key Biscayne, FL. 2014
64. American College of Cardiology Cardiovascular Summit: Solutions for Thriving in a Time of Change. Orlando, FL. 2015
 - a. Academic Realities in a New Economic World: Strategies to Preserve all the Missions
 - b. Case Studies in Disease Management: Doing Well by Doing Good: The Successful "Business" of a Preventive Cardiology Program
65. American Heart Association Epi/ Lifestyle meeting. Baltimore, MD. 2015
 - a. Moderator of ASPC Annual Debate- New Blood Pressure Guidelines (JNC 8): Right or Wrong?
 - b. Presented The William B. Kannel Memorial Lecture to Dr. Daniel Levy
 - c. Presented the 20th ASPC Joseph Stokes III Award to Dr. Virgil Brown
66. 64th American College of Cardiology meeting, San Diego, CA. 2015
 - a. A Seaside Chat with the Experts: Fighting Fats and Kicking "butts": How do we prescribe diet and help our patients quit smoking?
67. 7th Annual Advance in Heart Disease Prevention and Rehabilitation. Beaumont Health System. Time to focus on cardiovascular health (not CV disease). Troy, MI. 2015
68. Visiting Professor, Cardiology Grand Rounds, Weill Cornell Medical Center. Time to Focus on Cardiovascular Health (Not CV Disease). New York, N.Y., 2015
69. Visiting Professorship, Cardiology Grand Rounds, Stony Brook Medical Center. Time to Focus on Cardiovascular Health (Not CV Disease). Stony Brook, N.Y. 2015
70. Visiting Professorship, Cardiology Grand Rounds, Lynchburg General Hospital, Centra Heart & Vascular Center. Preventive Cardiology & the Future of Cardiovascular Medicine: Opportunities for Improvement. Lynchburg, VA. 2015
71. 28th Annual International Cardiovascular Disease Prevention Symposium
 - a. Co-Chair of joint session with the Ecuadorian Society of Cardiology, Quito, Ecuador
 - b. Time to Focus on CV Health (Not CV Disease), Quito, Ecuador. 2015

- c. Familial Hypercholesterolemia: Hidden in Plain Sight- Current & Novel Approaches; Joint Session with the Peruvian Society of Cardiology, Lima, Peru. 2015.
- 72. International Academy of Cardiology 20th Annual World Congress on Heart Disease, Vancouver, Canada. 2015.
 - a. Member of Scientific Executive Committee
 - b. Co-Chair of Session- Assessment & Management of CV Risk/ Modification of Lipoproteins
 - c. CAC Testing in 2015: Role in Shared Decision Making?
 - d. Cholesterol Goals & Targets: Opportunities for Improvement
- 73. American Society for Preventive Cardiology CV Disease Prevention Conference, Boca Raton, FL. 2015
 - a. Conference Co-Chair
 - b. Expert's Course- Time to Focus on Cardiovascular Health (Not Disease)
 - c. Risk Assessment-Have we Over-simplified the Task of Risk Stratification?
- 74. European Society of Cardiology Congress, London England, 2015
 - a. Debate- Are there metabolically healthy obese patients? Contra
 - b. Statin- Still the best preventive drug?
 - c. Chair of session- Diabetes Management: The way to control atherosclerosis
- 75. Moderator of session at American Society of Nuclear Cardiology meeting, Washington, D.C., 2015
 - a. Nuclear Cardiology in a Value system: Choosing the best test wisely
- 76. Sulpizio Cardiovascular Center Grand Rounds, UC San Diego , 2015
 - a. Preventive Cardiology & the future of Cardiovascular Medicine: Opportunities for Improvement
- 77. American Society for Preventive Cardiology's 7th Annual Orange County Symposium on Prevention of Cardiovascular Disease, Costa Mesa, CA. 2015
 - a. Roundtable Case Discussion- How do I best assess CVD Risk?
 - b. Focus on Cardiovascular Health(Not Disease)
- 78. The First China-US Cardiac Rehabilitation Forum: The 7th Jilin Provincial Atherosclerosis Conference. Changchun, China. 2015
 - a. Preventive Cardiology & the Future of Cardiovascular Medicine: Opportunities for Improvement
- 79. ACC Summit: Solutions for Thriving in a time of Change. Las Vegas, NV, 2016
 - a. National Drivers: Population Health- How to build a successful preventive cardiology program
 - b. Primary prevention program- A model that works
- 80. American Heart Association Epi/ Lifestyle meeting. Phoenix, AZ. 2016
 - a. Moderator of ASPC Annual Debate- WHO Sugar Guidelines
 - b. Presented The William B. Kannel Memorial Lecture to Dr. Peter Wilson
 - c. Presented the 21st ASPC Joseph Stokes III Award to Dr. Aaron Folsom

81. Jim Pattison Cardiac Rehabilitation Symposium sponsored by Mazankowski Alberta Heart Institute. Banff, BC, Canada, 2016
 - a. Comprehensive Cardiovascular Risk Reduction in Diabetes & the Metabolic Syndrome
82. The Future of Medicine Centura Health Conference. Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement. Colorado Spring, CO. 2016
83. World Congress of Cardiology and Cardiovascular Health. Mexico City, Mexico. 2016
 - a. Cardiac Rehabilitation & Preventive Cardiology: Time to Reinvent and Reinvigorate
 - b. Reconfiguring Cardiac Rehabilitation & Secondary Prevention into a New Service Model for a New World
84. Slovenian Society of Cardiology meeting. Ljubljana, Slovenia. 2016
 - a. Co-Chair session on Cardiovascular Prevention
 - b. Comprehensive cardiovascular risk reduction in the metabolic syndrome and diabetes
 - c. Preventive Cardiology & the Future of Cardiovascular Medicine: Opportunities for Improvement
85. 21st World Congress on Heart Disease. Boston, MA. 2016
 - a. Comprehensive cardiovascular risk reduction in the metabolic syndrome and diabetes
 - b. Co-Chair session on risk stratification and secondary prevention of CVD
86. European Society of Cardiology Congress, invited presentations, Rome, Italy, 2016
 - a. Evolution of the metabolic syndrome: Therapy by Stages
 - b. State of the art: Cardiobesity
87. American Society for Preventive Cardiology Expert's Course, Boca Raton, FL, 2016
 - a. Time to change our focus on optimal cardiovascular population health
88. American Society for Preventive Cardiology National Congress, Boca Raton , FL, 2016
 - a. Chair & Moderator of Young Investigator Presentations
 - b. Moderator of Keynote address session: Rethinking Dietary Fat
89. Sharp Grossmont Hospital Heart and Vascular Conference, San Diego, CA, 2016
 - a. Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement
90. 6th Asian Preventive Cardiology and Cardiac Rehabilitation Conference, Hong Kong, 2016
 - a. Hong Kong Heart Foundation Lecture- Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement
 - b. Diets and Cardiovascular Disease: An Evidence-based Assessment

- c. Treatment of Blood Cholesterol: New Approaches / New Agents
- d. The Art of Cardiovascular Risk Assessment
- 91. Invited presentation, Bart's Heart Centre, Preventive Cardiology and the Future of CV Medicine : Opportunities for Improvement, London, UK, 2016
- 92. Invited presentations, Imperial College, London, UK, 2016
 - a. Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement
 - b. The Art of CV Risk Assessment
- 93. 66th American College of Cardiology Meeting, Washington, D.C., 2017
 - a. Moderated Poster Judge- Obesity Management 2017: Weighing the Issues
 - b. Intensive Co-Chair- Are we there yet? The Long Journey to Health Equity
- 94. Cardiology Grand Rounds at the University of California San Francisco, 2017
 - a. Preventive Cardiology & the Future of CV Medicine: Opportunities for Improvement
- 95. Cardiology Grand Rounds, University of Minnesota Lillehei Heart Institute, Minneapolis, MN, 2017
 - a. Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement
- 96. Long Island State of the Art Cardiovascular Care for the Clinician. Melville, N.Y., 2017
 - a. Management of Blood Cholesterol: New Approaches / New Agents
- 97. National Lipid Association Annual Scientific Sessions, Philadelphia, PA, 2017
 - a. The Perplexing Exception of Lipoprotein-X Disease
- 98. Visiting Professorship, University of Nebraska Medical Center, Omaha, NE, 2017
 - a. Cardiology Grand Rounds- Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement
- 99. American College of Cardiology Managing CV Disease Risk in Diabetes Heart House Roundtable
 - a. Co-Chair
 - b. Adapting the "Heart Team" Approach for the Care of High-Risk Patients with T2DM
- 100. European Society of Cardiology meeting, Barcelona, Spain, 2017
 - a. Moderator for Poster Session Hypertension and Bedtime Stories
- 101. 1st International Symposium of the Kangbuk Samsung Diabetes and Vascular Center, Seoul, Korea, 2017
 - a. Preventive Cardiology and the Future of Cardiovascular Medicine: Focus on Comprehensive Risk Reduction in the Metabolic Syndrome and Diabetes
- 102. Familial Hypercholesterolemia (FH) Global Summit: Diagnosis, Treatment, and Access Across Diverse Populations, Miami, FL, 2017
 - a. Women and FH: Physician and Patient's Perspective
 - b. U.S. Representative for The Meeting of the Americas
- 103. Northwell Healthcare Invited presentations, New York, 2017

- a. Fellow's Journal Club, Lenox Hill Hospital
- b. Cardiology Grand Rounds, Northshore University Hospital, Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement
- 104. 9th Annual Sharp Grossmont Heart & Vascular Conference, San Diego, CA, 2017
 - a. Heart Healthy Dietary Patterns: A Recipe for Life
 - b. Management of Blood Cholesterol: New Approaches/ New Agents
- 105. ACC Global ASCVD Primary Prevention, Buenos Aires, Argentina, 2017
 - a. Risk factor burden and risk assessment of Cardiovascular Disease
- 106. 15th World Congress on Insulin Resistance, Diabetes, and CV Disease. Los Angeles, CA, 2017
 - a. Is "Extreme Risk" a Valid and Viable Cardiovascular Risk Category?
- 107. 67th American College of Cardiology Scientific Sessions, Orlando, FL. 2018
 - a. Session Co-Chair: Ensuring a bright future for patients with T2DM: Comprehensive Risk Management
 - b. Presentation- "Evolving role of the CV Clinician in Management of CVD Risk in T2DM
 - c. Presentation in Clinical Focus Session- "Who is involved: Your role in championing comprehensive diabetes care"
 - d. ACC Prevention Section Highlights "Top # presentations in diabetes most likely to impact or change clinical practice or research agendas"
 - e. ACCEL interview: " There's no sugar coating the new reality: Changing Paradigm for CVD risk reduction in T2DM
- 108. Association of Physician Assistants in Cardiology National Meeting, Atlanta, GA. 2018
 - a. Management of Blood Cholesterol: New Approaches / New Agent
- 109. Mazankowski Alberta Heart Institute Jim Pattison Cardiac Rehabilitation Symposium, Banff, Canada. 2018
 - a. Cardiac Rehabilitation and Secondary Prevention: New Care Models for a New World
- 110. Preventive Cardiology Grand Rounds, The Mayo Clinic, Rochester, MN, 2018
 - a. Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement
- 111. Visiting Professor for the 6th Emory-Tibet Medical Sciences Program, Men-Tsee-Khang School of Medicine, Dharamsala, India, 2018
 - a. Nutrition and Cardiovascular Risk Factors
- 112. 1st Annual SCCT / ASCP Cardiovascular Disease Prevention Symposium, Dallas, TX, 2018
 - a. Challenging Lipid/ Prevention Cases: Panel Discussion
 - b. Which patients should be treated with PCSK9 Inhibitors in 2018?
- 113. U.S. Center for Disease Control and Prevention's Science Seminar, Division for Heart Disease and Stroke Prevention, Atlanta, Ga, 2018
 - a. Management of Blood Cholesterol: New Approaches / New Agents

114. European Society of Cardiology Congress, Munich, Germany, 2018
 - a. The Year in Hypertension: Hot Papers in Epidemiology and Risk
115. Pre-meeting Session for AHA. Sex and Gender Influence on Cardiovascular Disease. Differences in Atherosclerotic Risk Factors in Men. Chicago, 2018.
116. American Heart Association Scientific Sessions, Chicago, 2018.
 - a. Presented 2018 Cholesterol Guidelines in Main Session, Statin Safety and Statin Associated Side Effects
 - b. Poster Professor, Cardiovascular Epidemiology
117. NIH/ NHLBI Reducing the Population Burden of Familial Hypercholesterolemia (FH): A Prototype for Translational Research and Implementation Science in Genomics and Precision Medicine Workshop. Assessing Current Treatment Options for FH: Improving Outcomes for Patients Transitioning from Pediatrics to Adult Health Care. Bethesda, MD. 2018.
118. 15th Global Cardiovascular Clinical Trialists Forum. CVCT-NHLBI Joint workshop- Maximizing the Impact of Clinical Trial Findings: NIH Funding Opportunities for Dissemination & Implementation Research. Grand Challenges: Clinical Trial Findings and Quality Cardiovascular Health Care Delivery. French Embassy, Washington, D.C. 2018
119. American College of Cardiology Second Heart House Roundtable on Managing CV Disease Risk in Diabetes. Washington, D.C. 2018
 - a. Co-Chair
 - b. Protecting the Heart of the Patient with Type 2 Diabetes: Insights from the Cardiology Community
120. Cardiovascular Grand Rounds, University of Chicago, 2018
 - a. Preventive Cardiology and the Future of Cardiovascular Medicine: Opportunities for Improvement
121. Vu-Medi Webinar- ASCP Update on the 2018 Cholesterol Guidelines, 2019
 - a. Approach to Risk Assessment and Shared Decision Making
122. Cardiology Grand Rounds, Cleveland Clinic of Florida, Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement, 2019
123. 68th American College of Cardiology Scientific Sessions, New Orleans, LA, 2019
 - a. Tell me the Facts about the 2018 Cholesterol Guidelines: Diabetes and Lipid Lowering Therapy
 - b. Overview of the WHF / IDF Diabetes Roadmap
 - c. Use of Non-Statins Therapies in Secondary Prevention: Evidence and Guidelines
 - d. Co-Chair of Session: Changing Paradigm in CV Risk Reduction in Diabetes
 - e. ACCEL Interview: Diabetes and Lipid Lowering Therapy
 - f. Secondary Prevention of CAD in Diabetic Patients
 - g. Prevention Section Meeting Highlights: Top 3 Presentations in Diabetes Most Likely to Impact or Change Clinical Practice or Future Research Agenda

124. Europrevent , European Congress on Preventive Cardiology, Lisbon, Portugal, 2019
 - a. Primary Cardiovascular Disease Prevention: Understanding International Guidelines
125. 26th Annual NMHI Current Concepts in Cardiovascular Disease. Albuquerque, NM, 2019
 - a. Lessons from the 2018 Cholesterol Guidelines
 - b. Cases in Preventive Cardiology workshops
126. 72nd World Health Assembly Event sponsored by World Heart Federation- Joining Forces to Fight CVD in People with Diabetes: Pathways to Solutions (Moderator), Geneva, Switzerland, 2019
 - a. Setting the Scene- Focus on CV Prevention in Diabetes / The WHF/ IDF Roadmap
127. American College of Cardiology Cardiovascular Health Promotion Course, Heart House, Washington, D.C., 2019
 - a. New Diabetes Therapies: When should the Cardiovascular Clinician Prescribe and Who should follow up?
 - b. Hitting the Easy Button: Conversations with Your Patient- The Latest Approaches for the Comprehensive management of DM2
128. Association of Black Cardiologists Access Roundtable Regroup, Heart House, Washington, D.C., 2019
 - a. Overcoming Access to Newer Diabetes Therapies: Importance of the Cardiologist
129. University of California Irvine, Irvine, CA, 2019
 - a. University Grand Rounds- Time to Focus on Cardiovascular Health (Not CV Disease)
 - b. Preventive Cardiology of Orange County meeting- Strategies to Manage Residual Risk in Patients with or at High Risk of CV Events
 - c. Cardiology Grand Rounds- Preventive Cardiology and the Future of CV Medicine: Opportunities for Improvement
130. 3rd Annual Heart in Diabetes meeting, Philadelphia, PA, 2019
 - a. Scientific Committee member
 - b. Co-Chair Session on Management & Prevention of ASCVD
 - c. Lessons from the 2018 Cholesterol Guidelines: Focus on Diabetes
131. American Society for Preventive Cardiology Congress on CVD Prevention, San Antonio, Texas, 2019
 - a. Moderator of Young Investigator Awardees Session
 - b. Panelist- Session on Prevention Guidelines and Cases
 - c. Co-Chair Session on Exercise and Preventive Practice
 - d. Presentation- “ Doing well by doing good: The Business of CV Prevention
132. European Society of Cardiology Congress / World Congress of Cardiology, Paris, France, 2019

- a. Tackling the Growing Burden of Diabetes and Cardiovascular Disease: Introducing the Roadmap on CVD Prevention among People Living with Diabetes
- 133. Inaugural NASH Leadership Forum, Washington, D.C., 2019
 - a. NAFLD and the Heart (Cardiovascular Linkage)
- 134. Preventive Cardiology Summit for Fellows, Chicago, IL, 2019
 - a. Approach to Cardiovascular Risk Assessment
 - b. The Interplay between Diabetes and Cardiovascular Disease
- 135. Case Western Reserve Harington Heart & Vascular Institute 13th Annual Cardiovascular Disease Update, Cleveland, OH, 2019
 - a. PCSK9 Inhibitors: New Data and Guideline Recommendations
- 136. 7th FH Global Summit, Familial Hypercholesterolemia: A Prototype for Precision Public Health, Atlanta, GA, 2019
 - a. Disparities in Care in FH
- 137. National Forum for Heart Disease & Stroke Prevention 17th Annual Meeting. Washington, D.C., 2019
 - a. Million Hearts 2022
- 138. HEP DART 2019. NAFLD and the Heart. Kauai, Hawaii. 2019
- 139. University of California San Diego Grand Rounds, The Future of Cardiovascular Prevention. San Diego, CA, 2020
- 140. National Press Foundation Event, Covering the Heart Beat, Million Hearts 2022. Palm Beach, FL, 2020
- 141. Million Hearts Collaborative Meeting, Million Hearts: Initiatives, Goals, and Priorities for 2020. Washington, D.C., 2020
- 142. Keynote Presentation, Mid-America Million Hearts Conference. Million Hearts 2022: How do we achieve the Million Heart's Vision in Mid-America? Blue Springs, MO, 2020
- 143. 20th Annual National Sarasota Congress on Cardiovascular Disease Prevention: Update 2020. Sarasota, FL, 2020
 - a. Risk Assessment Tools for Primary Cardiovascular Disease Prevention
 - b. Diabetes and Cardiovascular Disease (American College of Cardiology's Expert Consensus Decision Pathway)
- 144. CMS Quality Conference. Million Hearts 2022: Outcomes, Initiatives, and Focus on Quality Improvement. Baltimore, MD, 2020.
- 145. National Forum for Heart Disease and Stroke Prevention, Mid-Year meeting, Improving BP Control at the Community Level- Million Hearts Hypertension Control Champions, Webinar, 2020
- 146. American Heart Association / CDC COVID-19 Update for Healthcare Professionals, Webinar, 2020
- 147. Whole Health Cure Podcast, 100th Episode, The Heart of Cardiovascular Prevention, 2020

148. Health Resources & Services Administration (HRSA) National Men's Health Week Webinar, Heart to Heart. Million Hearts and Men's Cardiovascular Health, 2020.
149. Missouri Department of Health and American Heart Association Webinar, Provider's Perspective: Hypertension and COVID-19, Million Hearts 2022: Focus on Hypertension Control, 2020.
150. American Society for Preventive Cardiology 2020 Virtual Summit, Million Hearts: Moving the Prevention Needle for the Population, 2020
151. American Heart Association Million Hearts Collaboration Virtual Quarterly Meeting, Executive Director Update, 2020
152. Right Care Virtual University of Best Practice Symposium, Keynote Address, The (Post-COVID) Future of Cardiovascular Disease Prevention, 2020
153. Partnership to Advance Cardiovascular Health National Webinar, Pandemic Lessons- What COVID-19 Revealed About America's Healthcare System, Continuity of Care and the Promise of Telemedicine, 2020
154. Health Resources and Service Administration / Federal Office of Rural Health Care Services and Policy-Virtual Seminar. Cardiovascular Health and Prevention Remain a Priority in the Midst of a Pandemic. 2020
155. 4th Annual Heart in Diabetes Virtual Scientific Meeting, 2020
 - a. Member of Scientific Committee, Session Chair, and Oral Abstract Judge
 - b. The Impact of COVID-19 on Cardiovascular Care and the Post-Pandemic Future of Cardiovascular Prevention
 - c. NAFLD and the Heart as a Part of the Spectrum of Cardiometabolic Risk
156. American Heart Association House Calls: Real Docs, Real Talk: Focus on COVID and the Heart, 2020
157. CDC Business Health Executive Quarterly Meeting, Virtual, Million Hearts 2022- Breaking News, 2020
158. Association of Black Cardiologist Webinar: Avoiding Heartbreak- COVID-19 Complications and Risk Mitigation in Diverse Populations; Structural Racism, COVID-19, and Healthcare, panelist, 2020
159. 35th Annual American Association of Cardiopulmonary Rehabilitation Meeting, Virtual, Improving Cardiovascular Outcomes through Million Hearts Quality Improvement Tools and Agency for Healthcare Research and Quality's TAKEheart Initiative, 2020.
160. Houston Methodist DeBakey Heart and Vascular Center CVD Prevention Virtual Symposium. Cardiovascular Risk Stratification: Lipid and Inflammatory Biomarkers. 2020
161. American Heart Association Pre-PAD Summit Virtual Workshop. Building PAD into Current Initiatives- Million Hearts. 2020
162. NHLBI / CDC Implementation Science Virtual Workshop on Hypertension Control. Hypertension Control Rates in the U.S./ Hypertension Control as a

- National Priority. Discussant- Hypertension Control in the United States over Two Decades. 2020
163. Mexican Society of Cardiology 3rd Scientific Sessions (Virtual), Joint MSC-WHF Session, Tackling the Growing Global Burden: World Heart Federation Roadmap on the Prevention of CVD in People Living with Diabetes, 2020
 164. Million Hearts Cardiac Rehabilitation Think Tank Pre-meeting workshop, Cardiac Rehabilitation 101: Needs and Opportunities to Address Disparities, moderator, 2020
 165. Keynote Guest Speaker, Closing Ceremony of the Timisoara, Romania (Virtual) Cardio Culture Meeting, Timisoara CV Institute Annual Conference, 2020
 166. Chair, National Million Hearts Cardiac Rehabilitation Think Tank; Advancing New Care Models, 2020
 167. 12th Annual Orange County Symposium on CVD Prevention, The (Post-COVID) Future of Cardiovascular Disease Prevention, 2020
 168. Stanford Cardiology Grand Rounds, The (Post-COVID) Future of Cardiovascular Disease Prevention, 2020
 169. Invited Panelist, World Heart Federation Heart-To-Heart Diabetes Virtual Debate, Silos in Healthcare, Geneva, Switzerland, 2020
 170. World Heart Federation / Lund University Virtual Roundtable on Diabetes and Cardiovascular Disease, speaker and panelist, Malmo, Sweden, 2020
 - a. Roadmap on Prevention of Cardiovascular Disease in People Living with Diabetes.
 171. National Business Group on Health Webinar: Top Drivers of Healthcare Costs for Large Employers. Cardiovascular Disease: Driver of Healthcare Costs for Employers- Millions of Opportunities, 2021
 172. American College of Cardiology Webinar- Transform Cardiovascular Risk in Diabetes: Setting the Stage, 2021
 173. Northwell Heart Center Virtual Cardiology Grand Rounds, The (Post-COVID) Future of Cardiovascular Disease Prevention, 2021
 174. Million Hearts Value-Based Insurance Design Webinar: Opportunities for Cardiovascular Disease Prevention. Burden of CVD and Million Hearts 2022, 2021
 175. Familial Hypercholesterolemia Foundation Webinar, The (Post-COVID) Future of Cardiovascular Disease Prevention, 2021
 176. World Congress of Cardiology, Joint World Heart Federation- Chinese Society of Cardiology Session on Diabetes and Heart Failure. Tackling the Global Burden of Diabetes and Heart Failure: The WHF Roadmap on the Prevention of CVD in People Living with Diabetes, Japan, 2021
 177. Million Hearts SMBP Forum 1st Quarter Meeting. Making an Economic Case for Self-Measured Blood Pressure Monitoring. 2021
 178. National Hypertension Control Roundtable Steering Committee meeting. Introduction to the Federal Hypertension Control Leadership Council. 2021

179. CDC, Division for Heart Disease and Stroke Prevention Science Seminar. The Impact of COVID-19 on Cardiovascular Care and CVD Prevention, 2021
180. CMMI Million Hearts Innovation Model Learning Group Webinar, The Impact of COVID-19 on Cardiovascular Care and CVD Prevention, 2021
181. 70th Annual American College of Cardiology Virtual Meeting, 2021
 - a. Yes, Home May be an Option: Hybrid CR, Featured Session- the Telehealth Cardiac Team: Challenges and Opportunities
 - b. Lipid Management to Reduce ASCVD Risk: To Infinity and Beyond
 - c. Faculty Mentor Session for Fellows in Training
182. National Forum on Heart Disease and Stroke Prevention Mid-Year Virtual Convening. Answering the Surgeon's General's Call to Action to Control Hypertension: Success Stories, Million Hearts Hypertension Control Champions. 2021
183. National Adult and Influenza Immunization Summit Virtual meeting. Plenary Session, Expanding influenza vaccination among specialty medical providers and raising awareness of influenza's role in chronic disease. Influenza Vaccination- Opportunity to Extend Cardiovascular Disease Prevention to Millions of Hearts, 2021
184. American College of Cardiology Board Review Course, 2021
 - a. Epidemiology and Prevention of Metabolic Syndrome and Diabetes
 - b. Comprehensive Cardiovascular Risk Reduction in Diabetes
 - c. Diabetes Medications
185. Million Hearts Partners Call, Impact of COVID-19 on Cardiovascular Care and Cardiovascular Disease Prevention, 2021
186. 21st Annual National Sarasota Congress on Cardiovascular Disease Prevention, 2021
 - a. The (Post-COVID) Future of Cardiovascular Disease Prevention
 - b. Influenza Vaccination: Opportunity for Cardiovascular Disease Prevention
187. Invited Participant, Preventive Cardiology Nurses Association ASCVD Population Health Summit, 2021
188. American College of Cardiology Global Virtual Cardiometabolic Webinar, Cardiometabolic Medicine and Diabetes Care: Extending the Paradigm of Cardiovascular Disease Prevention, Guangzhou, China, 2021
189. American Society for Preventive Cardiology Virtual Summit on CVD Prevention, Chair of Early Career Abstract Presentations. Louisville, KY, 2021.
190. Million Hearts National Partner Call, COVID Vaccine-Associated Myocarditis and Pericarditis, 2021
191. CVD Prevention 101. Overview and Q & A. CDC Foundation Million Hearts Campaign Communications Team, 2021
192. 5th Annual Heart in Diabetes Conference, New York, NY, 2021
 - a. The Contemporary Role of Medications (And the Heart in Diabetes)
 - b. Co-Chair: Sessions on Contemporary Approach to ASCVD in Diabetes, and

Heart Disease in Women

c. Member of Scientific and Abstract Committees

193. Cardiology Grand Rounds, Indiana University, The (Post-COVID) Future of CVD Prevention, Virtual Presentation, 2021
194. Invited speaker, American College of Cardiology Federal Section Webinar, Alternate Careers in Cardiology, 2021
195. 12th Annual Emirates Cardiac Society Conference, The Impact of the Pandemic on Non-Communicable Diseases / Cardiovascular Disease: When Communicable meets Non-Communicable, Dubai, UAE, 2021
196. 36th Annual American Association of Cardiovascular and Pulmonary Rehabilitation meeting, Preparing for the Post-COVID Future of Cardiac Rehabilitation: Synergy with the Million Hearts 2022 Participation Goals, virtual presentation, San Antonio, Texas, 2021.
197. World Heart Federation Educational Session, Diabetes and Cardiovascular Disease, Geneva, Switzerland, virtual, 2021
198. CMS Innovation Center / CDC Million Hearts Value-based Insurance Design and Opportunities to Improve Medication Adherence for CVD Prevention, 2021
 - a. Inequities in Heart Disease and Stroke Burden
199. Faculty for the 5-day World Heart Federation Emerging Leaders Seminar (Diabetes and CVD Prevention), Lisbon, Portugal, 2021
 - a. WHF Roadmap for the Prevention of CVD among People Living with Diabetes
 - b. Co-faculty mentor for the America's Group
200. Great Wall of China-International Congress of Cardiology, JACC Asia at the GW-ICC Joint Session: From Vision to Executing on Quality, Virtual Beijing, China, 2021
 - a. Invited commentary on the 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes
 - b. member of panel discussion
201. Belarusian Society of Endocrinology and Metabolism: Diabetes and Metabolic Risk, Virtual, 2021
 - a. World Heart Federation Roadmap for the Prevention of Cardiovascular Disease among People Living with Diabetes
202. 19th World Congress on Insulin Resistance Diabetes and Cardiovascular Disease, Los Angeles, CA, 2021
 - a. NAFLD: The Heart of the Matter
203. 38th Annual University of San Francisco Annual Advances in Heart Disease, 2021
 - a. Heart Healthy Dietary Patterns: A Recipe for Life
204. Cardiology Grand Rounds, University of Utah, 2021
 - a. The (Post-COVID) Future of Cardiovascular Disease Prevention
205. CDC /CMS Million Hearts Partner Call, 2021
 - a. Million Hearts 2027: Aiming for Impact

206. Telemed Now: National Twitter Chat. Benefits and Challenges to Supporting Heart Health via Telemedicine, 2021
207. 22nd International Society for CVD Prevention Congress on CVD Prevention, Sarasota, FL, 2022
 - a. Lipid Management to Reduce CV Risk: To Infinity and Beyond
 - b. Non-Alcoholic Fatty Liver Disease: The Heart of the Matter
208. National Association of Community Health Centers Million Hearts Learning Lab: Optimizing Care for High Risk Patients with LDL-C > 190 mg/dL- Messaging and Management, 2022
209. Q1 Million Hearts Cardiac Rehabilitation Collaborative meeting, Million Hearts Cardiac Rehab Think Tank Innovation Model Development, 2022
210. 86th Annual Japanese Circulation Society / Asian Pacific Society of Cardiology Congress. Kobe, Japan, 2022
 - a. Non-Alcoholic Fatty Liver Disease: The Heart of the Matter
211. Q1 Million Hearts Collaboration Meeting (hosted by American Kidney Fund). Million Hearts 2027: Aiming for Impact, 2022
212. 71st American College of Cardiology Meeting, Washington, DC, 2022
 - a. Presentation to ACC Board of Governors, Million Hearts 2027: Aiming for Impact
 - b. Session Chair, Cardiometabolic Clinics: The Time has Come
213. Center for Medicare and Medicaid (CMS) Quality Conference: New Hope, New Health- Charting a Path Forward, Baltimore, MD, 2022
 - a. Session Moderator: Million Hearts 2027: Pandemic, Partnership, Progress, and Possibilities
 - b. Million Hearts 2027: Aiming for Impact
214. Kaiser Permanente Northern California Division of Research Seminar, 2022
 - a. Million Hearts 2027: Aiming for Impact
215. ACC Asia-Korean Society of Cardiology Conference- Hybrid, Gyeongju, Korea, 2022
 - a. Co-Chair for session: Cardiovascular Risk Assessment for Koreans: Opportunities for Improvement
216. 19th Annual Oregon ACC Cardiovascular Symposium, Portland, OR, 2022
 - a. The Battle of the Bulge: SGLT2i and GLP1-RA in the Prevention and Treatment of Cardiometabolic Disease
 - b. Faculty for Cardiology Fellows Case Presentations
217. NACHC / HRSA Healthchoice Network Cardiovascular Health Work Group, Chicago, IL, 2022
 - a. Statins Save Lives: Optimizing Cholesterol Management in High Risk Patients
218. Slovenian Society of Cardiology Contemporary Cardiology, Ljubljana, Slovenia, 2022
 - a. Aiming for Impact: Million Hearts 2027
219. 6th Annual Heart in Diabetes Conference, Philadelphia, PA, 2022

- a. Aspirin for Primary Prevention: Trials, Tribulations, and Trust
- b. Co-Chair: State of the Art Cardio-Renal-Metabolic Diseases
- c. Scientific Committee; Program Committee; Abstract Committee
- 220. National Minority Quality Forum Champions for Total Health webinar, 2022
 - a. Hypertension and Vaccines
- 221. State of California Master Plan meeting for Preventing Heart Attacks and Strokes, 2022
 - a. Aiming for Impact: Million Hearts 2027
- 222. European Society of Cardiology Congress, Barcelona, Spain, 2022
 - a. Co-Chair Research Gateway Sessions
 - 1. Cardiovascular Risk Assessment
 - 2. Cardiovascular Risk Assessment and COVID
 - 3. Cardiovascular Risk Assessment-SCORES 2
- 223. CDC Center for Global Health, COVID Clinical Mitigation Unit Seminar, 2022
 - a. Impact of COVID-19 on Cardiovascular Care and Cardiovascular Disease Prevention
- 224. Introduction to the Million Hearts Cardiovascular Disease and Climate Change Collaborative (in partnership with the Office on Climate Change and Health Equity, Environmental Protection Agency, and CDC National Center for Environmental Health), 2022
- 225. American Heart Association Scientific Sessions, 2022 Chicago
 - a. National Implementation Programs for Hypertension Control: Million Hearts and Beyond
- 226. International Diabetes Federation Congress, Joint WHF-IDF Session: Diabetes and CVD, Working together as one community Lisbon, Portugal, 2022
 - a. WHF-IDF Roadmap: Implementing Successful Changes
- 227. California Right Care Initiative Virtual University of Best Practices- Improving Health Outcomes by Reducing Health Disparities, 2023
 - a. Million Hearts 2027: Aiming for Impact- Core Focus on Health Equity
- 228. American Heart Month Facebook NHLBI Live Event, Getting to Know #OurHearts, Co-presenter with Dr. David Goff, Director of NHLBI Division Of Cardiovascular Sciences, 2023
- 229. Clinical Care Grand Rounds, Healthfirst, NY, 2023
 - a. Million Hearts 2027: Aiming for Impact- Core Focus on Health Equity
- 230. 72nd American College of Cardiology Meeting / WCC, New Orleans, 2023
 - a. The Alphabet Soup of New Diabetic Agents for CAD: Role of SGLT2-inhibitors and GLP-1 agonists
 - b. Million Hearts 2027: Targeting 70% Participation in Cardiac Rehabilitation Across the Nation
- 231. World Heart Federation Roundtable on CVD, Diabetes, and Obesity, Aburi, Aburi, Ghana, 2023
 - a. WHF-IDF Roadmap for the Prevention of CVD Among People Living with Diabetes: Implementing Successful Changes

232. Harrington Heart and Vascular Institute Grand Rounds, University Hospitals Case Western, Cleveland, OH, 2023
 - a. The (Post-COVID) Future of CVD Prevention
233. International Federation of Aging, Adult Vaccination Education Program 2023
 - a. Improving Vaccine Equity Among at-Risk Populations
234. CDC Office of Genomics and Precision Public Health Webinar-CHD, Family History, and Public Health: From FH to Lp(a), 2023
 - a. Familial Hypercholesterolemia: A Prototype for Precision Public Health
235. National Forum for Heart Disease and Stroke Prevention Mid-Year Convening, Improving Equity in Hypertension Prevention and Management, 2023
 - a. Interviewed by Dr. Marcus Plescia (CMO of ASTHO)
236. 7th Annual Heart in Diabetes Conference, Philadelphia, PA, 2023
 - a. Co-Chair Session: Management of ASCVD Circa 2023
 - b. Co-Chair Session: State-of-the Art Cardiovascular Disease and Diabetes
237. NACHC Million Hearts LinkedIn Live: Empowering Patients in Their Cholesterol Management, 2023
238. 31st International Congress on Preventive and Optimal Treatment of CVD, Arusha, Tanzania, 2023
 - a. Million Hearts 2027: Aiming for Impact- Core Focus on Health Equity
239. Cardiology Grand Rounds, Yale New Haven Hospital, 2023
 - a. The (Post-COVID) Future of CVD Prevention
240. American Society for Preventive Cardiology Pioneer in Prevention Award and Lecture, Arlington, Tx, 2023
 - a. My Journey in Cardiovascular Disease Prevention: Gratitude from the Heart
241. European Society of Cardiology Congress, Amsterdam, Netherlands, 2023
 - a. Co-Chair session- CV Risk Factors and Obesity
 - b. Co-Chair session-CV Risk Factors, Depression, and Psychosocial stress
 - c. Chair- World Heart Federation Session-Intersection of CKD and CVD
242. Dr. Radio Interview- Hypertension and CVD Prevention, 2023
243. NIA/ NHLBI/ Million Hearts You Tube Live- Heart Health and Aging, 2023
244. Presentation to CMS IQIG- Advancing CV Health Through CDC-CMS Partnership, 2023
245. Keynote, Opening Session 38th AACVPR meeting, Milwaukee, Wisconsin, 2023
 - a. Million Hearts 2027: Optimizing use of Cardiac Rehabilitation
246. Keynote presentation, 2nd Annual Motown Women's Heart Symposium, 2023
 - a. Gender and Geographic Disparities in Cardiovascular Care
247. 16th Annual Society to Improve Diagnosis in Medicine Conference, Cleveland, OH, 2023
 - a. Preventing ASCVD: Solving the Problem of Underdiagnosis and Undertreatment
248. Cardiology Grand Rounds, University of Chicago, 2023
 - a. The (Post-COVID) Future of CVD Prevention

249. Global Heart Hub Unite Summit, Barcelona, Spain, 2023
 - a. Keynote presentation- Early Detection, Diagnosis, and Prevention of CVD: Public Health / Health Systems Perspective
250. American Heart Association Scientific Sessions, Philadelphia, PA, 2023
 - a. Interdisciplinary Management for Patients with Cardiovascular-Kidney-Metabolic (CKM) Syndrome- Interactive Case Discussions
 - b. Debate- Pro: I Recommend Intermittent Fasting to My Patients
251. Panelist-Discussant ACC/ American College of Pharmacy Webinar, 2024
-key LBCT in CVD Prevention from AHA 2023(ACC Prevention Council)
252. 24th International Society for CVD Prevention Congress, Sarasota, 2024
 - a. Time Restricted Eating: A strategy for CVD Prevention?
 - b. Focus on CKMH to PREVENT CVD
252. Association of University Cardiologists Annual meeting, Charleston, SC, 2024
 - a. Impact of COVID-19 on CVD Outcomes, Care, and Prevention
253. NACHC- Million Hearts Learning Lab Webinar, 2024
 - a. A Statin is Indicated for Your Patient- Getting There Together
254. 75th American College of Cardiology meeting, Atlanta, GA, 2024
 - a. Presentation to BOG-Million Heart 2027: Aiming for Impact
 - b. Million Hearts 2027: Aiming for Impact- Focus on Rural Health and Health Equity
 - b. Co-Chair Session- Balancing the Scale: Unveiling the Truth about Weight Loss Pharmacotherapies
 - c. Add, Subtract or Both? Managing Anti-Hyperglycemic and CV Risk Reduction Agents in Patients with Diabetes
 - d. Revolutionizing Care with Innovative Care Models / WHF Panel
 - e. Million Hearts 2027: Empowering Communities for Heart Health
255. CMS Quality Conference, Baltimore, MD, 2024
 - a. Million Heart 2027: Aiming for Impact- Core Focus on Health Equity
256. Million Hearts Collaboration, 2024
 - a. Million Hearts 2027: Improving Cholesterol Management
257. Co-Chair of World Heart Federation Multimorbidity and Integrated Care Forum, Geneva, Switzerland, 2024
 - a. Setting the Stage to Address Metabolism-Related Multimorbidity Conditions
 - b. Moderator- Key Challenges and Opportunities to Integrate Metabolism-related Multimorbidity Conditions
 - c. Moderator- Life Course Approach to Treating and Preventing Metabolism-related Multimorbidity Conditions
 - d. Closing Remarks and Next Steps
258. 8th Annual Heart in Diabetes meeting, Philadelphia, PA, 2024
 - a. HDL Cholesterol: Helpful, Harmful, Hopeful, or Guilty by Association?
 - b. Co-Chair Session AHA Cardio-Kidney-Metabolic Health / PREVENT
259. National Association of Community Health Centers Harvest meeting / AMA National Office, Chicago, IL, 2024
 - a. Opening comments related to Million Hearts Preventing Heart Attacks and Strokes Project

- b. Expert Panel Discussion, Q & A
- 260. American Society for Preventive Cardiology Congress, SLC, Utah, 2024
 - a. co-moderator, session on the Future of CVD Clinical Trials
- 261. National Lipid Association, Clinical Lipid Update, Dallas, Tx, 2024
 - a. Focus on CKMH to PREVENT CVD
- 262. 10th Family Heart Global Summit, Dallas, Tx, 2024
 - a. Summit Co-Chair
 - b. Population Health Approaches to Accelerate the Prevention of CVD: Moving from Action to Impact
- 263. Invited 20th Anniversary of UTSW Preventive Cardiology Center Celebratory Grand Rounds speaker, Dallas, Tx, 2024
 - a. Looking Back and Looking Forward: The Next 20 Years of CVD Prevention
- 264. ACC NCD Academy, Influenza Vaccination: An Opportunity for CVD Prevention, 2024
- 265. Milken Institute Future of Health Summit, Washington, D.C., 2024
 - a. A Glimpse Ahead: The Future of R & D- panel
- 266. 100th American Heart Association Scientific Sessions, Chicago, IL, 2024
 - a. moderator-Applying Advances in Risk Prediction to PREVENT CVD
- 267. 22nd World Congress on Insulin Resistance, Diabetes, and CVD, Los Angeles, CA, 2024
 - a. A Multi-Disciplinary Approach to Obesity: The Battle of the Bulge with CV Benefits
- 268. Heart and Vascular Grand Rounds, Allegheny Health Network, Pittsburgh, PA, 2024
 - a. Focus on CKMH to PREVENT CVD
- 269. Cardiology Grand Rounds (Virtual), Virginia Commonwealth University, 2024
 - a. Focus on CKMH to PREVENT CVD
- 270. 25th Annual CardioSarasota Congress on CVD Prevention, Sarasota, FL, 2025
 - a. Focus on CKMH to PREVENT CVD
 - b. Looking Back and Looking Forward: The Next 25 Years of CVD Prevention
- 271. Cardiology Grand Rounds, Duke University, 2025
 - a. Focus on CKMH to PREVENT CVD
- 272. Cardiology Grand Rounds, UCLA, California, 2025
 - a. Focus on CKMH to PREVENT CVD
- 273. William B. Kannel Memorial lecture, AHA Epi/ Prevention Conference, New Orleans, LA, 2025
 - a. Risk Assessment: Foundation for Population Health and Precision Prevention
- 274. Boca Raton Regional Internal Medicine Conference, 2025
 - a. HDL-C: Helpful, Harmful, Hopeful, or Guilty by Association?
- 275. American College of Cardiology Scientific Sessions, Chicago, IL, 2025
 - a. LATTICE Consortium, FIND-FH
 - b. Moderator, WHF Heart Café, Heart Brain Connection
 - c. Co-Chair, Obesity Update: Hot Tips from Diets to Drugs
- 276. 4th Jim Pattison Cardiac Rehab Symposium, Canmore, Canada
 - a. COVID Pandemic: Wake-up Call and Accelerator for CR
- 277. University of Louisville, Cardiology Grand Rounds, Louisville, KY, 2025

- a. Focus on CKMH to PREVENT CVD
- 278. 9th Heart in Diabetes meeting, Philadelphia, PA, 2025
 - a. Co-Chair- Session on Implementation Science in Practice
 - b. Population Health Approaches to Accelerate the Prevention of CVD: Moving from Action to Impact
- 279. Panelist, International Academy of Cardiovascular Sciences Webinar, 2025
 - a. Lp(a) and Cardiovascular Disease: Pathophysiology and Emerging Treatments
- 280. Moderator, ASCP Congress, Early Career Research Presentations, Boston, MA, 2025
- 281. European Society of Cardiology / World Congress of Cardiology, Madrid, Spain, 2025
 - a. Co-Chair: Research Exchange Circle- CV Prevention and Public Health Perspectives
 - b. Co-Chair: Research Exchange Circle- Perspectives in Public Health and CVD
 - c. WHF Heart Café Moderator- Integrated Care Across CV, Kidney, and Metabolic Diseases
- 282. 11th Family Heart Foundation Global Summit, Atlanta, GA, 2025
 - a. Co-Host
 - b. Moderator for Session- Prevention Begins with Pediatrics and Primary Care
 - c. panel member, Corporate Advisory Council, FIND Initiative
- 283. Family Heart Foundation Homozygous Familial Hypercholesterolemia Gathering, Orlando, FL, 2025
 - a. Providing Help and Hope for Individuals and Families Living with HoFH
- 284. National Association for Continuing Education, Conversations in Primary Care Event, Webinar, 2025
 - a. Lp(a): Recognizing and Managing Hidden Cardiovascular Risk
- 285. World Heart Federation Webinar, 2025
 - a. Crossroads: Integrating Influenza, COVID, and Heart Health
- 286. American Heart Association Scientific Sessions, New Orleans, LA, 2025
 - a. Co-Chair- Late Breaking Science- Emerging Opportunities for Managing Cardiometabolic Syndrome
- 287. 30th HepDART meeting, Honolulu, Hawaii, 2025
 - a. Focus on CLMH with the Goal of Prevention
- 288. Cardiology Grand Rounds, Cedars Sinai, LA, CA, 2026
 - a. Looking Back and Looking Forward: The Future of CVD Prevention
- 289. Department of Medicine Distinguished Grand Rounds, UC Irvine, 2026
 - a. Looking Back and Looking Forward: the Future of CVD Prevention
- 290. 26th CardioSarasota Meeting, Sarasota, FL, 2026
 - a. Risk Assessment: Foundation for Population Health and Precision Prevention
 - b. Focus on Cardiovascular-Liver- Metabolic Health

- c. Lipoprotein(a): Recognizing and Managing a Hidden Cardiovascular Risk
- 291. Chair, Atlanta Hypertension Initiative Virtual Clinical Roundtable, 2026
- 292. American Diabetes Association CKD Quality Leadership Forum, Washington, D.C., 2026
 - a. Focus on CKD with the Goal of Integrated Prevention and Quality Outcomes
- 293. American College of Cardiology, New Orleans, LA, 2026
 - a. Chair World Heart Federation Heart Café- A Unified Approach to CVD and Long-Term Conditions: Introducing the WHF Roadmap
 - b. Prescribing Meals, not Just Meds: The Case for Medically Tailored Meals
- 294. Dan May visiting Professor and Lectureship, Vanderbilt University Medical Center, Nashville, TN, 2026
 - a. Cardiology Grand Rounds- Looking Back and Looking Forward: The Future of CVD Prevention
 - b. Medicine Grand Rounds- Focus on CKMH to PREVENT CVD
- 295. Cardiology Grand Rounds, California Pacific Medical Center, Sutter Health, San Francisco, CA, 2026
 - a. Looking Back and Looking Forward: The Future of CVD Prevention
- 296. American College of Physicians Annual Meeting Innovation Hub presentation, San Francisco, CA, 2026
 - a. Lipoprotein (a): Recognizing and Managing A Hidden Cardiovascular Risk
- 297. Monza Ares Cardiovascular Center Conference, Bucharest, Romania, 2026
 - a. The Future of CVD Prevention
- 298. Doctor Honoris Causa Ceremony, University of Medicine and Pharmacy, Victor Babes, Timisoara, Romania, 2026
 - a. The Future of CVD Prevention
- 299. ESC Preventive Cardiology, Ljubljana, Slovenia, 2026
 - a. Guidelines in Practice: Lipids on Both Sides of the Atlantic
 - b. Judge for Young Investigator Award- Primary Prevention and Risk Factor Management
- 300. 11th Annual Diabetes, Obesity, and Metabolic Disease Conference, New Orleans, LA, 2026
 - a. Updated Dyslipidemia Guideline: What's New, What's Not
 - b. Focus on Lipid-Related Risk as a Component of Comprehensive CKMH
 - c. Cases on Hypertension and Lipids
- 301. 10th Annual Heart in Diabetes Conference, Philadelphia, PA, 2026
 - a. Focus on CLMH with the Goal of Prevention
 - b. Session Co-Chair- ASCVD Circa 2026
 - b. planning committee member
 - c. abstract committee
- 302. American Society for Preventive Cardiology Congress, Scottsdale, AZ, 2026

- a. Debate (Pro): Risk Scores, Not Imaging are the Best Approach to Population Screening
- b. Oral Abstract and Poster Judge

25. **Other Activities:**

Local and national TV, newspaper, radio and magazine appearances (CNN, NBC national, Channels 2, 5, 11, PBS, *Atlanta Journal and Constitution*, *Newsweek*, *Time*, *Atlanta Magazine*)

26. **Bibliography:**

a. **Published and accepted research articles (clinical, basic science, other) in referred journals:**

1. **Sperling LS** and Horowitz JL. Methamphetamine-induced choreoathetosis and rhabdomyolysis. *Ann Int Med* 1994;121(12):986.
2. **Sperling LS** and Tumlin JA. Delayed hypercalcemia following rhabdomyolysis-induced acute renal failure. *Am J Med Sc* 1996;311(4):186-188.
3. **Sperling LS**, Du J, Marrero M, Delafontaine P. G protein and tyrosine kinase receptor cross talk in rat aortic smooth muscle cells: thrombin and angiotensin II-induced tyrosine phosphorylation of insulin receptor substrate-1 and insulin-like growth factor-1 receptor. *BBRC* 1996;218(3):934-939.
4. Morrison DJ, **Sperling LS**, Schwartz DA, Felner JM. Escherichia coli endocarditis of a native aortic valve. *Arch Pathol Lab Med* 1997;121:1292-1295.
5. Rice CR, Berkuysen M, Nauright L, **Sperling LS**. Phase II cardiac rehabilitation education: meeting the time challenge. *J Cardiopulm Rehab* 1999;19:347-351.
6. Frank E, **Sperling L**, Wu K. Aspirin use among women physicians in the United States. *Am J Cardiol* 2000;86:465-466.
7. Cole J, Miller JI, **Sperling LS**, Weintraub WS. Longterm follow-up of coronary artery disease presenting in young adults. *J Am Coll Cardiol* 2003;41:521-528.
8. Cole JH, **Sperling LS**. Premature coronary artery disease: Clinical risk factors and prognosis. *Current Atherosclerosis Reports* 2004;6:121-125.
9. Baman TS, Cole JH, Devireddy CM, **Sperling LS**. Risk factors and outcomes in patients with coronary artery aneurysms. *Am J Cardiol* 2004;93:1549-1551.
10. Gordon N, Salmon R, Franklin B, **Sperling L**, Hall L, Leighton R, Haskell W. Effectiveness of therapeutic lifestyle changes in patients with hypertension, hyperlipidemia, and/or hyperglycemia. *Am J Cardiol* 2004;94:1558-1561.

11. Parikh P, Mcdaniel MC, Ashen MD, Miller JI, Sorrentino M, Chan V, Blumenthal RS, **Sperling LS**. Diets and cardiovascular disease: An Evidence-based assessment. *J Am Coll Cardiol* 2005;45:1379-1387.
12. Sims DB, **Sperling LS**. ST segment elevation resulting from Hyperkalemia. *Circulation* 2005;111:e295-296.
13. DeFilippis AP, **Sperling LS**. Understanding Omega 3's. *Am Heart J* 2006;151:564-70.
14. DeFilippis AP, Larned JM, Cole JH, Nell C, Miller JI, **Sperling LS**. Clues to cardiovascular risk: An office based approach. *Preventive Cardiology* 2007;10(1):36-41.
15. Mackie BD, Satija S, Nell C, Miller J, **Sperling LS**. Monday, Wednesday, Friday dosing of Rosuvastatin in patients previously intolerant to statin therapy. *Am J Cardiol* 2007;99:291.
16. Liff DA, Kraft C, Pohlel FK, Wade J, **Sperling LS**, Chen EP, Paredes CF. Nocardia nova aortitis following coronary bypass surgery. *J Am Soc Echocardiogr* 2007;20(5):537.
17. Swerdlow DL, Roper MH, Morgan J, Schieber RA, **Sperling LS**, et al. and the Smallpox Vaccine Cardiac Adverse Events Working Group. Ischemic cardiac events during the Department of Health and Human Services smallpox vaccination program. *Clinical Infectious Diseases* 2008;46:S234-41.
18. Morgan J, Roper MH, **Sperling L**, et al. for the Smallpox Vaccine Adverse Monitoring and Response Activity. Myo/pericarditis and dilated cardiomyopathy following smallpox vaccination among civilians, United States, January-October, 2003. *Clin Infect Dis*. 2008;10:273-282.
19. Bavikati VV, **Sperling LS**, Salmon RD, Faircloth GC, Gordon TL, Franklin BA, Gordon NF. Effect of comprehensive therapeutic lifestyle changes on prehypertension. *Am J Cardiol* 2008;102:1677-1680.
20. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Am Heart J*. 2008;156(3):528-536.
21. Mora LF, Khan AH, **Sperling LS**. Cardiac complications after smallpox vaccination. *Southern Medical Journal* 2009;102(6):615-619.
22. Yehya A, Baer JT, Smiley W, Dollar A, **Sperling L**. Hypervitaminosis A altering the lipid profile in a hypercholesterolemic patient. *Journal of Clinical Lipidology* 2009, 3(3): 205-207.
23. Rowe D, DeFilippis A, Dantzler D, Doyle J, Kripalani S, **Sperling L**. Assessing housestaff gender specific preventive cardiovascular knowledge: Potential impact on cardiovascular management. *Gender Medicine* 2009, 6(3) 471 – 478.
24. The BARI 2D Study Group. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. *N Engl J Med* 2009 (360): 2503-2515.
25. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. *J Peripher Nerv Syst*. 2009;14(1):1-13.

26. Georgiopolou VV, Denker A, Bishop KL, Brown JM, Hirsh B, Wolfenden L, **Sperling L**. Metabolic abnormalities in adults with cystic fibrosis. *Respirology* 2010 Jul15(5):823-9.
27. Salman T, Satja S, Martin SF, **Sperling L**. Saddle pulmonary embolism in the setting of a 3-chamber thrombus: Successful resolution after thrombolytic therapy. *Texas Heart Insititute J*. 2010;37(2):234-236.
28. Shehab N, **Sperling LS**, Budnitz DS. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. *Arch Intern Med*. 2010; 170(21):1926-33.
29. Chaudhry S, Arian R, Hansen JE, Lewis GD, Myers J, **Sperling LS**, LaBudde B, Wasserman K. The Utility of Cardiopulmonary Exercise Testing to Detect and Track Early Stage Ischemic Heart Disease. *Mayo Clin Proc*. 2010;85(10):928-32.
30. Eapen DJ, Clements S, Block P, **Sperling LS**. Metastatic carcinoid disease inducing coronary vasospasm. *Tex Heart Inst J* 2012;39(1):76-78.
31. Yehya A, Jacobs S, Mashman W, **Sperling L**. Takotsubo cardiomyopathy in a patient with presumptive autoimmune polyendocrine syndrome II. *Cardiac Cath Lab Director* 2011, 1(3/4):117-119.
32. The BARI-2D Study Group. The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Diabetes Care* 2011;34(2):464-7.
33. Gordon NF, Habib A, Salmon RD, Bishop KL, Drimmer A, Reid KS, Wright BS, Faircloth GC, Gordon TL, Franklin BA, Rubenfire M, Gracik T, **Sperling LS**. Effect of exercise-based cardiac rehabilitation on multiple atherosclerotic risk factors in patients taking antidepressant medication. *Am J Cardiol*. 2013;111(3):346-51.
34. Eapen DJ, Valiani K, Reddy S, **Sperling L**. Management of familial hypercholesterolemia during pregnancy: case series and discussion. *Journal of Clinical Lipidology* 2012; 6(1): 88-91.
35. Abd T, Kobyliver A, Perry A, Miller J, **Sperling LS**. Work-related physical activity among cardiovascular specialists. *Clin Cardiol*. 2012;35(2):78-82
36. Kella DK, Shoukat S, **Sperling L**. Plasma exchange for severe hypertriglyceridemia-induced pancreatitis in an orthotopic heart transplant recipient. *J Clin Lipidol*. 2012;6(5):474-6.
37. Nieva R, Safavynia S, Bishop KL, **Sperling L**. Herbal, vitamin, and mineral supplement use in patients enrolled in a cardiac rehabilitation program. *The Journal of Cardiopulmonary Rehabilitation* 2012;32:1-8
38. Parashar S, Spertus JA, Tang F, Bishop KL, Vaccarino V, Jackson CF, Boyden TF, **Sperling L**. Predictors of early and late enrollment in cardiac rehabilitation, among those referred, after acute myocardial infarction. *Circulation*. 2012;126(13):1587-95.
39. Ramjee V, Guo Y, Bhatia N, Vaugh L, Nell-Dybdahl C, Baer J, Wilson PWF, Le NA, **Sperling LS**. Rebound kinetics of inflammatory and lipid markers after LDL apheresis: The INFLAME study (under review, *Am J Cardiol*)
40. Bhatia N, Eapen DJ, Stewart J, Babaliaros V, **Sperling L**. Right coronary artery aneurysm communication with the right atrium following NSTEMI treated with coil embolization. *Circulation*. 2013;127(14):e537-8.

41. Eapen D, Manocha P, Patel R, Hammadah M, Veledar E, Wassel C, Nanjundappa R, Sikora S, Malayter D, Wilson P, **Sperling LS**, Quyyumi A, Epstein S. Aggregate Risk Score Based on Markers of Inflammation, Cell Stress, and Coagulation is an Independent Predictor of Adverse Cardiovascular Outcomes. *J Am Coll Cardiol*. 2013;62(4):329-37.
42. Bittner V, Bertolet M, Feliz RB, Farkouh ME, Goldberg S, Ramanathan KB, Redmon JB, **Sperling L**, Rutter MK. Comprehensive Cardiovascular Risk Factor Control Improves Survival: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. *J Am Coll Cardiol* 2015;66:765-73.
43. Ghasemzadeh N, Hritani AW, De Staercke C, Eapen DJ, Veledar E, Al Kassem H, Khayata M, Zafari AM, **Sperling L**, Hooper C, Waller EK, Vaccarino V, Mavromatis K, Quyyumi A. Plasma stromal cell-derived factor-1 alpha/ CXCL12 level predicts long-term adverse cardiovascular outcomes in patients with coronary artery disease. *Atherosclerosis*. 2015;238(1):113-8.
44. Ghasemzadeh N, Patel RS, Eapen DJ, Veledar E, Al Kassem H, Manocha P, Khayata M, Zafari AM, **Sperling L**, Jones DP, Quyyumi, AA. Increased systemic oxidative stress is associated with pulmonary hypertension in humans. *Hypertension* 2014; 63:1270-1275.
45. Eapen DL, Manocha P, Ghasemzedah N, Patel RS, Al Kassem H, Hammadah M, Veledar E, Le NA, Pielak T, Thorball CW, Velegraki A, Kremastinos DT, Lerakis, **Sperling L**, Quyyumi AA. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future events. *J Am Heart Assoc*. 2014;3(5):e001118.
46. Mekonnen G, Corban MT, Hung OY, Eshtehardi P, Eapen DJ, AL-Kassem H, Rasoul-Arzrumly E, Gogas BD, McDaniel MC, Pielak T, Thorball CW, **Sperling L**. Quyyumi AA, Samady H. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease. *Atherosclerosis*. 2014;239(1):55-60.
47. Patel RS, Li Q, Ghasemzadeh N, Eapen DJ, Owens LM, Janjua AU, Manocha P, Al Kassem H, Veledar E, Samady H, Taylor WR, Zafari AM, **Sperling L**, Vaccarino V, Waller, EK, Quyyumi AA. Circulating CD34+ Progenitor Cells and Risk of Mortality in a Population with Coronary Artery Disease. *Circ Res*. 2015;116(2):289-97.
48. Ghasemzadeh N, Zhang L, Al Mheid I, Li Q, **Sperling L**, Waller EK, Taylor WR, Guest J, Quyyumi AA, Mavromatis K. Circulating progenitor cells are reduced in HIV positive , antiretroviral naïve patients. *Int J Cardiol*. 2014;176(3):1150-2.
49. Kim JH, Sher S, Wang F, Berkstresser B, Shoop JL, Galante A, Al Mheid I, Ghasemzadeh N, Hutter AM, Williams BR, **Sperling L**, Weiner RB, Quyyumi AA, Baggish AL. Impact of American-style Football on Vascular Function. *Am J Cardiol*. 2015;115(2):262-7.
50. Sahebkar A, Seban C, Ursoniu S, Wong ND, Muntner P, Graham IM, Mikhailidis DP, Rizzo M, Rysz J, **Sperling LS**, Lip GYH, Banach M. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Lack of

- effect of resveratrol on C-reactive protein and selected cardiovascular risk factors. Results from a systematic review and meta-analysis of randomized controlled trials. (accepted for publication, International Journal of Cardiology)
51. Ghasemzadeh N, Brooks MM, Vlachos H, Hardison MS, Sikora S, **Sperling L**, Quyyumi AA, Epstein SE. An Aggregate Biomarker Risk Score Predicts High Risk of Near-term Myocardial Infarction and Death: Findings from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). (accepted for publication, Journal of the American Heart Association).
52. Hayek S, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas M, Wei C, Hotton A, French A, **Sperling L**, Lerakis S, Quyyumi A, Reiser J. Elevated Soluble Urokinase-type Plasminogen Activator is a Predictor of Incident Chronic Kidney Disease. (accepted for publication, N Eng J Med)
53. Patel RS, Ghasemzadeh N, Eapen DJ, Sher S, Arshad S, Ko Y, Veledar E, Samady H, Zafari M, **Sperling L**, Vaccarino V, Jones DP, Quyyumi AA. A novel biomarker of oxidative stress is associated with risk of death in patients with coronary artery disease. (accepted to Circulation)
54. Patel RS, Ghasemzadeh N, Eapen DJ, Sher S, Arshad S, Ko Y, Veledar E, Samady H, Zafari M, **Sperling L**, Vaccarino V, Jones DP, Quyyumi AA. Response to letter regarding article A novel biomarker of oxidative stress is associated with risk of death in patients with coronary artery disease. (accepted to Circulation)
55. Gordon NF, Salmon RD, **Sperling LS**, Wright BS, Faircloth GC, Gordon TL, Berk MR, Rubenfire M, Franklin BA. Multi-center Study of Temporal Trends in the achievement of ASCVD Risk factor goals during cardiac rehabilitation. (accepted for publication- Journal of Cardiopulmonary Rehabilitation and Prevention).
56. Arnold SV, Inzucchi SE, McGuire DK, Mehta SN, Goyal A, **Sperling LS**, Maddox TM, Einhorn D, Wong ND, Ratner RE, Hammar N, Fenici P, Sheehan JJ, Wong JL, Kosiborod M. Evaluating the Quality of comprehensive cardiometabolic care for patients with Type 2 diabetes in the U.S.: The Diabetes Collaborative Registry, published in Diabetes Care.
57. Corban MT, Hung OY, Mekonnen G, Eshtehardi P, Eapen DJ, Rasoul-Aezrumly E, Al Kassem H, Manocha P, Sikora S, Ko YA, **Sperling LS**, Quyyumi AA, Samady H. elevated levels of serum fibrinogen and fibrinogen degradation products are independent predictors of larger coronary plaques and greater plaque necrotic core. (accepted for publication, Circulation)
58. Kim JH, Ko YA, MacNamara J, Awad M, Taylor W, Healy S, Aida H, Le NA, Wilson PW, White M, **Sperling LS**, Wilson JS, Baggish AI. The impact of moderate distance recreational running and aging on cardiac physiology. (accepted to Heart)
59. Hayek SS, Ko YA, Awad M, Del Mar Soto A, Ahmed H, Patel K, Yuan M, Maddox S, Gray B, **Sperling L**, Shah A, Vaccarino V, Quyyumi AA.

- Depression and Chest Pain in Patients with Coronary Artery Disease
(under review European Heart Journal)
60. Chaudhry S, Kumar N, Behbahani H, Bagai A, Singh B, Menasco N, Lewis GD, **Sperling L**, Myers. Abnormal heart-rate response during cardiopulmonary exercise testing identifies cardiac dysfunction in symptomatic patients with non-obstructive coronary artery disease. (accepted for publication, International Journal of Cardiology)
 61. Shin E, Ochuko P, Bhatt K, Howard B, McGorisk G, Delaney L, Langdon K, Khosravanipour M, Nambi AA, Grahovec A, Morris DC, **Sperling LS**, Shaw LJ, Castellano PZ, Goyal A. Electronic health record-based overestimation of failure to prescribe statins in patients with coronary artery disease in a large academic multispecialty clinic. *J Am Heart Assoc* 2018;7: e007762
 62. Arnold SV, Inzucchi SE, Tang F, McGuire DK, Mehta SN, Maddox TM, Goyal A, **Sperling LS**, Einhorn D, Wong ND, Kosiborod M. Real world use and modeled impact of glucose lowering therapies used in recent cardiovascular outcomes trials: Observations from the Diabetes Collaborative Registry (DCR). (submitted to JACC for consideration).
 63. Arnold SV, Inzucchi SE, McGuire DK, Tang F, Mehta SN, Goyal A, **Sperling LS**, Maddox TM, Einhorn D, Wong ND, Hammer N, Fenici P, Sheehan JJ, Kosiborod M. Quality of care in the initial patient cohort of the Diabetes Collaborative Registry. (submitted for consideration to Diabetes Care).
 64. Ghasemzadeh N, Hayek SS, Ko YA, Eapen DJ, Patel RS, Manocha P, Al Kassem H, Khayata M, Veledar E, Kremastinos D, Thorball C, Pielak T, Sikora S, Zafari M, Lerakis S, **Sperling L**, Vaccarino V, Epstein SE, Quyyumi AA. Pathway-specific Aggregate Biomarker Risk Score is Associated with Burden of CAD and Predicts near-term Myocardial Infarction and Death. *Circ Cardiovasc Qual Outcomes* 2017;10
 65. Hammadah M, Tamman AS, Al Mheid I, Wilmot K, Ramadan R, Kindya BR, Kelli HM, O'Neal WT, Sandesara P, Sullivan S, Almuwaqqat Z, Obideen M, Abdelhadi N, Alkhoder A, Pimple PM, Levantsevych O, Mohammed KH, Weng L, **Sperling LS**, Shah A, Sun YV, Pearce B, Kutner M, Ward L, Bremner D, Kim J, Waller EK, Raggi P, Sheps D, Vaccarino V, Quyyumi AA. Myocardial Ischemia and Mobilization of Circulating progenitor Cells. (under review, Circulation Research)
 66. Sandesara PB, Ramjee V, Ghasemzadeh N, Guo Y, Bhatia N, Li Q, Vaughn L, Nell-Dybdahl C, Waller EK, Mahar EA, Brigham K, Wilson PWF, Quyyumi A, Le NA and **Sperling LS**. Circulating progenitor cells in patients with familial hypercholesterolemia. *J Clin Apher.* 2017.
 67. Sandesara PB, O'Neal WT, Kelli HM, Samman-Tahhan A, Hammadah M, Quyyumi AA and **Sperling LS**. The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction. *Diabetes Care.* 2017.
 68. Samman Tahhan A, Sandesara PB, Hayek SS, Alkhoder A, Chivukula K, Hammadah M, Mohamed-Kelli H, O'Neal WT, Topel M, Ghasemzadeh N, Ko YA, Aida H, Gafeer M, **Sperling L**, Vaccarino V, Liang Y, Jones DP

- and Quyyumi AA. Association between oxidative stress and atrial fibrillation. *Heart Rhythm*. 2017.
69. Samman Tahhan A, Hayek SS, Sandesara P, Hajjari J, Hammadah M, O'Neal WT, Kelli HM, Alkhoder A, Ghasemzadeh N, Ko YA, Aida H, Gafeer MM, Abdelhadi N, Mohammed KH, Patel K, Arya S, Reiser J, Vaccarino V, **Sperling L** and Quyyumi A. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. *Atherosclerosis*. 2017;264:108-114.
70. Kim JH, Ko YA, Hedley J, MacNamara J, Awad M, Taylor W, Healy S, Aida H, Le NA, Wilson PW, White M, **Sperling LS**, Wilson JS, Jr. and Baggish AL. The impact of moderate distance recreational running and ageing on cardiac physiology. *Heart*. 2017;103:219-226.
71. Kelli HM, Hammadah M, Ahmed H, Ko YA, Topel M, Samman-Tahhan A, Awad M, Patel K, Mohammed K, **Sperling LS**, Pemu P, Vaccarino V, Lewis T, Taylor H, Martin G, Gibbons GH and Quyyumi AA. Association Between Living in Food Deserts and Cardiovascular Risk. *Circ Cardiovasc Qual Outcomes*. 2017;10.
72. Kelli HM, Corrigan FE, 3rd, Heintz RE, Dhindsa DS, Hammadah M, Samman-Tahhan A, Sandesara P, O'Neal WT, Al Mheid I, Ko YA, Vaccarino V, Ziegler TR, **Sperling LS**, Brigham K, Jones D, Martin GS and Quyyumi AA. Relation of Changes in Body Fat Distribution to Oxidative Stress. *Am J Cardiol*. 2017.
73. Hayek SS, Ko YA, Awad M, Del Mar Soto A, Ahmed H, Patel K, Yuan M, Maddox S, Gray B, Hajjari J, **Sperling L**, Shah A, Vaccarino V and Quyyumi AA. Depression and chest pain in patients with coronary artery disease. *Int J Cardiol*. 2017;230:420-426.
74. Gordon NF, Salmon RD, **Sperling LS**, Wright BS, Faircloth GC, Gordon TL, Berk MR, Rubenfire M and Franklin BA. Multicenter Study of Temporal Trends in the Achievement of Atherosclerotic Cardiovascular Disease Risk Factor Goals During Cardiac Rehabilitation. *J Cardiopulm Rehabil Prev*. 2017;37:11-21.
75. Ghasemzadeh N, Hayek SS, Ko YA, Eapen DJ, Patel RS, Manocha P, Al Kassem H, Khayata M, Veledar E, Kremastinos D, Thorball CW, Pielak T, Sikora S, Zafari AM, Lerakis S, **Sperling L**, Vaccarino V, Epstein SE and Quyyumi AA. Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death. *Circ Cardiovasc Qual Outcomes*. 2017;10.
76. Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA and Group B-DS. SYNTAX Score and Long-Term Outcomes: The BARI-2D Trial. *J Am Coll Cardiol*. 2017;69:395-403.
77. Ghasemzadeh N, Brooks MM, Vlachos H, Hardison R, Sikora S, **Sperling L**, Quyyumi AA and Epstein SE. An Aggregate Biomarker Risk Score Predicts High Risk of Near-Term Myocardial Infarction and Death: Findings From BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes). *J Am Heart Assoc*. 2017;6.

78. Chaudhry S, Kumar N, Behbahani H, Bagai A, Singh BK, Menasco N, Lewis GD, **Sperling L** and Myers J. Abnormal heart-rate response during cardiopulmonary exercise testing identifies cardiac dysfunction in symptomatic patients with non-obstructive coronary artery disease. *Int J Cardiol.* 2017;228:114-121.
79. Arnold SV, Inzucchi SE, Tang F, McGuire DK, Mehta SN, Maddox TM, Goyal A, **Sperling LS**, Einhorn D, Wong ND, Khunti K, Lam CS and Kosiborod M. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR(R) Research to Practice project. *Eur J Prev Cardiol.* 2017;24:1637-1645.
80. Arnold SV, Goyal A, Inzucchi SE, McGuire DK, Tang F, Mehta SN, **Sperling LS**, Maddox TM, Einhorn D, Wong ND, Hammar N, Fenici P, Khunti K, Lam CSP and Kosiborod M. Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry(R). *J Am Heart Assoc.* 2017;6.
81. Patel RS, Ghasemzadeh N, Eapen DJ, Sher S, Arshad S, Ko YA, Veledar E, Samady H, Zafari AM, **Sperling L**, Vaccarino V, Jones DP and Quyyumi AA. Novel Biomarker of Oxidative Stress Is Associated With Risk of Death in Patients With Coronary Artery Disease. *Circulation.* 2016;133:361-9.
82. Patel RS, Ghasemzadeh N, Eapen DJ, Sher S, Arshad S, Ko YA, Veledar E, Samady H, Zafari AM, **Sperling L**, Vaccarino V, Jones DP and Quyyumi AA. Response to Letter Regarding Article "Novel Biomarker of Oxidative Stress Is Associated With Risk of Death in Patients With Coronary Artery Disease". *Circulation.* 2016;133:e667.
83. Corban MT, Hung OY, Mekonnen G, Eshtehardi P, Eapen DJ, Rasoul-Arzrumly E, Al Kassem H, Manocha P, Ko YA, **Sperling LS**, Quyyumi AA and Samady H. Elevated Levels of Serum Fibrin and Fibrinogen Degradation Products Are Independent Predictors of Larger Coronary Plaques and Greater Plaque Necrotic Core. *Circ J.* 2016;80:931-7.
84. Arnold SV, Inzucchi SE, McGuire DK, Mehta SN, Goyal A, **Sperling LS**, Maddox TM, Einhorn D, Wong ND, Ratner RE, Hammar N, Fenici P, Sheehan JJ, Wong JL and Kosiborod M. Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. *Diabetes Care.* 2016;39:e99-e101.
85. Arnold SV, McGuire DK, Inzucchi SE, Tang F, Mehta SN, Lam CSP, Goyal A, **Sperling LS**, Wong N, Hammar N, Fenici P, Kosiborod M. Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). *J Diabetes Complications.* In press
86. Sandesara PB, O'Neal WT, Kelli HM, Topel M, Samman-Tahhan A, **Sperling LS**. Diastolic blood pressure and adverse outcomes in the Treatment of Preserve Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. *J Am Heart Assoc.* 2017
87. Samman Tahhan A, Sandesara P, Hayek SS, Hammadah M, Alkhoder A, Kelli HM, Topel M, O'Neal WT, Ghasemzadeh N, KoYA, Gafer MM,

- Abdehadi N, Choudhary F, Patel K, Beshiri A, Murtagh G, Kim J, Wilson P, Shaw L, Vaccarino V, Epstein SE, **Sperling L**, Quyyumi AA. High-sensitivity Troponin-I levels and coronary artery disease severity, progression, and long-term outcomes. *J Am Heart Assoc* 2018; In press
88. Sandesara PB, O'Neal WT, Samman AT, Hayek S, Lee SK, Khambhati J, Topel M,L, Hammadah M, Akhodar A, KoY, Gafeer MM, Beshiri A, Murtagh G, Kim mJ, Wilson P, Shaw L, Epstein SE, **Sperling LS**, Quyyumi AA. Comparison of the association between hs-troponin I and adverse outcomes in patients with versus without chronic kidney disease. *Am J Cardiol* 2018; In Press.
89. Sandesara P, O'Neal W, Kelli HM, Mekhoukh J, Sathiyakumar V, Martin S, Blaha M, Blumenthal R, **Sperling LS**. Clinical significance of zero coronary artery calcium in individuals with LDL-C (greater than or equal to) 190 mg / DL: The Multi-Ethnic Study of Atherosclerosis. *JACC CV Imaging* (under consideration) 2018
90. Arnold SV, Echouffo-Tcheuqui J, Lam CSP, Inzucchi SE, Tang F, McGuire DK, Goyal A, Maddox TM, **Sperling LS**, Fonarow GC, Masoudi F, Kosiborod M. Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). *Am Heart J*. 2018 (in press)
91. Kelli H, Tahhan AS, Kim JH, Hammadah M, Sullivan S, Sandesara P, Alkhode A, Choudhary F, Gafeer M, Patel K, Qadir S, Ko YA, Lewis T, Vaccarino V, **Sperling L**, Quyyumi A, Living in Food Deserts and Outcomes in Patients with Cardiovascular Disease. (accepted for publication in *JAHA*, 2018)
92. Hammadah M, Kim JH, Tahhan AS, Kindya B, Liu C, Ko YA, Al Mheid I, Wilmot K, Ramadan R, Alkhder A, Choudhary F, Gafeer MM, Abdehadi N, Pimple P, Sandesara P, Lima BB, Shah AJ, Ward L, Kutner M, Bremner D, Sheps D, Raggi P, **Sperling LS**, Vaccarino V, Quyyumi AA. Use of High-Sensitivity Cardiac Troponin for the Exclusion of Inducible Myocardial Ischemia. (published *Ann Intern Med*, 2018)
93. Wong N, Fan W, Song Y, Inzucchi S, **Sperling L**, Cannon C, Arnold S, Kosiborod M. Composite Cardiovascular Risk Factor Target Achievement in U.S. Adults with Diabetes: The Diabetes Collaborative Registry. (accepted for publication in *Obesity, and Metabolism*, 2019)
94. Sandesara PB, Dhindsa D, Hirsh B, Jokhadar M, Cole RT, **Sperling LS**. PCSK9 Inhibition in Patients with Heart Transplantation: A Case Series (accepted for publication, *J Clin Lipid*, 2019)
95. Arnold SV, Inzucchi SE, Echouffo-Tcheugui JB, Tang F, Lam C, **Sperling LS**, Kosiborod M. Understanding the Contemporary Use of Thiazolidinediones: An Analysis of the Diabetes Collaborative Registry(*Circulation Heart Failure*, 2019, in press)
96. Mehta A, Nayak A, Tahhan AS, Liu C, Ko YA, Dhindsa DS, Kim JH, Hayek SS, **Sperling LS**, Mehta PK, Sun Y, Uppal K, Jones DP, Quyyumi AA. Untargeted High-resolution Plasma Metabolomics Profiling to Predict Outcomes in Patients with Coronary Artery Disease. (accepted for publication, *PLOS One*, 2020).

97. Kelli HM, Mehta A, Tahhan AS, Kim JH, Dong TA, Dhindsa DS, Ghazzal B, Choudhary MK, Sandesara PB, Hayek SS, Topel ML, Alkhoder AA, Gafeer MM, Choudhary FK, Patel K, Liu C, Ko YA, Lewis TT, Vaccarino V, **Sperling LS**, Quyyumi AA. Low Educational Attainment is a Predictor of Adverse Outcomes in Patients with Coronary Artery Disease. (accepted, JAHA, 2019)
98. Sandesara PB, Mehta A, O'Neal WT, Kelli HM, Sathiyakumar V, Martin SS, Blaha MJ, Blumenthal RS, **Sperling LS**. Clinical Significance of Zero Coronary Artery Calcium in Individuals with LDL Cholesterol > 190 mg/ dL. The Multi-Ethnic Study of Atherosclerosis. (accepted for publication, Atherosclerosis, 2020)
99. Gawey BJ, Tannu M, **Sperling LS**, Henry TL. Statin-induced Necrotizing Autoimmune Myopathy. (accepted for publication, JACC Case Reports, 2020)
100. Sandesara PB, Mehta A, O'Neal WT, Mohamed Kelli H, Sathiyakumar V, Martin SS, Blaha MJ, Blumenthal RS, **Sperling LS**. Association of Elevated High-Density Lipoprotein Cholesterol and Particle Concentration With Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis. (accepted for publication, Circ Cardiovasc Imaging. 2020).
101. Mehta A, Desai SR, Ko YA, Liu C, Dhindsa DS, Nayak A, Hooda A, Martini MA, Ejaz K, **Sperling LS**, Reiser J, Hayek SS, Quyyumi AA. Sex Differences in Circulating Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) levels and Adverse Outcomes in Coronary Artery Disease. (accepted for publication, Journal of The American Heart Association, 2020; 9(5)).
102. Mehta A, Pandey A, Ayers CR, Khera A, **Sperling LS**, Szklo MS, Gottesman RF, Budoff MJ, Blaha MJ, Blumenthal RS, Nasir K, Joshi PH. Predictive Value of Coronary Artery Calcium Score Categories for Coronary Events versus Strokes: Impact of Gender and Race: Multiethnic Study of Atherosclerosis and Dallas Heart Study. Circulation Imaging 2020; 13(8).
103. Dhindsa DS, Jin Q, Sandesara PB, Mehta A, Liu C, Tahhan AS, Nayak A, Hooda A, Moazzami K, Islam SJ, Rogers SC, Almuwaqqat Z, Mokhtari A, Hesaroieh I, Ko YA, **Sperling LS**, Waller EK, Quyyumi AA. Circulating Progenitor Cells and Outcomes in Patients with Coronary Artery Disease. (accepted publication, Int J Cardiol, 2023).
104. Mehta A, Meng Q, Desai SR, D'Souza MS, Ho AH, Islam SJ, Dhindsa DS, Nayak A, Alkhoder AA, Hooda A, Varughese A, Ahmad SF, Mokhtari A, Hesaroieh I, **Sperling LS**, Ko YA, Waller EK, Quyyumi AA. Vascular Regenerative Capacity and the Obesity Paradox in Coronary Artery Disease. (accepted, Arteriosclerosis, Thrombosis, and Vascular Biology, 2021)
105. Patel J, Mehta A, Al Rafai M, Blaha MJ, Nasir K, McEvoy JW, Pandey A, Kanaya AM, Kandula NR, Virani SS, Abbate A, **Sperling L**, Joshi PH. Hypertension Guidelines and Coronary Artery Calcification Among South Asians: Mediators of Atherosclerosis in South Asians Living in America (MASALA) And Multi-Ethnic Study of Atherosclerosis (MESA). (Accepted for publication, American Journal of Preventive Cardiology, 2021).

106. Mehta A, Rigdon J, Tattersall MC, German CA, Barringer TA, Joshi PH, **Sperling LS**, Budoff MJ, Bertoni A, Michos ED, Blaha MJ, Stein JH, Shapiro MD. Association of Carotid Artery Plaque with Cardiovascular Events and Incident Coronary Artery Calcium in Individuals with Absent Coronary Calcification: The Multi-Ethnic Study of Atherosclerosis (MESA)- (accepted for publication, *Circulation Cardiovascular Imaging*, 2021)
107. Attipoe-Dorcoo S, Ritchey MD, Loustalot F, Thompson-Paul A, Bull L, **Sperling LS**, Yang P. Characteristics and Trends of PCSK9 Inhibitor Prescription Fills in the United States. *J Clin Lipidol* 2021;S1933-2874(21)0027-1.
108. Almuwaqqat Z, Kim JH, Islam SJ, Tahhan AS, Mehta A, Ahmad S, Vatsa N, Beydoun N, Ejaz K, Dhindsa D, Alkhoder A, Ko YA, **Sperling LS**, Rye D, Quyyumi AA. Usefulness of Restless Legs Symptoms to Predict Cardiovascular Outcomes in Men with Coronary Artery Disease. Accepted for publication, *American Journal of Cardiology*, 2021.
109. Okunrintemi V, Tibuakuu M, Virani S, **Sperling L**, Volgman A, Gulati M, Cho L, Leucker T, Blumenthal R, Michos E. Sex Differences in the Age of Diagnosis for Cardiovascular Disease and Its Risk Factors Among US Adults: Trends from 2008-2017- The Medical Expenditure Panel Survey. (accepted for publication, *JAHA*, 2020)
110. Fanous MM, Gianos EG, **Sperling LS**, Mintz GL, Majure DT, Hirsh BJ. Early use of PCSK9 inhibitor therapy after heart transplantation from Hepatitis C Virus Positive Donors: Practice Management Pearls learned through a Clinical Case Series (accepted to *Journal of Clinical Lipidology*, 2021)
111. Desai S, Dhindsa, DS, Ko YA, Sandesara PB, Mehta A, Liu C, Tahhan AS, Hayek SS, Ejaz K, Hooda A, Alkhoder A, Islam SJ, Rogers SC, Beshiri A, Murtagh G, Kim J, Wilson P, Almuwaqqat Z, **Sperling LS**, Quyyumi AA. Aggregate Clinical and Biomarker-Based Risk Model Predicts Adverse Outcomes in Patients with Coronary Artery Disease. (submitted to *Am J Card*, 2023)
112. Thompson-Paul AM, Gillespie C, Wall HK, Loustalot F, **Sperling L**, Hong Y. Recommended and Observed Statin Use Among U.S. Adults- National Health and Nutrition Examination Survey, 2011-2018. (accepted for publication to *Journal of Clinical Lipidology*, 2022)
113. Knijnik L, Fernandes M, Rivera M, Cardoso R, Goyal A, Liberman H, **Sperling LS**, McDaniel MC. Meta-analysis of Duraton of Dual Antiplatelet Therapy in Acute Coronary Syndrome treated with Coronary Stenting (accepted for publication, *Am J Cardiol*. 2021)
114. Mehta A, Vasquez N, Ayers C, Patel J, Hooda A, Khera A, Blumenthal R, Shapiro M, Rodriguez C, Tsai M, **Sperling L**, Virani S, Blaha M, Joshi P. Independent Association of Lipoprotein (a) and Coronary Artery Calcium with Atherosclerotic Cardiovascular Disease Risk. Accepted for publication, *Journal of the American College of Cardiology*, 2022
115. Liu C, Dhindsa D, Almuwaqqat Z, Ko YA, Mehta A, Alkhoder AA, Patel KJ, Hooda A, Wehbe M, **Sperling LS**, Sun YV, Quyyumi AA. U-Shaped Association between HDL-C Levels and Adverse Cardiovascular Outcomes in High-risk Populations. Published, *JAMA Cardiology*, 2022

116. Jain P, Hejjaji V, Thomas MB, Garcia RA, Tang Y, Tang F, Goyal A, **Sperling L**, Das SR, Hafida S, Enriquez JR, Arnold SV. Use of Bariatric Surgery among Patients with Obesity and Diabetes. Insights from the Diabetes Collaborative Registry. Accepted for publication, International Journal of Obesity, 2022.
117. Oster ME, Shay DK, Su JR, Gee JM, Marquez PL, Strid P, Woo J, Creech CB, Broder KR, Edwards K, Soslow JH, Dendy JM, Schlaudecker E, Lang SM, Barnett ED, Ruberg F, Smith MJ, Campbell MJ, Lopes R, **Sperling LS**, Baumbblatt JA, Thompson DL, Pugsley R, Reagan-Steiner S, DeStefano F, Shimabukuro TT. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US from December 2020 to August 2021. Accepted for publication, JAMA, 2022.
118. Nair PR, Jackson SL, Chang A, Schieb L, Loustalot F, Wall H, **Sperling LS**, Ritchey MD. Antihypertensive and Statin Medication adherence among Medicare Beneficiaries. Accepted for publication, American Journal of Preventive Medicine, 2022
119. Razavi AC, Iftekhhar Uddin SM, Dardari ZA, Berman DS, Budoff MJ, Miedema MD, Osei AD, Obisesan OH, Nasir K, Rozanski A, Rumberger JA, Shaw LJ, **Sperling LS**, Whelton SP, Mortensen MB, Blaha MJ, Dzaye O. Coronary Artery Calcium for Risk Stratification of Sudden Cardiac Death: The Coronary Artery Calcium Consortium. Accepted for publication, JACC Imaging), 2022.
120. Yang PK, Attipoe-Dorcoo S, Park SY, Jackson SL, Ritchey MD, **Sperling LS**. Trends and Characteristics of Blood Pressure fills during the COVID-19 Pandemic in the United States. (submitted for consideration, Hypertension), 2021.
121. Mehta A, Ahmad SF, Meng Q, Ho AH, Zuniga JV, Desai SR, Dhindsa DS, Islam SJ, Almuwaqqat Z, Nayak A, Hooda A, Mokhtari A, **Sperling LS**, Ko YA, Waller EK, Quyyumi AA. Circulating Progenitor Cells Outcomes in Patients with Coronary Artery Disease. (accepted for publication, International Journal of Cardiology), 2022.
122. Mosteoru S, Luca SA, Maximov D, Bucur A, Crisan S, **Sperling L**, Gaita D. Striving to improve the good clinical practice in the time of pandemic: Experience of a Romanian Centre: Preliminary data on COVID-19 Infection. Accepted for publication, Journal of Clinical and Diagnostic Research, 2021.
123. Jain V, Al Rafai M, Khan S, Kalra A, Rodriguez F, Samad Z, Pokharel Y, Misra A, **Sperling LS**, Rana J, Ullah W, Medhekar A, Virani SS. Association between Social Vulnerability Index and Cardiovascular Disease; A Behavioral Risk Factor Surveillance System (BRFSS) Study. Accepted, Journal of American Heart Association, 2022.
124. Keteyian S, Jackson SL, Chang A, Brawner CA, Wall Hk, Forman DE, Sukul D, Ritchey MD, **Sperling LS**. Tracking Cardiac Rehabilitation Utilization in Medicare Beneficiaries-2017 Update. Accepted for publication. Journal of Cardiopulmonary Rehabilitation and Prevention, 2022

125. Abbas A, Hannan J, Stolp H, Coronado F, **Sperling LS**. Commitment to Hypertension Control during the COVID-19 Pandemic- Million Hearts Exemplars. Accepted for publication, Preventing Chronic Disease, 2022
126. Garney WR, Patterson MS, Panjwani S, Garcia K, Spadine MN, Muraleetharan D, Hahn LK, Clymer J, **Sperling L**. A Mixed Methods Network Evaluation of a National Cardiovascular Disease Prevention Effort: The Million Hearts Collaboration (under consideration, Journal of Prevention and Health Promotion, 2021)
127. Minhas AMK, Wyand RA, Ariss RW, Nazir S, Jain V, Al-Kindi SG, Shapiro MD, Clark D, **Sperling L**, Virani SS. Rural-Urban Trends in Congenital Heart Disease-related Mortality in the United States, 1999-2019. Accepted to JACC Advances, 2022.
128. Martin BI, Walter M, Javier G, Carolina R, Fernando G, Mariano G, Gerardo P, Mariano T, Federico A, Silvia , Luis G, Rodolfo, **Sperling L**. Survey of Latin American cardiologists' attitude on Type 2 Diabetes Treatment. (submitted to Global Heart for consideration), 2022.
129. Issa R, Nazir S, Khan Minhas AM, Lang J, Ariss RW, Kayani WT, Khalid MU, **Sperling L**, Shapiro MD, Jneid H, Gupta R. Demographic and Regional Trends in Peripheral Arterial Disease Mortality in the United States, 2000-2019. (accepted for publication, Vascular Medicine), 2023.
130. Khan Minhas AM, Ijaz SH, Javed N, Sheikh AB, Jain V, Michos ED, Greene SJ, Fudim M, Warraich HJ, Shapiro MD, Al-Kindi SG, **Sperling L**, Virani SS. National Trends and Disparities in Statin Use for Ischemic Heart Disease from 2006-2018: Insights from the National Ambulatory Medical Care Survey. Accepted for publication, Am Heart Journal). 2022
131. Liu C, Dhindsa D, Almuwaqqat Z, Ko YA, Mehta A, Alkhoder AA, Alras Z, Desai SR, Patel KJ, Hooda A, Wehbe M, **Sperling LS**, Sun YV, Quyyumi AA. Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations. (accepted for publication, JAMA Cardiol. 2022).
132. Faaborg-Andersen CC, Liu C, Subramaniam V, Desai SR, Sun YV, Wilson PWF, **Sperling LS**, Quyyumi AA. Very High Apolipoprotein A1 Levels are Associated with Increased Mortality. (accepted for publication, European Journal of Preventive Cardiology). 2022
133. Woodruff RC, Garg S, George MG, Jackson SL, Loustalot F, Patel K, Taylor CA, Wortham JM, Whitaker M, Reingold A, Alden NB, Meek J, Anderson E, Weigel A, Henderson J, Bye E, Davis SS, Bennett NM, Barney G, Shiltz E, Sutton M, Talbot HK, Price A, **Sperling LS**, Havers FP for the COVID-19 –Associated Hospital Surveillance Network. Acute Cardiac Events during COVID-19-Associated Hospitalizations-The COVID-19-Associated Hospitalization Surveillance Network. (accepted for publication, JACC, 2023)
134. Ford ND, DeSisto CL, Galang R, Kuklina E, **Sperling L**, Ko Y. Cardiac Arrest during Delivery Hospitalizations, United States, 2007-2019. published, Annals of Internal Medicine, 2023
135. Razavi AC, Dzaye O, Michos ED, Budoff MJ, Allen NB, Lima JAC, Polak JF, Post WS, Nasir K, Blumenthal RS, **Sperling LS**, Blaha MJ, Whelton SP. Non-traditional Risk Markers for Incident Coronary Calcium among

- Persons > 65 Years Old: The Multi-Ethnic Study of Atherosclerosis..(accepted for publication to JACC Advances), 2023.
136. Sekkarie A, Park S, Therrien NL, Jackson SL, Woodruff RC, Attipoe-Dorcoo S, Yang PK, **Sperling L**, Loustalot F, Thompson-Paul AM. Trends in Lipid Lowering Prescriptions: Increasing Use of Guideline Concordant Pharmacotherapies, U.S., 2017-2022. (accepted for publication, American Journal of Preventive Medicine, 2023)
137. Razavi AC, van Assen M, De Cecco CN, Dardari ZA, Berman DS, Budoff MJ, Miedema MD, Nasir K, Rozanski A, Rumberger JA, Shaw LJ, **Sperling LS**, Whelton SP, Mortensen MB, Blaha MJ, Dzaye O. Discordance between Coronary Artery Calcium Area and Density Predicts Long-term Atherosclerotic Cardiovascular Disease Risk. (accepted for publication, JACC CV Imaging, 2022)
138. Arnold SV, Gosch k, Kosiborod M, Wong ND, **Sperling LS**, Newman JD, Vaduganathan M. Contemporary Use of Cardiovascular Risk Reduction Strategies in Type 2 Diabetes: Insights from the Diabetes Collaborative Registry. Accepted for publication, American Heart Journal, 2023
139. Tso JV, Turner CG, Liu C, Miller AB, Eapen DJ, **Sperling LS**, Kim JH. Exercise Blood Pressure Changes and Aortic Dilatation in Male Masters Endurance Athletes. published, European Journal of Preventive Cardiology, 2022
140. Kracalik I, Oster ME, Broder KR, Cortese MM, Glover M, Shields K, Creech CB, Romanson B, Novosad S, Soslow J, Walter EB, Marquez P, Dendy JM, Woo J, Valderrama AL, Ramirez-Cardenas A, Assefa A, Campbell MJ, Su JR, Magill SS, Shay DK, Shimabukuro TT, Basavaraju SV; Myocarditis Outcomes After mRNA COVID-19 Vaccination Investigators and the CDC COVID-19 Response Team. Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study. (accepted for publication, Lancet Child Adolesc Health, 2022.).
141. Faaborg-Andersen CC, Liu C, Subramaniam V, Desai SR, Sun YV, Wilson PWF, **Sperling LS**, Quyyumi AA. U-shaped relationship between apolipoprotein A1 levels and mortality risk in men and women. (accepted for publication, Eur J Prev Cardiol. 2023).
142. Varghese MS, Beatty A, Song Y, Xu J, **Sperling LS**, Fonarow GC, Keteyian SJ, McConeghy KW, Penko J, Yeh RW, Figueroa JF, Wu WC, Kazi DS. Cardiac Rehabilitation and the COVID-19 Pandemic: Persistent Declines in CR Participation and Access Among U.S. Medicare Beneficiaries. (accepted for publication, Circulation: Cardiovascular Quality and Outcomes, 2022)
143. He S, Park S, Lundeen E, Kuklina E, Therrien N, Lampley K, Wall H, Pierce AL, Kompaniyets L, **Sperling L**, Jackson S. Leveraging electronic health records to construct a phenotype for hypertension surveillance in the United States. (submitted to American Journal of Hypertension)
144. Ijaz SH, Minhas AMK, Jain V, Al Rifai M, Mehta A, Dani SS, Fudim M, Al-Kindi SG, **Sperling L**, Shapiro MD, Alam M, Virani SS, Goel SS, Nasir K, Khan SU. Characteristics and outcomes in acute myocardial infarction hospitalizations among the older (Age > 80) population in the United

- States, 2004-2018. (published in Archives of Gerontology and Geriatrics , 2023)
145. Razavi AC, Van Assen M, De Cecco CN, **Sperling LS**, Whelton SP, Blaha MJ, Dzaye O. Discordance Between Coronary Artery Calcium Area and Density Predicts Long-Term Atherosclerotic Cardiovascular Disease Risk. <http://www.acc.org>. Sept 28, 2022
146. Minhas A, Jain V, Li M, Ariss R, Fudim M, Michos E, Virani S, **Sperling L**, Mehta A. Family Income and Cardiovascular Disease Risk in American Adults (accepted for publication, Nature: Scientific Reports, 2023)
147. Asghar A, Talha KM, Waqar E, **Sperling LS**, Shafiq M, Sharafkhaneh A, Virani SS, Ballantyne CM, Nambi V, Minhas AMK. Trends in Sleep Apnea and Heart Failure-Related Mortality in the United States from 1999 to 2019. (submitted to American Heart Journal for consideration, 2023)
148. Jain V, Mehta A, Lee T, Liu C, Chew NWS, Ko YA, Siddiqui MS, Gold ME, Gold DA, Vatsa N, Desai SR, Kim JH, Shalimar, Rahbar A, Haroun Y, Ijaz K, **Sperling LS**, Sanval AJ, Quyyumi AA. Immune Activation and Inflammation Mediate Association of Advanced Hepatic Fibrosis with Adverse Outcomes in patients with Coronary Artery Disease. (published, JAHA, 2023)
149. Mohamed GA, Daly D, Aboul-Nour H, Morales PR, Alabyad D, Minja F, Lemuel-Clarke M, Henriquez L, Navalkele D, **Sperling L**, Lundberg G, Mehta A, Nahab F. Elevated Lipoprotein (a) is Associated with Embolic Stroke of Undetermined Source (ESUS). (submitted to BMJ Stroke and Vascular Neurology for consideration, 2023)
150. Jain V, Minhas AMK, Ariss RW, Nazir S, Khan SU, Khan MS, Al Rafai M, Michos E, Mehta A, Qamar A, Vaughan EM, **Sperling L**, Virani SS. Demographic and Regional Trends of Cardiovascular Disease and Diabetes Mellitus-related Mortality in the United States from 1999 to 2019. (accepted for publication, Am J Med, 2023)
151. Razavi AC, Dzaye O, Michos ED, Budoff MJ, Allen NB, Lima JAC, Polak JF, Post WS, Nasir K, Blumenthal RS, **Sperling LS**, Blaha MJ, Whelton SP. Nontraditional Risk Markers for Incident Coronary Artery Calcium Among Persons ≥ 65 Years of Age. (accepted for publication, JACC Adv. 2023).
152. Varghese MS, Song Y, Xu J, Dahabreh I, Beatty AL, **Sperling LS**, Fonarow GC, Keteyian SJ, McConeghy KW, Yeh RW, Wu WC, Kazi DS. Availability and Use of In-Person and Virtual Cardiac Rehabilitation Among U.S. Medicare Beneficiaries: A Post-Pandemic Update. (accepted for publication, JCRP, 2023).
153. Daly D, Nour HA, Morales PR, Alabyad D, Minja F, Lemuel-Clarke M, Henriquez L, Navalkele D, **Sperling L**, Lundberg G, Mehta A, Nahab F. Elevated Lipoprotein (a) is Associated with Embolic Stroke of Undetermined Source (ESUS). (submitted to the Journal of Clinical Lipidology for consideration, 2023)
154. Ford N, DeSisto C, Womack L, Galan R, Hollier L, **Sperling L**, Wright J, Ko J. Hospitalization with Cardiovascular Conditions in the Postpartum

- Year Among U.S. Commercially Insured Women. (Research Letter, accepted for publication, JACC, 2024).
155. Ye Z, Gilchrist S, Omeaku N, Shantharam S, Ritchey M, Coleman King SM, **Sperling L**, Holl J. Acute Stroke Care Coordination: Variation in State Laws for Emergency Medical Services and Hospitals. (accepted for publication, Journal of Stroke and Cerebrovascular Diseases, 2024).
156. Asghar A, Talha KM, Waqar E, **Sperling LS**, DiNino EK, Sharafkhaneh A, Virani SS, Ballantyne CM, Nambi V, Minhas AMK. Trends in Sleep Apnea and Heart Failure Related Mortality in the United States from 1999 to 2019, (accepted for publication, Current Problems in Cardiology, 2023).
157. Yang P, Park SY, Jackson SL, Attipoe-Dorcoo S, Gray E, Ritchey MD, **Sperling LS**. Trends and Characteristics of Blood Pressure Prescription Fills Before and During the COVID-19 Pandemic in the United States. (accepted for publication, Am J Hypertension, 2023).
158. Razavi AC, Kim C, van Assen M, De Cecco CN, Berman DS, Budoff MJ, Quyyumi AA, Vaccarino V, Miedema MD, Nasir K, Rozanski A, Fernandez C, Rumberger JA, Shaw LJ, Mortensen MB, Wong ND, Blumenthal RS, **Sperling LS**, Whelton SP, Blaha MJ, Dzaye O. Thoracic Aortic Calcium Density and Area in Long-Term Atherosclerotic Cardiovascular Disease Risk Among Men versus Women. (submitted for consideration, Circulation Cardiovascular Imaging, 2023)
159. Vatsa N, Higgins M, Huang J, Desai SR, Gold DA, Gold ME, Jain V, Fatade YK, Rahbar A, Kimble LP, Ko YA, **Sperling LS**, Quyyumi AA, Mehta PK. Patients with Non-Obstructive Coronary Artery Disease and Chest Pain: Impact of Obesity and Depression. (submitted to JAHA for consideration, 2023)
160. Razavi AC, Shaw LJ, Berman DS, Budof MJ, Wong ND, Vaccarino V, Van Assen M, De Cecco CN, Quyyumi AA, Mehta A, Muntner P, Miedema MD, Rozanski A, Rumberger JA, Nasir K, Blumenthal RS, **Sperling LS**, Mortensen MB, Whelton SP, Blaha MJ, Dzaye O. Left Main Coronary Artery Calcium and Diabetes Confers Very-High Risk Equivalence in Patients with Coronary Artery Calcium > 1000. (accepted for publication, JACC Cardiovasc Imaging, 2024)
161. Almuwaqqat Z, Islam S, Desai S, Mehta A, Haroun Y, Martini A, Fueller D, Alras Z, Ko YA, **Sperling LS**, Quyyumi AA. Neighborhood Social Vulnerability and Adverse Cardiovascular Events in Patients with Cardiovascular Disease: The Role of Inflammation. (submitted to Circulation Outcomes for consideration, 2023).
162. Nguyen DQ, Keshvani N, Alebna PL, Dixon DL, Shapiro MD, Michos ED, **Sperling LS**, Pandey A, Mehta A. Temporal Trends and Race-and Sex Differences in LDL Cholesterol Control among US Adults with Atherosclerotic Cardiovascular Disease. Published, American Journal of Preventive Cardiology, 2024
163. Mehta A, Jain V, Lee TB, Liu C, Chew NWS, Ko YA, Siddiqui MS, Patel N, Gold ME, Gold DA, Vatsa N, Desai S, Fudim M, Pandey A, Arora P, Bugianesi E, **Sperling LS**, Sanyal AJ, Quyyumi AA. Association of N-terminal Prohormone of Brain Natriuretic Peptide and Advanced Hepatic

- Fibrosis with Adverse Outcomes in Patients with Coronary Artery Disease. (submitted to JACC Advances for considerations), 2023
164. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, Blaha M, Carson AP, Chang AR, Ciemins E, Go AS, Gutierrez OM, Hwang SJ, Jassal SK, Kovesdy CP, Lloyd-Jones DM, Shlipak M, Palaniappan LP, **Sperling L**, Virani SS, Tuttle K, Neeland IJ, Chow SL, Rangaswami J, Pencina MJ, Ndumele C, Coresh J (For the Chronic Kidney Disease Prognosis Consortium and American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group). Development and Validation of the Predicting Risk of Cardiovascular Disease EVENTS (PREVENT) Equations. Accepted for publication, Circulation. 2023.
 165. Woodruff RC, Melgar M, Pham H, **Sperling LS**, Loustalot F, Kirley PD, Austin E, Yousey-Hindes K, Openo KP, Ryan P, Brown C, Lynfield R, Davis SS, Barney G, Tesini B, Sutton M, Talbot HK, Zahid H, Kim L, Havers F, for the Respiratory Syncytial Virus-Associate Hospitalization Surveillance Network (RSV-NET). Acute Cardiac Events among Adults Aged > 50 Years Hospitalized with Respiratory Syncytial Virus. (published, JAMA Internal Medicine, 2024).
 166. Minhas AMK, Gupta K, Michos ED, Sauer AJ, **Sperling LS**, Nambi V, Abushamat L, Ballantyne CM, Abramov D. County-level Association between Unhealthy lifestyle and Premature Mortality. (submitted to Am J Cardiology for consideration, 2023).
 167. Khan S, Matsushita K, Sang Y, Ballew S, Grams M, Surapaneni A, Blaha M, Carson A, Chang A, Clemins E, Go A, Gutierrez O, Hwang SJ, Jassal S, Kovesdy C, Lloyd-Jones D, Shlipak M, Palaniappan L, **Sperling L**, Virani S, Tuttle K, Neeland I, Chow S, Rangaswami J, Pencina M, Ndumele C, Coresh J. Development and Validation of the Predicting Risk of Cardiovascular Disease EVENTS (PREVENT) Equations. (accepted to Circulation for publication, 2023).
 168. Minhas AMK, Matthew RO, **Sperling LS**, Nambi V, Virani S, Shapiro MD, Abramov D. Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States (accepted as Research Letter, JACC, 2024)
 169. Razavi AC, Richardson L, Dzaye O, Whelton SP, Mehta A, Quyyumi AA, Vaccarino V, Budoff MJ, Nasir K, Blaha MJ, Blumenthal RS, Coronado F, **Sperling LS**. Aspirin use for Primary Prevention Among U.S. Adults with and without Elevated Lipoprotein(a). (submitted to JAMA Cardiology for consideration, 2023).
 170. Osei J, Razavi AC, Otchere B, Bonful G, Akoto N, Akyea R, Qureshi N, Coronado F, Moonesinghe R, Kolor K, Mensah G, **Sperling L**, Khoury MJ. A Scoping Review of electronic health records (EHR)-based screening algorithms for Familial Hypercholesterolemia: Big Potential for Big Data. (submitted for consideration, JACC Advances, 2023).
 171. Razavi AC, Richardson LC, Coronado F, Dzaye O, Bhatia HS, Mehta A, Quyyumi AA, Vaccarino V, Budoff MJ, Naisr K, Tsimikas S, Whelton SP, Blaha MJ, Blumenthal RS, **Sperling LS**. Aspirin Use of Primary Prevention among U.S. Adults with and without Elevated Lipoprotein (a). (accepted for publication, American Journal of Preventive Cardiology) 2024

172. Razavi AC, Zhang AMC, Dardari ZA, Nasir K, Khorsandi M, Mortensen MB, Al-Mallah MH, Shapiro MD, Daubert MA, Blumenthal RS, **Sperling LS**, Whelton SP, Blaha MJ, Dzaye O. Applying the SELECT Trial to MESA, JACC Imaging. 2024.10.004
173. Gold ME, Kulkarni S, Yadalam A, Patel K, Gold DA, Vatsa N, Jain V, Razavi A, Ko YA, Liu C, Varounis C, Murtagh G, Gupta D, **Sperling LS**, Quyyumi AA. Vitamin D, Cardiac Allograft Vasculopathy, and Cardiovascular Outcomes Following Heart Transplantation. (submitted for consideration, JACC HF, 2024).
174. Kim K, Faruque SC, Lam S, Kulp D, He X, **Sperling LS**, Eapen DJ. Implications of Diagnosis Through a Machine Learning Algorithm on Management of People with Familial Hypercholesterolemia. (accepted for publication, JACC Advances, 2024).
175. Razavi AC, Richardson L, Coronado F, Bhatia HS, Tsimikas S, Shapiro MD, Quyyumi AA, Vaccarino VA, Dzaye O, Marvel FA, Martin SS, Blaha MJ, Whelton SP, Blumenthal RS, **Sperling LS**. Prevalence and Correlates of Lipoprotein (a) Testing in a Diverse Cohort of U.S. Adults: The All of US Research Study. (submitted for consideration, AJPC, 2024)
176. Vatsa N, Dave E, Higgins M, Huang J, Desai SR, Gold DA, Gold ME, Jain V, Fatade YK, Rahbar A, Kimble LP, Ko YA, **Sperling LS**, Quyyumi AA, Mehta PK. Patients with Nonobstructive coronary Artery Disease and Chest Pain: Impact of Obesity and Depressive Symptoms. (accepted for publication, J Am Heart Assoc. 2024).
177. Razavi AC, Mehta A, Wong ND, Rozanski A, Budoff MJ, Gianos E, Vaccarino V, van Assen M, De Cecco CN, Miedema MD, Rumberger JA, Mortensen MB, Shaw LJ, Nasir K, Blumenthal RS, Rohatgi A, Quyyumi Aa, **Sperling LS**, Whelton SP, Blaha MJ, Berman DS, Dzaye O. Coronary Artery Calcium for Risk Stratification Among Persons with Very-High HDL-Cholesterol (accepted for publication, JACC Advances, 2024)
178. Kim K, Faruque SC, Kulp D, Lam S, **Sperling LS**, Eapen DJ. Primary care clinician engagement in implementing a machine-learning algorithm for targeting screening of Familial Hypercholesterolemia. Accepted for publication, AJPC, 2024.
179. Woodruff RC, Melgar M, Pham H, **Sperling LS**, Loustalot F, Kirley PD, Austin E, Yousey-Hindes K, Openo KP, Ryan P, Brown C, Lynfield R, Davis SS, Barney G, Tesini B, Sutton M, Talbot HK, Zahid H, Kim L, Havers. Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection. (accepted for publication, JAMA Intern Med. 2024).
180. Mousavi I, Nambi V, Abushamat LA, Al-Kindi SG, Shapiro MD, Sperling LS, Virani SS, Minhas AMK. Bempedoic Acid in Secondary Prevention. Accepted for publication, AJPC, 2024.
181. Vatsa N, Bennett J, Vatsa S, Rahbar A, Gold D, Jain V, Gold ME, Razavi A, Yadalam A, Desai S, Owais M, Hartsfield J, Ko YA, **Sperling L**, Vaccarino V, Mehta PK, Quyyumi AA. The Impact of Changes in Depression on Cardiovascular Outcomes in Patients with Coronary Heart Disease. Accepted for publication. JACC Advances. 2024.

182. **Sperling, LS**. The “Ticking Clock” of Impending Diabetes: Cause for Concern or Window of Opportunity? (accepted for publication, J Am Coll Cardiol. 2024).
183. Razavi AC, Reyes MP, Wilkins JT, Szklo M, Tsai MY, Whelton SP, **Sperling L**, Tsimikas S, Bhatia HS. Traditional Risk Factors, Optimal Cardiovascular Health, and Elevated Lipoprotein (a). (accepted for publication, EJPC, 2024).
184. Pollack LM, Chang A, Wall HK, Stolp H, **Sperling LS**, Keyeyian SJ, Thompson MP, Jackson SL. Cardiac Rehabilitation Metrics by Hospital-level Tiers of Cardiac Care. (accepted for publication, AHJ, 2024)
185. Razavi AC, Dzaye O, Cainzos-Achirica M, Dardari Z, Van Assen M, Quyyumi AA, Nasir K, Car JJ, Budoff MJ, Blumenthal RS, Raggi P, De Cecco CN, **Sperling LS**, Blaha MJ, Whelton SP. Association of Thoracic Aortic Calcium with Incident Cardiovascular Disease and All-Cause mortality Across the Spectrum of Coronary Artery Calcium Buren. (accepted for publication, AJPC, 2024).
186. Pollack LM, Kompaniyets L, Chang A, Thompson MP, Keyeyian SJ, Stolp H, Wall HK, **Sperling LS**, Jackson SL. Cardiac Rehabilitation Trends Among Commercially Insured Adults in the United States, 2017-2023. (accepted for publication, Circulation Cardiovascular Quality and Outcomes, 2025).
187. Minhas AMK, **Sperling LS**, Al-Kindi S, Abramov D. Underlying and Contributing Causes of Mortality from CDC WONDER- Insights for Researchers. American Heart Journal Plus. 2025; (50); 100499.
188. Abramov D, Minhas AMK, Gupta K, Michos ED, Sauer AJ, **Sperling L**, Nambi V, Abushamat L, Ballantyne C. Count-level Association between Modifiable Health Behaviors and Premature Mortality in the United States. (accepted for publication, Preventive Medicine Reports, 2025).
189. Vatsa N, Rahbar A, Kauser T, Kirksey A, Gold DA, Jain V, Gold ME, Wang H, Mehta C, Moran CA, Smith AK, Hagen K, Ofotokun I, Lahiri CD, **Sperling L**, Vaccarino V, Mehta PK, Quyyumi AA, Neigh GN, Michopoulos V. Posttraumatic Stress Disorder Is Associated With Endothelial Dysfunction in Women With HIV. (accepted for publication, JACC Adv. 2025),
190. Razavi AC, Cao Zhang AM, Dardari ZA, Nasir K, Khorsandi M, Mortensen MB, Al-Mallah MH, Shapiro MD, Daubert MA, Blumenthal RS, **Sperling LS**, Whelton SP, Blaha MJ, Dzaye O. Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA. (accepted for publication, JACC Cardiovasc Imaging, 2025).
191. Essa M, RR Decker S, Liang L, Song Y, Verghese M, Figueroa J, **Sperling L**, Fonarow G, Keteyian S, Thompson M, Beatty A, Kazi D. Use of Cardiac Rehabilitation in Older Patients with Myocardial Infarction Complicated by Cardiogenic Shock. (accepted for publication, JACC, 2025).
192. Chong B, Jayabaskaran J, Jauhari S, Chia J, le Roux C, Mehta A, Dimitridis G, Chen Y, Toh S, Mania Y, Al Mahmeed W, Chan SP, Goh R, Nagarajan S, Li H, Kong G, Chin YH, Wang JW, Chew HS, Kontopantelis E, Muthiah M, Tan J, Hausenloy D, Figtree G, Mamas M, Richards M,

- Nicholls S, Chan M, Lip g, Roth G, Mensah G, **Sperling L**, Chew N. The Global Syndemic of Modifiable Cardiovascular Risk Factors Projected from 2025 to 2050. (accepted for publication, JACC, 2025).
193. Bhatia HS, Ambrosio M, Razavi Ac, Alebna PL, Yeang C, Spitz J, Patel J, Tsai MY, **Sperling L**, Shapiro MD, Tsimikas S, Mehta A. Evaluation of the AHA PREVENT Equations and Lipoprotein (a): Insights from MESA and the UK Biobank. published, JAMA Cardiology, 2025.
194. Razavi AC, Richardson L, Coronado F, Vesper H, Lyle A, Bhatia H, Tsimikas S, Quyyumi A, Vaccarino V, Eapen D, Isiadinso I, Mehta A, Yadalam A, Osei J, Jacobson T, Yao Z, Dzaye O, Martin S, Nasir K, Shapiro M, Blaha M, Whelton S, Blumenthal R, **Sperling L**. Prevalence and Correlates of Lipoprotein (a) Testing in a Diverse Cohort of United States Adults. published, JACC Advances, 2025.
195. Gold ME, Kulkarni S, Yadalam A, Patel KJ, Gold Da, Vatsa N, Jain V, Razavi A, Ko YA, Liu C, Varounis C, Murtagh G, Gupta D, **Sperling LS**, Quyyumi AA. Cardiac Allograft Vasculopathy Mediates the Relationship Between Vitamin D Deficiency and Cardiovascular Mortality Following Heart Transplantation. accepted for publication, American Heart Journal, 2025.
196. Osei J, Razavi AC, Quyyumi AA, Eapen DJ, Sun YV, Khoury MJ, **Sperling L**. Sex and Racial Differences in Prevalence and Clinical Characteristics of People Living with LDLR and PCSK9 Familial Hypercholesterolemia Genetic Variants: Data from the All of Us Research Program. published, American Journal of Preventive Cardiology, 2025.
197. Peng A, Razavi A, Wilkins J, Allen N, **Sperling L**, Rana J, Bimal T, Whelton S, Blaha M, Blumenthal R, Gianos E. Long-Term Cumulative LDL-Cholesterol Exposure and CVD Events in Young Adults with CAC=0: Insights from the CARDIA Study. published, JACC, 2025)
198. Chong B, Jayabaskaran J, Jauhari SM, Chia J, le Roux CW, Mehta A, Dimitriadis GK, Chen Y, Toh SA, Manla Y, Al Mahmeed W, Pang S, Goh R, Nagarajan S, Li H, Kong G, Chin YH, Wang JW, Chew J, Kontopantelis E, Muthiah M, Tan JWC, Hausenloy D, Figtree GA, Mamas MA, Richards AM, Nicholls SJ, Chan MY, Lip GYH, Roth G, Mensah GA, **Sperling LS**, Chew NWS. The Global Syndemic of Modifiable Cardiovascular Risk Factors Projected From 2025 to 2050. published, JACC, 2025.
199. Razavi AC, Bhatia HS, Dardari ZA, Mehta A, Nasir K, Blankstein R, Isiadinso I, Quyyumi AA, Vaccarino V, Fialkow JA, Khoury MJ, Coronado F, Budoff MJ, Blumenthal RS, Whelton SP, Mortensen MB, **Sperling LS**, Matsushita K, Blaha MJ, Dzaye O. Family History of Premature Atherosclerotic Cardiovascular Disease and Lipoprotein (a) Levels: A Multi-Cohort Analysis. published, EJPC, 2025.
200. Yadalam AK, Liu C, Hui Q, Razavi A, **Sperling LS**, Quyyumi AA, Sun Y. Large-Scale Proteomics-Based Risk Score for the Prediction of Incident Cardio-Kidney Metabolic Disease Risk. accepted for publication, Circulation: Genomic and Precision Medicine, 2025.
201. Razavi AC, Chen J, Yang W, Sha D, Dzaye O, Bhatia HS, Tsimikas S, Lash J, Kansal M, Rincon-Coles H, Jacobson TA, Budoff MJ, Blumenthal RS, Whelton SP, **Sperling LS**, Blaha MJ, He J and the CRIC Study

- Investigators. Primary Prevention Aspirin, Lipoprotein (a), and Cardiorenal Outcomes in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort. Accepted for publication in JACC Advances, 2025.
202. Gu J, Sanchez RJ, Koumas A, Tripathi S, Dixit H, Amer A, **Sperling L**, Ballantyne CM. Simulation Model to Estimate pretreatment (baseline) Untreated LDL-C Levels in People Living with Homozygous Familial Hypercholesterolemia- Calculator. (accepted for publication, JCL, 2025).
203. Brook RD, Roa PA, Levy PD, Bauer SJ, Korzeniewski S, **Sperling LS**, Al-Kindi S, Rajagopalan S. Are Daily Fine Particulate Matter Air Quality Index Activity Guidelines an Effective Public Health Strategy for Preventing Cardio-pulmonary events in the United States? (published AJPC, 2025).
204. Gershon G, Barr JR, Razavi AC, Yang Y, Momin E, Dzaye O, Whelton SP, Blaha MJ, Blumenthal RS, **Sperling LS**, De Cecco C. Coronary Artery Calcium Burden Across the Pooled Cohort Equation versus the American Heart Association PREVENT Risk Calculator. (published, AJPC, 2025).
205. Huang J, Leon A, Ossi J, Ko YA, Alcaro L, Ahmed T, Medina-Inojosa JR, Harris K, Alkhoder A, Yang H, Al Kasem M, Lodhi R, Lodhi S, Eldaidamouni A, Hritani W, Haroun N, Hasan M, **Sperling LS**, Quyyumi AA, Mehta PK. A multi-proteomic Biomarker Risk Score Predicts Adverse Cardiovascular Outcomes in Patients with Angina and Non-Obstructive Coronary Artery Disease. (submitted to ATVB for consideration, 2025).
206. MacDougall DE, Ferdinand K, Baum SJ, **Sperling L**, Hartsuff BK, Wilemon KA, Nissen SE. Cholesterol Management in US Adults with ASCVD in the Family Heart Database during 2022-2023: Current State of Care and Opportunities for Improvement. Published. AJPC, 2025.
207. Razavi AC, Bhatia HS, Marrero N, Dzaye O, Post WS, Nasir K, Tsai M, Vaccarino V, Vasan RS, Thanassoulis G, Tsimikas S, **Sperling LS**, Budoff MJ, Blumenthal RS, Blaha MJ, Whelton SP. Regular Aspirin Use, Lipoprotein (a), LDL-Cholesterol, and Calcific Aortic Valve Disease: The Multi-Ethnic Study of Atherosclerosis. (accepted for publication, EHJ, 2025)
208. Bardach SH, Chernichky-Karcher S, Hawke A, MacDougall D, Wilemon K, **Sperling LS**. Examining Barriers and Facilitators to Assessment of Lipoprotein (a): Understanding At-Risk Individual and Clinician Perspectives. (accepted for publication, Journal of Clinical Lipidology, 2025)
209. Osei J, Najarro G, **Sperling L**, Khoury MJ, Sun YV. Trends in Adoption of Familial Hypercholesterolemia Diagnostic Code E78.01 Across U.S. Healthcare Databases, 2016-2024. (accepted for publication, JACC Advances, 2025)
210. Razavi AC, Dzaye O, Bhatia, HS, Vaccarino V, Mehta A, Rotter JI, Guo X, Taylor KD, Yao J, Li X, Rich SS, Budoff MJ, Tsai MY, Blankstein R, Shapiro MD, Nasir K, Tsimikas S, Blumenthal RS, Whelton SP, Blaha MJ, **Sperling LS**. Modeling Benefits of Aspirin According to Lipoprotein (a) and Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis. (accepted for publication, JACC Imaging, 2025)
211. Alebna PL, Ambrosio M, Dod R, Campbell M, Carbone S, Chew N, Pagidipati N, Quyyumi AA, **Sperling L**, Salloum FN, Shapiro MD, Mehta A.

- Evaluation of the PREVENT risk assessment tool and visceral adiposity: Insights from the UK Biobank. (accepted for publication, *Progress in Cardiovascular Diseases*, 2025).
212. Dapamede T, Urooj A, Joshi V, Gershon G, Li F, Chavoshi M, Brown-Mulry B, Isacc RS, Mansuri A, Robichaux C, Ayoub C, Arsanjani R, **Sperling L**, Gichoya J, van Assen M, O'Neill WC, Banerjee I, Trivedi H. Artificial intelligence-based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality. Published EHJ 2026. Ehag128. 09 March 2026
 213. Himan HR, Chen Y, Yazicioglu Y, Kong G, Tan EE, Intaran MAU, Zhou XD, Zheng MH, Khan MS, Mamas M, Chan MYY, Vidal-Puig, A. Mensah G, Shapiro M, Ray K, **Sperling L**, Chew N. Comparison of AHA Cardiovascular-Kidney-Metabolic and EAS Systemic Metabolic Disorder Frameworks: Stage Classification, Multi-Organ Imaging, and 10-Year Cause-Specific Mortality Outcome. (under review, *Circulation*, 2026).
 214. Rokosh RS, **Sperling L**, Quyyumi A, Rajani RR, Duwayri Y, Garcia-Toca M, Mena-Hurtado C, Smolderen KG, Romain G, Alabi O. Premature peripheral arterial disease (PAD) is associated with worse outcomes after endovascular peripheral vascular intervention. (accepted for publication, *Journal of Vascular Surgery*, 2026).
 215. Lian LY, Chen QF, Xia T, Huang CX, Wei YX, Targher G, Byrne CD, **Sperling LS**, Lip GYH, Pang Y, Wu SS, Ju S, Zhou XD, Zheng MH. Trajectory of liver-related events following incident cardiovascular disease in MASLD: 15-year population-based cohort study. (published, *Metabolism*. 2026(183): 156692.
 216. Huang J, Liu C, **Sperling LS**, Quyyumi AA, Sun YV. Proteomic Mediators Linking Autoimmune Diseases to Major Adverse Cardiovascular Events: Insights from the UK Biobank. (accepted for publication, *Proteomes*, 2026).
 217. Tioh JK, Tsubasa T, Mori K, Takahashi H, Muthiah M, Mehta A, **Sperling L**, Ng CH, Huang W, Yoneda M. Performance of Cardiovascular Risk Equations for Cardiovascular Mortality Prediction in Adults with Metabolic-Dysfunction-Associated Steatotic Liver Disease. (accepted for publication, *American Journal of Cardiology*, 2026).

c. **Review articles / Guidelines / Scientific Statements:**

1. **Sperling LS** and Delafontaine P. The current use of calcium antagonists. *Resident and Staff Physician* 1998; 44(6):68-72.
2. **Sperling, LS**, Nell C, Adams L, Barakat I. Case studies in preventive cardiology. *Cardiology Board Review Manual Hospital Physician* 1999; 5(3):1-12.
3. Kirby JF and **Sperling LS**. Electron beam computed tomography: a noninvasive method to evaluate coronary artery disease. *Physician Assistant Journal* 2000; 24(1):32-50.
4. Sorrentino M, **Sperling L**. The diet dilemma: Finding a rational resolution. *Lipid Letter* 2003; 3(2):1-9.
5. **Sperling, LS**. Follow-up of PROVE-IT. *ACC Current Journal Review*. 2004; 13(10):13-15.

6. **Sperling, LS.** TLC: Strategies for promoting a heart-healthy lifestyle. *Lipid Letter.* 2004; 4(2): 1-7.
7. Blumenthal RS and **Sperling LS.** Identifying and managing the vulnerable family. *Lipid Letter* 2005; 5(1):2-11.
8. Pacini R, Patel DR, Bavikati V, **Sperling LS.** Prehypertension: Detection, evaluation, and management. *Current Treatment Options in Cardiovascular Medicine* 2008;10:273-282.
9. Pandian A, **Sperling LS,** Khan BV. Targeting multiple dyslipidemias with fixed combinations-A focus on extended release niacin and simvastatin. *Vascular Health/Risk Management*, 2008 October; 4(5): 1001–1009.
10. Smiley WH, Khan BV, **Sperling LS.** Management of the statin-intolerant patient. *Current Treatment Options in Cardiovascular Medicine* 2009, 11:263-271.
11. Mehta PK, Baer J, Nell C, **Sperling LS.** Low-density lipoprotein apheresis as a treatment option for hyperlipidemia. *Current Treatment Options in Cardiovascular Medicine* 2009, 11:279-288.
12. Ramsden CE, Favrot KR, Carera-Bastos P, Cordain L, DeLorgeril M, **Sperling LS.** Dietary fat quality and coronary heart disease prevention: A unified theory based on evolutionary, historical, global and modern perspectives. *Current Treatment Options in Cardiovascular Medicine* 2009, 11:289-301.
13. Brown WV, Brown AS, Raggi P, **Sperling LS.** Appropriate use of non-invasive vascular measures in prevention of arterial disease. *Journal of Clinical Lipidology*, 2009 3(5).
14. Bajpai A, Goyal A, **Sperling L.** Should we measure C-Reactive Protein on Earth or just on Jupiter? *Clinical Cardiology* 2010 33(4):190-198.
15. Bhatt KN, Wells BJ, **Sperling LS,** Baer J. High Density Lipoprotein Therapy: Is There Hope? *Current Treatment Options in Cardiovascular Medicine.* 2010;12(4):315-28.
16. Abraham, NS, Hlatky MA, Antman AM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, **Sperling LS,** Tomaselli GF. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: a Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. *J Am Coll Cardiol.* 2010;56(24):2051-66.
17. Abraham, NS, Hlatky MA, Antman AM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, **Sperling LS,** Tomaselli GF. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: a Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. *Am J Gastroenterol.* 2010;105(12):2533-49..
18. Abraham, NS, Hlatky MA, Antman AM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley

- EM, Scheiman J, **Sperling LS**, Tomaselli GF. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: a Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. *Circulation*. 2010;122(24):2619-33.
19. Abd, TT, Eapen DJ, Bajpai A, Goyal A, Dollar A, **Sperling L**. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: Implications from the JUPITER trial. *Curr Atheroscler Rep* 2011;13:154-161..
20. Ramjee V, **Sperling LS**, Jacobson TA. Non-HDL versus ApoB in Cardiovascular Risk Stratification: Do the Math. *J Am Coll Cardiol* 2011;58 (5):457-63.
21. Eapen DJ, Manocha P, Valiani K, Mantini N, **Sperling L**, McGorisk GM. Alcohol and the Heart: An ounce of Prevention. *Current Treatment Options in Cardiovascular Medicine*, 2011 Volume 13, Issue 2: 313-25
22. Burroughs Pena M, Patel DR, Rodriguez Leyva D, Khan BK, **Sperling L**. Lifestyle Risk Factors and Coronary Heart Disease in Cubans and Cuban Americans. *Cardiol Res Pract*. 2012;470705.
23. Shen J, Goyal A, **Sperling L**. The Emerging Epidemic of Obesity, Diabetes, and the Metabolic Syndrome in China. *Cardiol Res Pract*. 2012;178675.
24. Ramjee V, **Sperling LS**, Jacobson TA. The good, the bad, and the atherogenic.(Author reply) *J Am Coll Cardiol* 2012;59(14):1334.
25. Ramjee V, Eapen DJ, **Sperling LS**. Optimal lipid targets (OLT) in the new era of cardiovascular prevention. *Ann NY Acad Sci*.2012; 1254:106-14.
26. **Sperling, LS**. Lessons about the heart, of the heart, and from the heart: Remembering J. Willis Hurst. *Clin. Cardiol*. 2012. 35,4,199
27. Martin SS, Metkus TS, Horne A, Blaha M, Hasan R, Campbell CY, Yousuf O, Joshi P, Kaul S, Miller M, Michos E, Jones SR, Gluckman TJ, Cannon CP, **Sperling LS**, Blumenthal RS. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines and, in the meantime, some challenges and recommendations. *Am J Cardiol*. 2012;110(2):307-13.
28. Ramjee V, Jacobson T, **Sperling LS**. What should we measure to calculate CV risk- LDL, non-HDL, or apo B? (published as expert opinion in ACC Cardiosource);2012.
29. Daruwalla J, Nell C, **Sperling L**, Book W. All in the family? Review of pregnancy associated cardiomyopathy. *J Med Assoc Ga*. 2013;102(3):24-5.
30. Knowles JW, O'Brien EC, Greendale K, Wilemon K, Genest J, **Sperling LS**, Neal WA, Rader DJ, Khoury MJ. Reducing the burden of disease and death from familial hypercholesterolemia: A call to Action. *Am Heart J* 2014;168:807-11.
31. Knapper J, Schultz JC, Das G, **Sperling L**. Cardiac platypnea-orthodeoxia syndrome: an often unrecognized malady. *Clin Cardiol*. 2014;37(10):645-9.

32. Gaita D, Mosteoru S, **Sperling L**. Diabetes management: Lowering cardiovascular risk. *European Cardiology Review* 2014;9(1):7-9.
33. Feldman DI, Blaha MJ, Santos RD, Jones SR, Blumenthal RS, Toth PP, **Sperling LS**, Martin SS. Recommendations for the management of patients with Familial Hypercholesterolemia. *Curr Atheroscler Rep*. 2015;17(1):473.
34. Wilmot KA, Khan A, Krishnan S, Eapen DJ, **Sperling L**. Statins in the Elderly: A Patient-focused Approach. *Clin Cardiol*. 2015;38(1):56-61.
35. Lambert CT, Sandesara PB, Isadinso I, Gongora CN, Eapen D, Bhatia NK, Baer JT, **Sperling**. Current Treatment of Familial Hypercholesterolemia. *European Cardiology Review* 2014;9(2):76-81.
36. Sandesara PB, Lambert CT, Gordon NF, Franklin BA, Wenger NK, **Sperling L**. Cardiac Rehabilitation and Risk Reduction: Time to "Rebrand and Reinvigorate" *J Am Coll Cardiol* 2015;65:389-95.
37. Martin SS, **Sperling LS**, Blaha MJ, Wilson PWF, Gluckman TJ, Blumenthal RS, Stone NJ. Spotlight on the Clinician-patient risk discussion for ASCVD Prevention: Importance to implementation of the 2013 ACC / AHA Guidelines. *J Am Coll Cardiol* 2015;65(13):1361-1368.
38. Shen J, Wilmot KA, Ghasemzadeh N, Molloy DL, Burkman G, Mekonnen G, Gongora CM, Quyyumi AA, **Sperling LS**. Mediterranean Dietary Pattern and Cardiovascular Health. (accepted for publication in the *Annual Review of Nutrition*, volume 35).
39. **Sperling LS**. Safety and Trust, Above All Else. *J Am Coll Cardiol* 2015;65:1593-1594.
40. Hirsh BJ, Smilowitz NR, Rosenson RS, Fuster V, **Sperling LS**. Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy after Acute Coronary Syndrome: Opportunities for Improvement. *J Am Coll Cardiol* 2015;66:184-92.
41. MacNamara JP, Eapen DJ, Quyyumi AA, **Sperling L**. Novel biomarkers for Cardiovascular risk assessment: Current status and future directions. *Future Cardiology*, accepted for publication in September of 2015.
42. **Sperling LS**, Mechanick JI, Neeland IJ, Herrick CJ, Despres JP, et al. The Cardiometabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. *J Am Coll Cardiol* 2015;66:1050-67.
43. **Sperling LS**, Nelson JR. History and Future of Omega-3 Fatty Acids in Cardiovascular Disease (under review, *Mayo Clinic Proceedings*)
44. Kopecky S, Baum S, Foody JM, Koren M, McKenney J, **Sperling L**, Wong N. Insights into Statin Intolerance. *Clin Cardiol* 2015;38(9):520-526.
45. Lambert CT, Sandesara PB, Hirsh B, Shaw LT, Lewis W, Quyyumi AA, Schinazi RF, Post WS, **Sperling L**. HIV, HAART, and the Heart: A Cellular to Epidemiologic Review. (accepted to *HIV Medicine*).
46. Knapper JT, Ghasemzadeh N, Khayata M, Patel SP, Quyyumi AA, Mendis S, Mensah GA, Taubert K, **Sperling LS**. Time to Change our Focus: Defining, Promoting, and Impacting Cardiovascular Population Health. *J Am Coll Cardiol* 2015;66:960-71.
47. Forman DE, Alexander K, Brindis RG, Curtis AB, Maurer M, Rich MW, **Sperling L**, Wenger NK. Improved Cardiovascular Disease Outcomes in

- Older Adults. (accepted for publication, F1000Faculty Reviews, Jan 2016:112)
48. **Sperling LS**, Nelson JR. History and Future of Omega-3 Fatty Acids in Cardiovascular Disease. (accepted to Current Medical Research and Opinion)
 49. Varghese T, Schultz WM, McCue AA, Lambert CT, Sandesara PB, Eapen DJ, Gordon NF, Franklin BA, **Sperling LS**. Physical Activity in the Prevention of CHD: Implications for the Clinician. (accepted for publication, BMJ-Heart, 2016)
 50. Schultz WM, Varghese T, Heintz RE, Dhindsa DS, Mahlof EN, Cai HC, Southmayd G, Sandesara PB, Eapen DJ, **Sperling LS**. Natural Approaches in Diabetes management: A review of diet, exercise, and natural products. (accepted for publication, Current Pharmaceutical Design).
 51. Heintz RE, Dhindsa DS, Mahlof EN, Schultz WM, Ricketts J, Varghese T, Esmaeeli A, Allard-Ratick M, Kelli HM, Sandesara PB, Eapen DJ, **Sperling L**. Comprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in the Metabolic Syndrome and Diabetes. (accepted for publication Canadian Journal of Cardiology)
 52. Eapen DJ, Schultz WM, Heintz RE, Ghasemzadeh N, Varghese T, Kurian DE, Mathai CE, Sandesara P, Kindya BR, Allard-Ratick MP, Bhatia NK, Isiadinso I, **Sperling LS**. Primary Prevention of Cardiovascular Disease. (accepted to Cardiovascular Innovations and Applications)
 53. Wong ND, **Sperling LS**, Baum SJ. The American Society for Preventive Cardiology: Our 30 Year Legacy. (accepted to Clinical Cardiology)
 54. Heintz RE, Ricketts JC, Tennant HM, Sandesara PB, Moriarty PM, **Sperling L**. Lipoprotein X Disease in the Setting of Severe Cholestatic Hepatobiliary Autoimmune Disease. (accepted for publication, Journal of Clinical Lipidology)
 55. **Sperling LS**, Sandesara PPB, Kim JH. Exercise is Medicine: Proof ...and Possibilities? (invited editorial, accepted for publication in JACC Imaging)
 56. Hammadah M, Kindya BR, Allard-Ratick MP, Jazbeh S, Eapen D, Wilson Tang WH, **Sperling L**. Navigating Air Travel and Cardiovascular Concerns: Is the Sky the Limit? (under review, Clinical Cardiology)
 57. Isakadze N, Sandesara PB, Patel R, Baer J, Isiadinso I, Alonso A, Lloyd M, **Sperling L**. Atrial Fibrillation: Focus on Prevention (under review, JAMA IM)
 58. Lee SK, Khambhati J, Varghese T, Stahl E, Kumar S, Sandesara PB, Wenger NK, **Sperling L**. Comprehensive Primary Prevention of Cardiovascular Disease in Women. (under review, Clinical Cardiology)
 59. Khambhati J, Allard-Ratick M, Dhindsa D, Lee S, Chen J, Sandesara PB, Quyyumi AA, Wong ND, Blumenthal RB, **Sperling L**. The Art of Cardiovascular Risk Assessment. (under review, JAMA Cardiology)
 60. Franklin BA, Brinks J, Berra K, Lavie CJ, Gordon NF, **Sperling LS**. Using Metabolic Equivalents in Clinical Practice. *Am J Cardiol*. 2017.
 61. **Sperling LS**, Sandesara PB and Kim JH. Exercise Is Medicine: Proof . . and Possibilities? *JACC Cardiovasc Imaging*. 2017.

62. Lee SK, Khambhati J, Varghese T, Stahl EP, Kumar S, Sandesara PB, Wenger NK and **Sperling LS**. Comprehensive primary prevention of cardiovascular disease in women. *Clin Cardiol*. 2017;40:832-838.
63. Heintz RE, Tennant HM, Ricketts JC, Rice CR, Robinson CB, Sandesara PB, Moriarty PM and **Sperling L**. Lipoprotein-X disease in the setting of severe cholestatic hepatobiliary autoimmune disease. *J Clin Lipidol*. 2017;11:282-286.
64. Hammadah M, Kindya BR, Allard-Ratick MP, Jazbeh S, Eapen D, Wilson Tang WH and **Sperling L**. Navigating air travel and cardiovascular concerns: Is the sky the limit? *Clin Cardiol*. 2017;40:660-666.
65. Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Z, Ray KK, Rizzo M, Sahebkar A, Serban MC, **Sperling LS**, Toth PP, Vinereanu D, Vrablik M, Wong ND and Banach M. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. *Arch Med Sci*. 2017;13:965-1005.
66. Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Z, Ray KK, Rizzo M, Sahebkar A, Serban MC, **Sperling LS**, Toth PP, Vinereanu D, Vrablik M, Wong ND and Banach M. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. *Nutr Rev*. 2017;75:731-767.
67. Wong ND, **Sperling LS** and Baum SJ. The American Society for Preventive Cardiology: Our 30-year legacy. *Clin Cardiol*. 2016;39:627-630.
68. Varghese T, Schultz WM, McCue AA, Lambert CT, Sandesara PB, Eapen DJ, Gordon NF, Franklin BA and **Sperling LS**. Physical activity in the prevention of coronary heart disease: implications for the clinician. *Heart*. 2016;102:904-9.
69. **Sperling LS** and Nelson JR. History and future of omega-3 fatty acids in cardiovascular disease. *Curr Med Res Opin*. 2016;32:301-11.
70. Schultz WM, Varghese T, Hein RE, Dhindsa DS, Mahlof EN, Cai HC, Southmayd G, Sandesaraa PB, Eapen DJ and **Sperling LS**. Natural Approaches in Diabetes Management: A Review of Diet, Exercise, and Natural Products. *Curr Pharm Des*. 2016.
71. Lambert CT, Sandesara PB, Hirsh B, Shaw LJ, Lewis W, Quyyumi AA, Schinazi RF, Post WS and **Sperling L**. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review. *HIV Med*. 2016;17:411-24.
72. Heintz RE, Dhindsa DS, Mahlof EN, Schultz WM, Ricketts JC, Varghese T, Esmaeeli A, Allard-Ratick MP, Millard AJ, Kelli HM, Sandesara PB, Eapen DJ and **Sperling L**. Comprehensive Cardiovascular Risk Reduction and Cardiac Rehabilitation in Diabetes and the Metabolic Syndrome. *Can J Cardiol*. 2016;32:S349-S357.

73. Forman DE, Alexander K, Brindis RG, Curtis AB, Maurer M, Rich MW, **Sperling L** and Wenger NK. Improved Cardiovascular Disease Outcomes in Older Adults. *F1000Res*. 2016;5.
74. Wilmot KA, Khan A, Krishnan S, Eapen DJ and **Sperling L**. Statins in the elderly: a patient-focused approach. *Clin Cardiol*. 2015;38:56-61.
75. Franklin BA, Brinks J, Berra K, Lavie CJ, Gordon NJ, **Sperling LS**. Using Metabolic Equivalents in Clinical Practice. (accepted for publication *Am J Cardiol*)
76. Khambhati J, Allard-Ratick M, Dhindsa D, Lee S, Chen J, Sandesara PB, O'Neal W, Quyyumi AA, Wong ND, Blumenthal RB, **Sperling L**. The Art of Cardiovascular Risk Assessment. (accepted for publication, *Clinical Cardiology*)
77. Sandesara PB, **Sperling LS**. Caloric Restriction as a therapeutic approach to Heart Failure: Can less be more in (mice) and men? *Circ Heart Fail* 2018;11 e004930.
78. Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, Quyyumi AA, Taylor HA, Gulati M, Harold JG, Mieres JH, Ferdinand KC, Mensah GA, **Sperling LS**. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. *Circulation*. 2018. 137;2166-2178.
79. Khambhati J, Engels M, Allard-Ratick M, Sandesara PB, Quyyumi AA, **Sperling LS**. Immunotherapy for the Prevention of Atherosclerotic Cardiovascular Disease: Promise and Possibilities. (accepted for publication, *Atherosclerosis*, 2018)
80. Sandesara PB, Dhindsa D, Khambhati J, Lee SK, Varghese T, O'Neal WT, Harzand A, Gaita D, Kotseva K, Connolly S, Jennings C, Grace SL, Wood DA, **Sperling LS**. Reconfiguring Cardiac Rehabilitation to Achieve Panvascular Prevention: New Care models for a New World. (accepted for publication, *Canadian Journal of Cardiology*, 2018)
81. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire ML, Morris PB, **Sperling LS**. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol*. 2018 Dec 18
82. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, **Sperling L**, Virani SS, Yeboah J. 2018
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *Circulation*. 2019; 139:e1082
83. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr,

- Sperling L**, Virani SS, Yeboah J. 2018
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PC
NA Guideline on the Management of Blood Cholesterol. J Am Coll
Cardiol 2019 73(24); e285-350
84. Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC Jr, **Sperling LS**,
Virani SS, Blumenthal RS. Use of Risk Assessment Tools to Guide
Decision-Making in the Primary Prevention of Atherosclerotic
Cardiovascular Disease. Circulation. 2018 Nov 10
85. Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, **Sperling
LS**. Nonalcoholic Fatty Liver disease and the Heart. J Am Coll Cardiol
2019 73(8): 948-63
86. Dhindsa DS, Mehta A, Sandesara PB, **Sperling LS**, Baer JT. Is there
still a role for Aspirin in Primary Prevention? (accepted for publication in
The NLA Lipid Spin, 2018)
87. Isakadze N, Sandesara PB, Patel R, Baer J, Isiadinso I, Alonso A, Lloyd
M, **Sperling LS**, Life's Simple 7 Approach to Atrial Fibrillation
Prevention. JAFIB 2018; 11(3)
88. Mehta A, Dhindsa DS, Reidel VJ, Quyyumi AA, **Sperling LS**. The Need
for Academic Preventive Cardiology Training: The Katz Fellowship
Program at Emory University. (accepted for publication, EHJ
Cardiopulse, 2019)
89. Allard-Ratick M, Sandesara PB, Quyyumi AA, **Sperling LS**. Everything
in Moderation: Investigating the U-Shaped link between HDL-Cholesterol
and Adverse Outcomes. (accepted for publication in U.S. Cardiology
Review, 2019).
90. Thobani A, Dhindsa DS, DeMoss BD, Sandesara PB, Raad M, **Sperling
LS**, Baer JT. Aspirin in Cardiovascular Disease: Rethinking Aspirin's
Role in Primary Prevention. (accepted for publication, Am J Cardiol,
2019)
91. Allard-Ratick MP, Kindya BR, Khambhati J, Engels MC, Sandesara PB,
Rosenson RS, **Sperling LS**. HDL: Fact, Fiction, or Function? HDL
Cholesterol and Cardiovascular Risk. (accepted for publication in
European Journal of Preventive Cardiology, 2019)
92. Dhindsa DS, Mehta A, **Sperling L**. Comprehensive Cardiovascular Risk
Reduction in Patients with Diabetes: Emphasis of the 2018 Cholesterol
Guidelines. (Guest Editorial accepted for publication in NLA Lipid Spin)
93. Dhindsa DS, Mehta A, Sandesara PB, Thobani A, Brandt S, **Sperling
LS**. Strategies for Appropriate Selection of SGLT2-I vs. GLP1-RA in
Persons with Diabetes and Cardiovascular Disease. (requested review,
Current Cardiology Reports, 2019)
94. Dixon DL, Sharma G, Sandesara P, Yang E, Braun L, Mensah G,
Sperling L, Deedwania P, Virani SS. The Epidemic of Therapeutic
Inertia in Cardiovascular Disease Prevention: Time to Move the Bar. J
Am Coll Cardiol (accepted for publication, 2019)
95. Grundy SM, Stone NJ; Writing Committee for 2018 Cholesterol
Guidelines. 2018 Cholesterol Clinical Practice Guidelines: Synopsis of
the 2018 AHA/ ACC/ Multispecialty Cholesterol Guideline. Ann Intern
Med 2019 doi: 10.7326/M19-0365

96. Mitchell S, Malanda B, Damasceno A, Eckel R, Gaita D, Kotsova K, Januzzi JL, Mensah G, Plutzky J, Prystupivk M, Ryen L, Thierer J, Virani S, **Sperling L**. A Roadmap on the Prevention of Cardiovascular Disease Among People Living with Diabetes. (accepted for publication, Global Heart, 2019)
97. Shapiro M, Maron D, Virani S, Bhatt D, Khera A, Kosiborod M, Morris P, Sandesara P, **Sperling L**, Fazio S. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: Coming to Consensus. (accepted to JACC for publication)
98. Mehta A, Dhindsa DS, Hooda A, Nayak A, Massad CS, Rao B, Makue LF, Rajani RR, Alabi O, Quyyumi AA, Escobar GA, Wells BJ, **Sperling LS**. Premature Atherosclerotic Peripheral Arterial Disease: An Under-recognized and Undertreated Disorder with a Rising Global Prevalence(accepted, Trends in Cardiovascular Medicine, 2020)
99. Mehta A, Mahtta D, Gulati M, **Sperling LS**, Blumenthal RB, Virani SS. Major Cardiovascular Disease Prevention Studies Presented at the 2019 American Heart Association Scientific Sessions. (accepted for publication, Current Atherosclerosis Reports, 2019)
100. Ritchey M, Hannan J, Wall H, George M, **Sperling L**. Million Hearts Hypertension Control Champions, 2012-2019. (accepted for publication, MMWR Morb Mortal Wkly Rep, 2020)
101. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL, Kalyani RR, Kosiborod M, Magwire ML, Morris PB, **Sperling LS**. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular risk Reduction in Patients with Type 2 Diabetes (published, JACC, 2020)
102. Dong TA, Sandesara PB, Dhindsa DS, Mehta A, Arneson LC, Dollar AL, Taub PR, **Sperling LS**. Intermittent Fasting: A Heart Healthy Dietary Pattern? (accepted, American Journal of Medicine, 2020)
103. Joseph J, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, DiPalo KE, Golden SH, **Sperling LS**. Comprehensive Management of Cardiovascular Risk Factors for Adults with Diabetes Mellitus: A Scientific Statement from the American Heart Association. published in Circulation, 2022
104. Mehta A, **Sperling LS**, Wells BJ. Postexercise Ankle Brachial Index Testing to Diagnose Peripheral Artery Disease-Reply (published, JAMA, 2021)
105. Dong T, D'Souza M, **Sperling L**. The Cardiovascular Benefits of Intermittent Fasting. (accepted as Letter, New England Journal of Medicine). 2020
106. Mehta A, Singh S, Saeed A, Mahtta D, Bittner VA, **Sperling LS**, Virani SS. Pathophysiological Mechanisms Underlying Excess Risk for Diabetes and Cardiovascular Disease in South Asians: The Perfect Storm. (invited and submitted to Current Diabetes Review, 2021)
107. Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Jones DL, Orringer CE, Saseen JJ, Smith SC, **Sperling LS**, Virani SS. High Intensity Statins Benefit High Risk Patients: Why and How to Do Better. (accepted for publication, Mayo Clinic Proceedings, 2021)

108. **Sperling LS**. The Future of Cardiovascular Prevention: Unprecedented Times. (accepted to Circulation, 2020)
109. Ritchey MD, Wall HK, Hannan J, **Sperling LS**. Million Hearts 2012-2016 Final Report Addendum: Significant Impact, Significant Opportunity. (CDC NCCDPHP DHDSP Million Hearts Website, 2020).
110. Wall HK, Stolp H, Wright JS, Ritchey MD, Thomas RJ, Ades PA, **Sperling LS**. The Million Hearts Initiative: Catalyzing Utilization of Cardiac Rehabilitation and Accelerating Implementation of New Care Models. *Journal of Cardiopulmonary Rehabilitation and Prevention* 2020; 40: 290-293.
111. Dhindsa D, Wong ND, **Sperling L**. Cardiovascular and Cardiometabolic Prevention: High Level Priority in the Era of COVID-19. (published, *Cardiovascular Endocrinology and Metabolism*, 2020)
112. D'Souza MS, Dong TA, Ragazzo G, Dhindsa DS, Mehta A, Sandesara PB, Freeman AM, Taub P, **Sperling LS**. From Fad to Fact: Evaluating the Impact of Emerging Diets on the Prevention of Cardiovascular Disease. (accepted for publication, *American Journal of Medicine*, 2020)
113. **Sperling LS**, Albert MA, Koppaka R. Disparities in Influenza Vaccination: Opportunity to Extend Cardiovascular Prevention to Millions of Hearts. *JAMA Cardiology*, 2021 Jan 1;6(1):11-12.
114. Varughese A, Patel P, Dhindsa D, Eapen DJ, **Sperling LS**. Telehealth Visits in the Real World- How best to Use Them, For Whom, and in What Payment Models? Editorial, *Lipid Spin*, 2020).
115. King SC, Parker-Fiebelkorn A, **Sperling LS**. Influenza Vaccination: Proven and Effective Cardiovascular Disease Prevention. ACC Expert Analysis for Prevention Clinical Topic Collection, 2020.
116. Mehta A, **Sperling LS**, Wells BJ. JAMA Letter in Reply. Further Considerations for Post-Exercise ABI Testing. 2020.
117. **Sperling, L**. Overcoming Silos: The Case for Connected Healthcare. (World Economic Forum Agenda, 2020)
118. Karagiannis AD, Mehta A, Dhindsa Ds, Virani SS, Orringer CE, Blumenthal RS, Stone NJ, **Sperling LS**. How Low is Safe? The Frontier of Very Low (< 30 md/dL) LDL Cholesterol. (published, *European Heart Journal*, 2021)
119. Patel P, Dhindsa D, Eapen DJ, Khera A, Gulati M, Stone NJ, Yancy CW, Rumsfeld JS, **Sperling LS**. Optimizing the Potential for Telehealth in Cardiovascular Care (In the Era of COVID-19): Time Will Tell. *Am J Med*. 2021 Apr 9: S0002-9343(21)00218-7.
120. Beatty AL, Brown TM, Corbett M, Diersing D, Keteyian SJ, Mola A, Stolp H, Wall HK, **Sperling LS**. Million Hearts Cardiac Rehabilitation Think Tank: Accelerating New Care Model. (published, *Circulation Cardiovascular Quality and Outcomes*, 2021)
121. Keteyian SJ, Ades P, Beatty A, Gavic A, Hines S, Lui K, Schopfer D, Thomas RJ, **Sperling LS**. A Review of the Design and Implementation of a Hybrid Cardiac Rehabilitation Program: An Expanding Opportunity for Optimizing Cardiovascular Care. (accepted to the *Journal of Cardiopulmonary Rehabilitation and Prevention*, 2021)
122. Thobani A, McLaughlin TJ, **Sperling LS**. Global Prevention of

- Cardiovascular Disease among People Living with Diabetes: Leading with Heart. ACC Expert Analysis. 2021.
123. Burke MA, **Sperling LS**, Dotson WD, Khoury MJ. An Expanding List of Tier 1 Genomic Applications: Evidence-based Guidelines for Hypertrophic Cardiomyopathy and Public Health. CDC Blog, 2021
 124. **Sperling LS**. Taking Up Arms Against the Flu. World Heart News, 2021
 125. Khoury MJ, Bowen S, Dotson WD, Drzymalla E, Green RF, Goldstein R, Kolor K, Liburd LC, **Sperling LS**, Bunnell R. Health Equity in the Implementation of Genomics and Precision Medicine: A Public Health Imperative. accepted for publication, Genetics in Medicine, 2022
 126. Commodore-Mensah Y, Loustalot F, Himmelfarb CD, Desvigne-Nickens P, Sachdev V, Bibbens-Domingo K, Cohen D, Egan BM, Fendrick MA, Ferdinand KC, Graham GN, Jaffe MG, Krumholz H, Levy PD, Mays GP, McNellis R, Muntner P, Ogedegbe OG, Milani RV, Polgreen L, Sanchez E, **Sperling LS**, Wall HK, Whittens L, Wright JT, Wright JS, Fine L. Proceedings from a National Heart, Lung, and Blood Institute and the Centers for Disease Control and Prevention Workshop to Control Hypertension. Published. American Journal of Hypertension, 2022
 127. Razavi AC, Agatston AS, Shaw LJ, De Cecco C, Van Assen M, **Sperling LS**, Bittencourt MS, Daubert MA, Nasir K, Blumenthal RS, Mortensen MB, Whelton SP, Blaha MJ, Dzaye O. Evolving Role of Calcium Density in Coronary Artery Calcium Scoring and Atherosclerotic Cardiovascular Risk. (accepted for publication, JACC CV Imaging), 2022.
 128. Razavi A, Prabakaran S, Sawan M, Tummula L, Onuorah I, Amin SB, Van Assen M, DeCecco C, Quyyumi AA, Whelton S, **Sperling L**, Rollin F. Transient Left Bundle Branch Block Associated with Very High Coronary Calcium. (submitted for consideration, Therapeutic Advances in Cardiovascular Disease, 2023)
 129. Razavi AC, Mehta A, **Sperling LS**. Statin Therapy for the Primary Prevention of Cardiovascular Disease: Pros. Accepted. Atherosclerosis, 2022)
 130. Armstrong KA, Halbert CH, Bedard AC, Bowen S, Bunnell R, Coronado F, Friedman S, Green RF, Grosse SD, Henrikson NB, Knowles JW, Kolor K, Liburd LC, Lubin IM, Lyon M, Pemu PE, Rahm AK, Roberts MC, Rodriguez JL, Senier L, Schrader KA, Schully SD, Shelburne N, **Sperling LS**, Trepanier AM, Wilemon KA, Clyne M, Dotson WD, Khoury MJ. Effective and Equitable Implementation of Cascade Genetic Testing: Determinants, Strategies, Actions, and Research Agenda. (submitted for consideration, Genetics in Medicine, 2022)
 131. Dicken W, Mehta A, Karagiannis A, Jain V, Vavuranakis M, **Sperling L**, Cassimatis D. Statin Associated Muscle Symptoms: An update and Review (accepted for publication, Progress in Cardiovascular Disease, 2022)
 132. Brown MT, Bortfeld KS, **Sperling LS**, Wenger NK. Where has all the aspirin gone? (invited review submitted to Current Cardiology Reviews, 2022)

133. Lewis SA, Koch RL, Britt WM, Razavi AC, Patel P, D'Souza MS, **Sperling LS**. Can Age be a Modifiable Risk Factor? The Impact of Dietary Patterns on the Molecular Mechanisms that Underlie Cardiac Aging. (invited review, Journal of Cardiovascular Aging, 2023)
134. Mehta A, Dixon DL, Saeed A, Kelly MS, Gulati M, Shapiro MD, **Sperling LS**, Ballantyne C, Virani SS. With Current Safety and Efficacy Data, Should Statins be Made Available as Nonprescription Over-the-Counter Drugs? published, Current Cardiology Reports, 2023
135. Brown MT, Bortfeld KS, **Sperling LS**, Wenger NK. Redefining the Roles of Aspirin Across the Spectrum of Cardiovascular Disease Prevention. Current Cardiology Reviews 2023. 19(6).
136. Razavi AC, Walden LI, **Sperling LS**. Lessons in Cardiovascular Disease Prevention from Number 42: The Told and Untold Stories of Jackie Robinson. published, Circulation, 2023
137. Lewis SA, Britt WM, Koch RL, Razavi AC, Patel P, D'Souza MS, **Sperling LS**. Can Age be a Modifiable Risk Factor? The Impact of Dietary Patterns on the Molecular Mechanisms that Underlie Cardiovascular Aging. published, Journal of Cardiovascular Aging, 2023
138. Wall HK, Wright JS, Fleisher LA, **Sperling LS**. Improving Blood Pressure Control in the U.S.: At the Heart of Million Hearts 2027. (accepted for publication, invited commentary, Am J Hypertension, 2023)
139. Razavi AC, Jain V, Grandhi GR, Patel P, /Karagiannis A, Patel N, Dhindsa DS, Liu C, Desai SR, Almuwaqqat Z, Sun YV, Vaccarino V, Quyyumi AA, **Sperling LS**, Mehta A. Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease? (accepted for publication, Journal of Cardiovascular Endocrinology and Metabolism, 2023)
140. Razavi AC, Whelton SP, Blumenthal RS, **Sperling LS**, Blaha MJ, Dzaye O. Coronary Artery Calcium and Sudden Cardiac Death: Current Evidence and Future Directions. (invited review, Current Opinions in Cardiology, 2023)
141. Gianos E, Duell PB, Moriarty PM, Toth PP, Moriarty PM, Thompson GR, Brinton EA, Hudgins LC, Nametka M, Hudgins LC, Byrne KH, Raghuveer G, Nedungadi P, **Sperling LS**. Lipoprotein Apheresis- Utility, Outcomes, and Implementation in Clinical Practice. A Scientific Statement From the American Heart Association. (published ATVB, 2024)
142. Yasin A, Nguyen M, Sidhu A, Majety P, Spitz J, Asgharpour A, Siddiqui MS, **Sperling LS**, Quyyumi AA, Mehta A. Liver and Cardiovascular Disease Outcomes in Metabolic Syndrome and Diabetic Populations: Bi-directional Opportunities to Multiply Preventive Strategies. Accepted for publication, Diabetes Research and Clinical Practice Journal, 2024.
143. **Sperling LS**, Jain V, Razavi AC. Primary Atherosclerotic Cardiovascular Disease Prevention: Optimally Active, Agile, and Accountable. Invited editorial. JACC Advances. 2023.
144. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, Coresh J, Mathew RO, Baker-Smith CM, Carnethon MR, Despres JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, Lekavich

- CL, Lewis EF, Lo KB, Ozkan B, Palaniappan LP, Patel SS, Pencina MJ, Powell-Wiley TM, **Sperling LS**, Virani SS, Wright JT, Singh RR, Elkind MSV; on behalf of the American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory from the American Heart Association. published, *Circulation*, 2023.
145. Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, Coresh J, Baker-Smith CM, Carnethon MR, Despres JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, Lekavich CL, Lewis EF, Lo KB, Ozkan B, Palaniappan LP, Patel SS, Pencina MJ, Powell-Wiley TM, **Sperling LS**, Virani SS, Wright JT, Singh RR, Elkind MSV, Rangaswami J on behalf of the American Heart Association. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement from the American Heart Association. published, *Circulation*, 2023
146. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, Blaha M, Carson AP, Chang AR, Ciemins E, Go AS, Gutierrez OM, Hwang SJ, Jassal SK, Kovesdy CP, Lloyd-Jones DM, Shlipak M, Palaniappan LP, **Sperling L**, Virani SS, Tuttle K, Neeland IJ, Chow SL, Rangaswami J, Pencina MJ, Ndumele C, Coresh J. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health. (accepted for publication, *Circulation*. 2023).
147. Razavi AC, Mehta A, Jain V, Patel P, Liu C, Patel N, Eisenberg S, Vaccarino V, Isadinso I, **Sperling LS**, Quyyumi AA. High-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Risk Assessment: Exploring and Explaining the “U” Shaped Curve. Accepted for publication, *Current Cardiology Reports*, 2023.
148. Gianos E, Duell PB, Toth PP, Moriarty PM, Thompson GR, Brinton EA, Hudgins LC, Nemetka M, Byrne KH, Raghuvver G, Nedungadi P, **Sperling LS**. Lipoprotein Apheresis- Utility, Outcomes, and Implementation in Clinical Practice: A Scientific Statement from the American Heart Association. (submitted for review, *ATVB*, 2023).
149. **Sperling, LS**. Making House Calls. *Circulation* 2024. 149(17: 1326-1327.
150. Eisenberg S, Gold D, Mehta PK, Leshnower BL, **Sperling LS**. Supraaortic Aortic Stenosis in Homozygous Familial Hypercholesterolemia: Contemporary Management. (accepted for publication, *JACC Case Reports*, 2024)
151. Guynn N, Regis K, Eckert A, D’Souza MD, Turbow S, Westerman S. **Sperling L**, Lloyd M. Sustained Monomorphic Ventricular Tachycardia Accurately Detected by Wearable Technology. (accepted for publication, *JACC Case Reports*, 2024)
152. Osei J, Razavi AC, Otchere B, Bonful G, Akoto N, Akyea R, Qureshi N, Coronado F, Moonesinghe R, Kolor K, Mensah GA, **Sperling L**, Khoury MJ. A Scoping Review of Electronic Health Records-based Screening Algorithms for Familial Hypercholesterolemia. Accepted for publication, *JACC Advances*, 2024.
153. Banach M, Surma S, Guzik T, Penson PE, Blaha MJ, Luscher T,

- Sperling LS. Upfront Lipid-lowering combination therapy in patients at very high cardiovascular risk- Time to stop debating and start effective prevention. *Cardiovasc Res* 2025; 121(6): 851-859.
154. Chew NWS, Mehta A, Goh R, Zhang A, Chen Y, Chong B, Chew J, Shabbir A, Brown A, Dimitriadis GK, Huang DQ, Foo R, le Roux CW, Figtree GA, Fudim M, Pandey A, Mamas MA, Hausenloy D, Richards AM, Nicholls SJ, Chan MY, Muthiah M, Sanyal A, **Sperling LS**. Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via a Modified Delphi Approach. Accepted for publication, *Circulation*, 2024.
155. Dotson WD, Clyne M, Khoury MJ, Armstrong KA, Hughes-Halbert C, Bedard AC, Bowen MS, Coronado F, Friedman S, Green RF, Grosse SD, Hendrickson NB, Knowles JW, Kolor K, Liburd LC, Lubin IM, Rahm AK, Roberts MC, Rodriguez JL, Senier L, Schrader KA, Schully SD, **Sperling LS**, Trepanier AM, Wilemon KA. A Public Health Approach to Effective and Equitable Implementation of Cascade Genetic Testing: An Implementation Science Agenda (accepted for publication, *Genes*, 2025).
156. Gupta P, Bast JA, Razavi AC, Canonico ME, Shahzad A, Naeem M, Bonaca MP, **Sperling LS**, Quintana Raymundo A. Hypertension in Atherosclerotic Cardiovascular Disease: Insights into Epidemiology, Management Strategies and Outcomes. (accepted for publication, *Current Opinion in Cardiology*, 2025)
157. Chew NWS, Mehta A, Goh R, Koh J, Chen Y, Chong B, Chan M, Khan M, Muthiah M, Butler J, Sanyal A, **Sperling L**. Global cardiovascular-liver-metabolic syndemic: Epidemiology, Forecast Trends, Challenges and Future Directions accepted for publication, *Nature Reviews Cardiology*, 2025.
158. Goodman RA, Posner SF, **Sperling LS**, del Rio C, Rasmussen SA. Infectious Versus Chronic Conditions: Time to Dismantle Silos in Public Health. accepted for publication, *The Lanet Regional Health-Americas*, 2025
159. Mansoor T, Nambi V, Parikh S, Misra A, Ismayl M, Sullivan C, **Sperling L**, Virani SS, Al Rafai M, Koshy SKG, Abramov D, Minhas AMK. Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors. published, *Am J of Cardiovascular Drugs*, 2025.
160. Patel NH, Agusala V, Chuckaree ID, Wang M, Gangavelli A, Padove L, **Sperling LS**, Mehta PK. Hyperlipidemia in the Peripartum: Epidemiology, Physiology, and Treatment Options. accepted for publication, *EJPC*, 2025.
161. Kalra DK, Shotwell M, Garg A, Duell PB, Wilson DP, Martin SS, Soffer DE, Rosenson RS, Shapiro MD, Ahmad Z, Underberg J, **Sperling L**, Jortani SA, Remaley A. Lipoprotein X-Pathophysiology, diagnosis, and

- management. (accepted for publication, Journal of Clinical Lipidology, 2025).
162. Medina-Inojosa JR, Chacin Suarez AS, Murtala AB, Harris K, Hicks JB, Bennett J, **Sperling LS**. COVID-19 Pandemic: Wake-up Call and Accelerator for Cardiac Rehabilitation. (accepted for publication, Canadian Journal of Cardiology, 2025)
163. Foraker R, **Sperling L** (Vice Chair), Bratzke L, Budoff M, Leppert M, Razavi AC, Rodriguez F, Shapiro MD, Whelton S, Wong ND, Yang E, on behalf of the AHA Prevention Science Committee of the Council on Epidemiology and Prevention and Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Cardiovascular Radiology and Intervention. AHA Scientific Statement: Opportunistic Detection of Coronary Artery Calcium on Non-Cardiac Chest Computed Tomography: An Emerging Tool for Cardiovascular Disease Prevention. Published, Circulation, 2025
164. Medina-Inojosa JR, Rodriguez F, Lopez-Jimenez F, **Sperling LS**. Precision Cardiovascular Medicine: Global Imperative for Equity Through Innovation. Invited policy outlook commentary, Frontiers in Cardiovascular Medicine, 2026).
165. Bardach SH, Blike G, **Sperling L**, Kim K, Furman BW, Kulp DRG, Lam S, Eapen D, Orr JA, Hennessey KC, McGowan MP, Khera A, Gulati M, Ahmad Z, Triana T, Mittman B, Wilemon K. Novel strategies to FIND people living with genetic dyslipidemias: The Family Heart Foundation Flag, Identify, Network, and Deliver (FIND) Familial Hypercholesterolemia Collaborative Learning Network. AJPC 2025; 23:101275.
166. McLean P, Mathew D, Chandrasekhar S, Guynn N, Razavi AC, Quyyumi A, Mehta A, **Sperling L**. HDL-C: Helpful, Harmful, Hopeful, or Guilty by Association. (accepted for publication, Journal of Clinical Lipidology, 2025).
167. Flyer JN, Malik S, Hartz J, Farnell JL, Riley CE, Wiskind R, Baker-Smith C, de Ferranti SD, Rea C, Ware AL, **Sperling L**, Daniels SR. Accelerating Guideline Recommended Universal Pediatric Lipid Screening: Launch of the LEAD Pediatric Initiative. (accepted for publication, Journal of Pediatrics, 2025).
168. Razavi AC, Blaha MJ, **Sperling LS**, Blumenthal RS, Whelton SP. Lp(a) and Inflammation in Atherosclerotic Cardiovascular Disease: On the Horizon for Risk Assessment and Future Therapies. (invited editorial, published, JACC, 2025)
169. Zhou XD, Lazarus JV, Krittanawong C, Targher G, Byrne CD, Younossi ZM, Tacke F, Chen QF, Mantzoros CS, Tilg H, Mehal WZ, **Sperling LS**, Lip GYH, Stefan N, Zheng MH. Pharmacotherapy for MASH: Heart-Liver Co-

- Management. (Accepted for publication, Lancet Gastroenterology and Hepatology, 2025).
170. **Sperling LS**, Gulati M. Family Heart Summit Special Issue, Guest Editor Overview / Message. (accepted for publication, AJPC, 2025)
171. Mansoor T, Ismayl M, Virani SS, Nambi V, Misra A, Jia X, Fudim M, Greene S, **Sperling L**, Parikh S, Al Rifai M, Koshy SKG, Abramov D, Minhas AMK. Lipid-lowering Therapies to Target Cardiac Allograft Vasculopathy after Heart Transplantation: Current Evidence and Future Directions. (accepted for publication, Journal of Clinical Lipidology, 2025).
172. Razavi AC, Troy AL, **Sperling LS**, Blumenthal RS. Bundled Measurement of LDL-Cholesterol, Lipoprotein (a), and High Sensitivity C-Reactive Protein Across the Spectrum of Cardiovascular Risk. (accepted for publication, AJPC, 2025)
173. Osei J, Bennett Josiah, Seo G, Eisenberg SD, Nyenhuis R, Raval O, Gershon G, Stresemann S, Akkaya S, Bhattacharya A, Razavi AC, Mehta , **Sperling LS**. Lipoprotein (a) in Cardiovascular Disease Prevention: Current and Emerging Therapeutic Approaches. (submitted invited review, Current Treatment Options in Cardiovascular Medicine, 2026).
174. Jackson-Morris A, Halpern B, Segafredo G, Baur L, Sealey K, Kushner RF, **Sperling L**, Mutnagi H, Schwartz P, Buse K, Ralston J. GLP-1 Receptor Agonist-based Therapies- Their significance in the wider obesity agenda; key challenges and opportunities. (accepted for publication, Lancet Global Health, 2026).
175. Razavi AC, Sokolsky M, Belanger M, Blazoski C, Spitz JA, **Sperling LS**, Blumenthal RS, Whelton SP. Progress in Risk Assessment and Management: Forecasting Updates Across International Cholesterol Guidelines. (accepted for publication, AJPC, 2026).
176. Osei J, Kodukula S, Otchere B, Raval O, Donaldy W, Suresh A, Bardach SH, Farnell J, Dodge A, MacDougall D, Wilemon K, Razavi AC, Sun YV, Khoury M, **Sperling L**. Integrating Genomics into Population Health Practice through the Experience of Familial Hypercholesterolemia. (accepted for publication, Public Health Genomics, 2026).
177. Yadalam AK, Gold ME, Patel KJ, Razavi AC, Flowers A, Seo G, Britt WM, Eisenberg S, Book WM, Rollins JB, van Beuningen A, Vega D, Butler J, Givertz MM, Quyyumi AA, **Sperling LS**. Dyslipidemia and Therapies after Heart Transplantation: Current Evidence and Future Direction. (accepted for publication, Journal of Clinical Lipidology, 2026).
178. Gold ME, Chandrasekhar S, Kulshreshtha A, Britt M, Guynn N, Gold DA, Jain V, Razavi AC, Vatsa N, Yadalam A, Bennett J, McLean P, Dodson S, Vaccarino V, Quyyumi AA, Lah J, Levey A, Benson R, Lloyd-Jones DM, **Sperling LS**. Life's Essential 8: Essential for Brain and Cognitive Health.

- (accepted for publication, JAHA, 2026).
179. **Sperling L**, Irazola V, Partarrieu J, Raspil L, Banach M, Banerjee A, Bukhman G, George M, Kato ET, Lopez-Jimenez F, Macari S, Miranda J, Mocumbi A, Perel P, Prabhakaran D, Barragan AP, Sherifali D, Santos R. WHF Roadmap for Integrated Care in People Living with-or at Risk of Cardiovascular Disease and Multiple Long-Term Conditions. Published in Global Heart,2026.
 180. Safarova MS, **Sperling L**, Mehta A, Bhatia HS, Rodriguez F. The Role of Lipoprotein (a)in Premature Cardiovascular Disease: Primed for Prevention. Accepted for publication EJPC , 2026).
 181. Blumenthal RS, Morris PB, et al. 2026 ACC/ AHA/ Multi-Society Dyslipidemia Guideline. Circulation 2026 (member Peer Review Committee; Guideline Collaborator)
 182. Bennett J, Medina-Inojosa JR, **Sperling LS**. Integrating Measures of Remnant Cholesterol and Inflammation: Risky Business? (invited editorial, Archives of Medical Science, 2026)
 183. Khan SS, Bhawe N, Blumenthal RS, Coresh J, Huang X, Joseph JJ, Khera A, Ho JE, Lloyd-Jones DM, Low Wang CC, Lu Y, Morris PB, Nasir K, Natarajan P, Rangaswami J, Rodriguez F, **Sperling LS**, Virani SS, Zhang S, Ndumele CE. AHA/ ACC Scientific Statement: Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease (in production, Circulation, 2026).
 184. Suresh A, Kodukula SS, Bardach S, Peng A, Marvel F, Khandelwal A, Waring A, Clary J, Benjamin H, Almeida S, Isiadinso I, Razavi A, Blumenthal R, **Sperling L**, Martin SS. From Identification to Implementation: A Narrative Review of Strategies to Close the Implementation Gap in Patients with Familial Hypercholesterolemia. (accepted for publication, Journal of Clinical Lipidology, 2026).
 185. Krittananawong C, Morihara C, Benavente K, Virk HH, Abushanab D, **Sperling L**, Birnbaum Y, Virani S, Lavie C, Park C. Financial Toxicity: Inequities and Impact on Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2026.
 186. Medina-Inojosa JR, Rodriguez F, Lopez-Jimenez F, **Sperling LS**, Precision Cardiovascular Medicine: Global Imperative for Equity Through Innovation. (accepted for publication, Frontiers in Cardiovascular Medicine, 2026).
 187. Razavi AC, Blumenthal RS, **Sperling LS**. Inclisiran for LDL-Cholesterol Reduction: Guidelines, Gaps, and Future Directions. (invited editorial, JACC Advances, 2026)
 188. Rubin J, Eisenberg S, Gold M, Deng N, Shikhare A, Patel S, Kumar S,

- Lateef A, Mehta P, **Sperling L**. Clostridium perfringens Infective Endocarditis: Revisiting a Forgotten Pathogen. (accepted for publication, JACC Case Reports, 2026).
189. Beveridge E, Medina-Inojosa JR, Goel R, Philipsborn R, Martin ZT, Harris K, Newman N, Rajagopalan S, **Sperling L**. HeatRisk and Air Quality risk Recommendations: A narrative review and action algorithm for the care of people at risk for and living with cardiovascular disease. (accepted for publication, AJPC, 2026).
190. Osei J, Bennett J, Raval O, Seo G, Eisenberg SD, Nyenhuis R, Gershon G, Stresemann S, Akkaya S, Bhattacharya A, Razavi AC, Mehta A, **Sperling LS**. Lipoprotein(a) in Cardiovascular Disease Prevention: Current and Emerging Therapeutic Approaches. (accepted for publication, Current Treatment Options in Cardiovascular Medicine, 2026).
191. Rajagopalan S, Al-Kindi S, Balmes J, Bhatnagar A, Flatt VB, Ganatra S, Landrigan PJ, Munzel T, Navas-Acien A, Newman JD, **Sperling L**, Solomon C, Brook RD. Cardiovascular Health Implications of Environmental Deregulation in the United States. (accepted for publication, JACC, 2026)
192. Zhou XD, Zannad F, Fudim M, Loomba R, Stefan N, **Sperling LS**, Wheeler DC, Lazarus JV, Wanner C, Chew NW, Tacke F, Sanyal A, Zheng MH. Toward a CKLM Framework for Integrated Clinical Trial Design. (accepted for publication, Gut, 2026).

e. **Book chapters:**

1. **Sperling LS**, Cutler DA, and Runge MS. Thrombolytic therapy: risks, complications, and limitations, in complications of interventional procedures. Topics in Clinical Cardiology, Igaku-Shoin Publishers, N.Y., 1995.
2. **Sperling LS** (contributing author). Hurst's The Heart. Pretest self-assessment and review, 9th edition, McGraw-Hill, 1998.
3. **Sperling LS**. Effective coordination of care, in A Successful Transition (a cardiology fellow's guide to applying clinical skills to office-base care), Dowden Publishing Company, Montvale, N.J., 1999.
4. Guest TM, **Sperling LS**, Ballard DJ, and Weintraub WS. Cardiovascular complications of diabetes, in Clinical Diabetes Mellitus: a Problem-Oriented Approach, 3rd edition, Thieme medical publishers, N.Y., 2000.
5. Sayar S, Nell CL, **Sperling LS**. Atherosclerosis: pathophysiology and preventive strategies, in The AHA Clinical Cardiology Consult, Lippincott, Williams and Wilkens, Philadelphia. 2001
6. **Sperling LS**, Miller JI. Management of Ischemic Heart Disease, in Office Practice of Medicine, 4th Edition, Saunders, 2003.
7. **Sperling LS**. Diets and Cardiovascular disease, in Living Well by Montel Williams. Viking-Penguin New American Library. Pages 163-164. 2008.

8. Georgiopoulou VV, Kalogeropoulos A, **Sperling LS**, Butler J. Heart Failure Prevention, in Prevention of Cardiovascular Disease (A Companion to Braunwald's Heart Disease). Elsevier, accepted for publication, 2010.
9. Nieva R, Achtchi A, Eapen D, Dollar AL, Baer J, Mavromatis K, **Sperling LS**. Impact of Medical Therapy on Cardiovascular Secondary Prevention, in *Lifestyle Medicine*, 2nd Ed. 2012
10. Eapen D, Achtchi A, Nieva R, Valiani K, Zarreen F, Patel A, Dollar A, Isadinso I, Parashar S, Baer J, Mavromatis K, **Sperling L**. Impact of Preventive Therapies on Clinical Management and Outcomes, in *Atherosclerosis: Risk, Mechanism, and Therapy*. Wiley and sons.
11. Ashen MD, Nell-Dybdahl CL, **Sperling L**, Blumenthal RS. Development of a Center for Cardiovascular Disease Prevention, in *The American Society for Preventive Cardiology Manual of Preventive Cardiology*, Demos Medical, 2014.
12. Eapen DJ, Ghasemzadeh N, Bhatia N, Patel A, Clermont E, Cassimatis D, Isadinso I, **Sperling L**. Primary Prevention of Cardiovascular Disease Guidelines, in *The American Society for Preventive Cardiology Manual of Preventive Cardiology*, Demos Medical, 2014
13. Eapen DJ, Ghasemzadeh N, Bellam N, Bhatia N, Viliani K, Shen J, VanDam RJ, Flueckiger P, Molloy DL, Kay J, Achtchi A, Wells BJ, Baer JT, Wenger NK, **Sperling L**. Principles of Primary and Secondary Prevention of Cardiovascular Disease, in *Panvascular Medicine*, 2015
14. Sandesara PB, Eapen D, **Sperling L**. Exercise Rehabilitation and Exercise for Prevention. American College of Cardiology Self-Assessment Program 9 (ACCSAP 9, 6.8). 2017
15. Gaita D, **Sperling L**. Prevention and Control of Cardiovascular Disease: What Works, in *Prevention of Cardiovascular Diseases- From Current Evidence to Clinical Practice*. Springer. 2015
16. Dhindsa DS, Shen J, Sandesara PB, **Sperling LS**. Integrative Approach in Cardiovascular Disease (Chapter 20), in *Nutrition, Fitness, and Mindfulness: An Evidence-based Guide for Clinicians*
17. Lee SK, Khambhati J, Sandesara PB, Eapen D, Lundberg G, Margolis B, Gordon N, Franklin B, **Sperling LS**. Comprehensive Secondary Prevention and Cardiac Rehabilitation after CABG Surgery. In DP Taggart, JD Puskas (ed.), *Coronary Artery Bypass Grafting*. London. Oxford Press.
18. Shen J, Eapen DJ, Wong ND, Deedwania P, **Sperling L**. Diabetes and Metabolic Syndrome. American College of Cardiology Self-Assessment Program 10 (ACCSAP 10, 5.5) 2019
19. Khetan AK, **Sperling L**, Josephson RA. Exercise Rehabilitation and Exercise for Prevention. American College of Cardiology Self-Assessment Program 10 (ACCSAP 10) 2019
20. Dhindsa D, Mehta A, **Sperling L**. Focus on Cardiovascular Health Promotion and Disease Prevention: Opportunities for Improvement. In *The American Society for Preventive Cardiology Manual of Preventive Cardiology*, 2020

21. D'Souza MS, Dong TA, Dhindsa DS, Mehta A, **Sperling LS**. Optimal Dietary Approaches for those Living with Metabolic Syndrome to prevent Progression to Diabetes and Reduce the Risk of Cardiovascular Disease. 1st Edition of Nutritional and Dietary Approaches to the Prevention and Treatment of Cardiovascular Disease. Contemporary Cardiology Book Series, 2021 Springer-Nature
 22. Shen J, Eapen DJ, Wong ND, Deedwania P, **Sperling L**. Diabetes and Metabolic Syndrome. American College of Cardiology Self-Assessment Program 10 Update (ACC 10), 2020.
 23. Mehta A, Dhindsa DS, **Sperling LS**. Global Approaches to Cardiovascular Risk Assessment- the U.S. Guidelines. Cardiovascular Risk Assessment in Primary Prevention. Springer Nature. 2021.
 24. Eapen DJ, Faaborg-Andersen C, DeStefano RJ, Karagiannis AD, Quintana RA, Dhindsa D, Chaudhuri M, Searles CD, **Sperling LS**. Defining and Optimizing Vascular Health. The Vasculome: From Many, One. Elsevier / Academic Press. 2022.
 25. Khetan AK, **Sperling L**, Josephson RA. Exercise Rehabilitation and Exercise for Prevention. American College of Cardiology Self-Assessment Program 10 Update, 2021.
 26. Shen J, Eapen DJ, Wong ND, Deedwania P, **Sperling L**. Diabetes and Metabolic Syndrome. American College of Cardiology Self-Assessment Program 10 Update , 2021.
 27. Agrawal A, Thobani A, Garcia M, Fatade Y, Tummala LS, **Sperling L**, Isadinso I. NAFLD and Cardiovascular Risk- At a Crossroads. Chapter 26 in Need to Know NAFLD: The Complete Guide to Non-Alcoholic Fatty Liver Disease for Clinicians, 2022
 28. Cheung B, Faruque S, Kim K, Lam S, Faaborg-Anderson C, McLaughlin TJ, **Sperling LS**, Eapen D. Focused Cardiovascular Risk Assessment and Approaches in Men. Preventive Cardiovascular Nursing (expected publication, 2024)
 29. Medina-Inojosa JR, Harris KA, Bennett J, Hansen D, Forman DE, Wenger NK, **Sperling LS**. Secondary Prevention and Cardiac Rehabilitation: Principles and Practice. (European Society of Cardiology Textbook of Preventive Cardiology, 2nd edition), 2026.
- d. **Other publications:**
1. Miller J, **Sperling LS**, Nell C, Agahtehrani A, Weintraub W. Premature coronary artery disease: 15 year follow-up in patients under the age of 40. *J Am Coll Cardiol* 2001;37(2A):504A.
 2. Tirrito SJ, **Sperling LS**, Vega D, Smith AL, Book WM. Aggressive lipid lowering does not prevent early transplant arteriopathy following cardiac transplantation (abstract presented at 8th World Congress on Heart Failure) 2002.
 3. Badenhop D, Franklin B, **Sperling L**, Digenio R, Salmon R, Gordon N. Risk factor status on entry into contemporary phase 2 cardiac rehabilitation programs. *J Cardiopulm Rehab* 2001;21:321.
 4. Gordon N, Franklin B, **Sperling L**, Badenhop D, Digenio A, Mitchell B, Salmon R. Stage of readiness to change multiple behaviors at entry to

- phase 2 cardiac rehabilitation programs. *J Cardiopulm Rehab* 2001;21:321.
5. Bonzheim K, Watson C, Fraanklin B, **Sperling L**, Badenhop D, Digenio A, English R, Gordon N. Need for continued cardiovascular disease risk reduction intervention after completion of a contemporary phase 2 cardiac rehabilitation program. *J Cardiopulm Rehab* 2001;21:321.
 6. Haapaniemi SS, Franklin BA, **Sperling LS**, Badenhop DT, Salmon RD, English CD, Gordon NF. Clinical effectiveness of a phase 2 cardiac rehabilitation program in participants with and without arthritis (abstract presented at 2002 ACSM meeting).
 7. Miller J, Fukai T, **Sperling L**, Landmesser U, Spiekerman S, Harrison D. Extracellular superoxide dismutase activity and protein expression in normal subjects and subjects with coronary artery disease. *Circulation* (Supplement II) 2001;104(17):294.
 8. Galt JR, Krawczynska EG, Ingram F, Poole RA **Sperling LS**, Halkar RK. Optimization of simultaneous 201 Tl/99mTc BRU59-21 SPECT for myocardial viability determination. *J Nuc Med* 2002;43(5):183P.
 9. Savona T, Salmon R, English C, **Sperling L**, Pickel S, Leighton R, Franklin B, Gordon N. Clinical effectiveness of a community-based cardiovascular risk reduction program in participants with versus without prediabetes. *J Cardiopulm Rehab* 2002;22:362.
 10. Maynard T, **Sperling L**, Franklin B, Hall L, Salmon R, Gordon N. Effect of a phase 2 cardiac rehabilitation program on serum lipids and lipoproteins in patients with versus without known peripheral arterial disease. *J Cardiopulm Rehab* 2002;22:349.
 11. Doughty M, **Sperling L**, Bishop-Lindsay KL, Salmon R, Mitchell B, Franklin B, Gordon N. Effect of educational status on clinical outcomes in participants in a contemporary phase 2 cardiac rehabilitation program. *J Cardiopulm Rehab* 2002;22:349.
 12. **Sperling L**, Kallish S, Thiel J, Leighton R, Levinrad I, Salmon R, Franklin B, Gordon N. Clinical effectiveness of a community-based cardiovascular risk reduction program in participants with versus without the metabolic syndrome. *J Cardiopulm Rehab* 2002;22:362.
 13. Haapaniemi S, Franklin B, Badenhop D, **Sperling L**, Salmon R, Gordon N. Clinical effectiveness of a phase 2 cardiac rehabilitation program in patients with versus without diabetes. *J Cardiopulm Rehab* 2002;22:362.
 14. Larned J, Miller J, Mansour C, **Sperling L**. Clinical markers of cardiovascular risk (accepted as abstract for 10/03 AACVPR meeting).
 15. Webb J, Hall L, Franklin B, **Sperling L**, Lewis A, Faircloth C, Levinrad I, Salmon R, Gordon N. Getting to goal: Is lifestyle intervention worth the effort in patients with an elevated blood glucose level? (presented at 10/03 AACVPR meeting).
 16. Lewis A, Franklin B, Hall L, **Sperling L**, Faircloth C, Levinrad I, Salmon R, Gordon N. Getting to goal: Is lifestyle intervention worth the effort in patients with hypertension? (presented at 10/03 AACVPR meeting).
 17. Franklin B, Hall L, Biggerstaff D, **Sperling L**, Pickel S, Kallish S, Thiel J, Mitchell B, Salmon R, Gordon N. Clinical effectiveness of a

- comprehensive cardiovascular risk reduction program in female vs. male participants (presented at 10/03 AACVPR meeting).
18. Hall L, Franklin B, Biggerstaff D, Pickel S, **Sperling L**, Thiel J, Kallish S, Mitchell B, Salmon R, Gordon N. Clinical effectiveness of a comprehensive cardiovascular risk reduction program in pre-menopausal vs. post-menopausal women (presented at 10/03 AACVPR meeting).
 19. Morgan J, Schieber R, Swerdlow D, Roper M, Neff L, **Sperling L**. Myopericarditis following smallpox vaccination among civilians, United States, January-April 2003 (presented at IDSA meeting).
 20. Baman T, Devireddy C, Cole J, **Sperling LS**. Coronary artery aneurysms are an independent predictor of high five-year mortality. *J Am Coll Cardiol* 2004;43(5A):282A.
 21. Schieber RA, Morgan J, Roper M, Neff L, Chapman L, Iskander J, Mootrey G, **Sperling L**, Robinson RM. Cardiac complications among civilians vaccinated against smallpox, U.S., 2003. *Circulation* (Supplement IV) 2003;108(17):751.
 22. Esteves F, **Sperling L**, Miller J, Morris D, Schuster D, Halkar. PET/CT for comprehensive non-invasive assessment of the coronaries: a single stop test (accepted as abstract to Society of Molecular Imaging).2003
 23. Gordon NF, **Sperling LS**, et al. Getting risk factors to goal: Lifestyle intervention is worth the effort in patients with hypertension, hyperlipidemia, and hyperglycemia. *J Am Coll Cardiol* 2004;43(5A):27A.
 24. Miller J, McDaniel MC, **Sperling L**, STARR investigators. Inpatient cardiac risk factor management program can promote therapeutic lifestyle change. *J Am Coll Cardiol* 2004;43(5A):503A.
 25. O'Neal RG, **Sperling LS**, Franklin BA, Salmon RD, Faircloth GC, Mitchell BS, Levinrad I, Gordon NF. Effectiveness of a tobacco cessation intervention, administered as a component of a comprehensive cardiovascular risk reduction program, in participants in different stages of readiness to quit smoking. *J of Cardiopulm Rehab* 2004;24(5):347.
 26. Gordon NF, Salmon RD, Gordon TL, Biggerstaff ED, Reid KS, Saxon WE, Faircloth GC, Levinrad I, Mitchell BS, Leighton RF, Verma A, **Sperling LS**, Hall LK, Bairey-Merz CN, Wenger NK, Franklin BA, Haskell WL. Clinical effectiveness of therapeutic lifestyle changes in pre-menopausal versus post-menopausal women. *Circulation* 2005;111:e65.
 27. Gordon NF, Salmon RD, Levinrad I, Faircloth GC, Leighton RF, Berk MR, Hall LK, **Sperling LS**, Dafoe WA, Rubenfire M, Vogel D, Bairey Merz CN, Haskell WL, Franklin BA. Multicenter study of the clinical effectiveness of a contemporary cardiac rehabilitation program in elderly versus younger patients. *J Am Coll Cardiol* 2005;45(3A):187A.
 28. Gordon NF, Salmon RF, Reid KS, Saxon WE, Faircloth GC, Levinrad I, Mitchell BS, Leighton RF, Verma A, Berk MR, **Sperling LS**, Haskell WL, Franklin BA. Clinical effectiveness of therapeutic lifestyle changes in African American versus Caucasians. *J Am Coll Cardiol* 2005;45(3A):422A.
 29. Bavikati VV, **Sperling LS**, Salmon RD, Faircloth GC, Leighton RF, Franklin BA, Gordon NF. Clinical effectiveness of therapeutic lifestyle

changes in patients with prehypertension (presented at national AACVPR meeting 10/06).

30. Bavikati VV, **Sperling LS**, Salmon RD, Faircloth GC, Gordon TL, Franklin BA, Gordon NF. Effect of gender and ethnicity on effectiveness of therapeutic lifestyle changes in patients with prehypertension. *J Am Coll Cardiol* 2007;49(9A):392A.
31. Jackson CF, Vaccarino V, Reid KJ, Grow P, Bavikati V, **Sperling LS**, et al. Association of cardiac rehabilitation and healthy lifestyle after acute myocardial infarction (presented at AHA Quality of Care and Outcomes Research in CV Disease and Stroke Conference 2007).
32. Georgiopoulou VV, Lindsay KL, Brown J, Hirsch B, **Sperling LS**. Metabolic abnormalities in adults with cystic fibrosis. *Chest* 2008;134(suppl).
33. Yehya A, Jacobs S, Mashman W, **Sperling LS**. Stress cardiomyopathy (Takotsubo) in a patient with presumptive Autoimmune Polyendocrine Syndrome II. *J Hosp Med*. 2010;5(3) suppl 2.
34. Burroughs M, Patel D, Rodriguez D, Khan, **Sperling LS**. Comparing Coronary Artery Disease Risk Factors in Cubans and Cuban Americans. Presented at the Global Health Education Consortium, April 2010, Cuernavaca, Mexico.
35. Bishop KL, Salmon R, Habib A, **Sperling L**, PinzonA, Rubenfire M, Reid K, Faircloth G, Wright B, Drimmer A, Franklin B, Gordon N. Effect of Cardiac Rehabilitation on Self-Reported Health Status in Patients Taking Antidepressants. Accepted to 2010 AACVPR meeting.
36. Habib A, Salmon R, Bishop KL, **Sperling L**, Pinzon A, Rubenfire M, Reid K, Faircloth G, Wright B, Drimmer A, Franklin B, Gordon N. Effect of Cardiac Rehabilitation on Coronary Heart Disease Risk Factors in Patients taking Antidepressants. Accepted to 2010 AACVPR meeting.
37. Chowdhury M, Abd T, Wirth D, **Sperling LS**. Incidence of bleeding events in patients on warfarin, aspirin, and/or clopidogrel in an anticoagulation clinic of a tertiary medical center. Presented at the 2010 AHA meeting
38. Bittner V, Bartolet M, Barraza R, Farkouh M, Goldberg S, Ramanathan K, Redmon J, **Sperling L**, Rutter M. Risk factor control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI2D) Trial. presented at the 2010 AHA meeting
39. **Sperling L**. HIV, Inflammation, and Cardiovascular Disease, *Global Antiviral Journal*, 2010; 6(1):14-15.
40. Nieva RS, Safavynia SA, Bishop KL, **Sperling LS**. Use of omega-3 polyunsaturated fatty acids in patients enrolled in a cardiac rehabilitation program. (presented, AHA NPAM meeting, 3/11)
41. Nieva RS, Safavynia SA, Johnson C, Bishop KL, **Sperling LS**. Use of herbal supplements in patients enrolled in a cardiac rehabilitation program. (presented, ACC meeting, 4/11)
42. Achtchi A, Alvarez R, Nell C, Smiley W, **Sperling L**. Alternate day rosuvastatin dosing for statin intolerant patients. (presented, ACC meeting, 4/11)
43. Eapen D, Manocha P, Kassas I, **Sperling LS**, Quyyumi AA. Percent body fat is not an independent predictor of arterial stiffness in south asians

- unlike caucasians. (presented, ACC meeting 4/11)
44. Eapen D, **Sperling L**, Brigham K, Quyyumi A. Midaxillary subcutaneous fat is the best independent predictor of arterial stiffness in black woman as opposed to abdominal fat in white woman. (presented, Arteriosclerosis, Thrombosis, and Vascular Biology, 2011)
 45. Bittner V, Bertollet M, Farkouh M, Howard N, Lu J, **Sperling L**, Rutter M. Comprehensive risk factor control improves survival: The Bypass Angioplasty Revascularization Investigation 2 Diabetes. (accepted for oral presentation, AHA 11/11)
 46. Eapen DJ, Manocha P, Patel R, Nanjundappa R, Veledar E, Wassel C, Voland J, Malayter D, Kassas I, Alradawi S, Kelli H, Poole J, Neuman R, **Sperling L**, Quyyumi A, Epstein S. Aggregate risk score based on markers of inflammation, immunity, and thrombosis is an independent predictor of adverse cardiovascular outcomes. (accepted for presentation AHA 11/11)
 47. Manocha P, Nanjundappa RA, Eapen DJ, Kassas I, Sher S, Liu YX, Ahmed A, Kodura S, Raddawi S, **Sperling L**, Quyyumi A. Triglycerides are independently associated with diabetes among south asian females in the U.S. (presented at the World Congress of Heart Diseases, 7/11)
 48. Ramjee V, Le A, **Sperling L**. Inflammatory and Lipid Markers pre- and post-LDL apheresis in patients with familial hypercholesterolemia (The INFLAME Study). (accepted for presentation, ACC 2012)
 49. Ramjee V, Le A, **Sperling L**. The recovery of LDL after apheresis in patients with familial hypercholesterolemia: A need for more frequent treatment? (accepted for presentation, ACP 2012)
 50. Corrigan F, Eapen D, Manocha P, Hammadah M, Al Kassem H, Vazquez J, Cunningham L, Uphoff I, **Sperling L**, Alexander RW, Brigham K, Quyyumi A. Reduced bone mass predicts impaired arterial elasticity. (presented , ACC 2012)
 51. Corrigan F, Eapen D, Moanocha M, Hammadah M, Kabbany MT, Vazquez J, Cunningham L, Uphoff I, **Sperling L**, Alexander RW, Brigham K, Quyyumi A. Body fat distribution as a predictor of arterial stiffness. (presented , ACC 2012)
 52. Corrigan F, Eapen D, Manocha P, Hammadah M, Alradawi S, Vazquez J, Cunningham L, Uphoff I, **Sperling L**, Alexander RW, Brigham K, Quyyumi A. Low testosterone level is associated with impaired microvascular function in men. (presented , ACC 2012)
 53. Eapen DJ, Manocha P, Patel R, Hammadah M, Kabbany MT, Veledar E, Wassel C, Alradawi S, Corrigan F, Al Kassem H, Nanjundappa R, Mantini N, Wilmot KA, Poole J, Neuman R, Malayter D, Sikora A, **Sperling L**, Quyyumi A, Epstein S. An aggregate of pathway-related biomarkers predict risk of acute myocardial infarction and death. (presented, ACC 2012)
 54. Mantini NA, Eapen D, Corrigan F, Manocha P, Hammadah M, Vazquez J, Cunningham L, Uphoff I, **Sperling L**, Alexander RW, Brigham K, Quyyumi A. Obstructive sleep apnea is associated with increased severity of coronary artery disease and worse cardiovascular outcomes. (presented, ACC 2012)

55. Bhatia N, Patel A, Ramjee V, Epperson MF, Le NA, Vaughn L, Nell C, Baer J, Wilson PWF, **Sperling LS**. Cardiometabolic recovery kinetics post-apheresis in a model of accelerated atherosclerosis. (accepted for presentation, AHA BCVS meeting, 2012)
56. Parashar S, Spertus JA, Tang F, Bishop KL, Vaccarino V, Jackson CF, Boyden TF, **Sperling L**. Predictors of early and late enrollment in cardiac rehabilitation among those referred after acute myocardial infarction. (accepted for presentation, AHA meeting Nov. 2012)
57. Nanjundappa RPA, Eapen D, Kumar G, Manocha P, Patel R, Sher S, Al Kassem H, Hammadah M, Tahhan AS, Ghasemzadeh N, Farook N, Qadir MS, Emir V, **Sperling L**, Zafari AM, Samady H, Quyyumi AA. Mean platelet volume is an independent predictor of left ventricular systolic dysfunction and is associated with adverse cardiovascular outcomes. (accepted for presentation, AHA meeting Nov. 2012)
58. Corban MT, Eshtehardi P, Eapen DJ, Pankaj M, Al Kassem H, Le A, Pielak T, Thorball CW, **Sperling LS**, Quyyumi AA, Samady H. Elevated levels of soluble plasma urokinase plasminogen activator receptor is an independent predictor of coronary microvascular function. (accepted for presentation AHA 2012)
59. Corban MT, Eshtehardi P, Eapen DJ, Rasoul-Arzrumly E, Al Kassem H, Manocha P, Patel AD, Sikora S, **Sperling LS**, Quyyumi AA, Samady H. Elevated levels of fibrin degradation products are associated with intravascular ultrasound-defined features of plaque vulnerability in patients with coronary artery disease. (accepted for presentation, AHA 2012)
60. Corban MT, Eshtehardi P, Eapen DJ, Rasoul-Arzrumly E, Al Kassem H, Manocha P, Patel AD, Manocha P, Patel, AD, Sikora S, Mekonnen G, Hassanyar MR, **Sperling LS**, Quyyumi AA, Samady H. Elevated levels of fibrin degradation products is an independent predictor of intravascular ultrasound-defined features of plaque vulnerability in patients with coronary artery disease. (submitted for consideration, ACC 2013)
61. Ghasemzadeh N, Lam A, Reingold J, Margolis B, **Sperling LS**, Superko R. Potential use of coronary artery calcium scoring as a screening method for subclinical atherosclerosis in community firefighters. (submitted for consideration, ACC 2013)
62. Lam A, Ghasemzadeh N, Reingold J, Margolis B, **Sperling LS**, Superko R. Lack of association between Lipoprotein (a) with coronary artery calcium score in asymptomatic community firefighters. (submitted for consideration, ACC, 2013)
63. Weiss M, Eapen DJ, Veledar E, Kim J, Engberding N, BeDell P, Huey M, Williams BR, Lerakis S, **Sperling L**. Race and type of sport independently predict echocardiographic findings in Division I college athletes. (submitted for consideration, ACC, 2013)
64. Weiss M, Eapen DJ, Veledar E, Kim J, Engberding N, BeDell P, Huey M, Williams BR, Lerakis S, **Sperling L**. Prevalence of abnormal findings on preseason screening echocardiograms in NCAA Division I college athletes. (submitted for consideration, ACC, 2013)
65. Bhatia N, Ramjee V, Ghasemzadeh N, Guo Y, Li Q, Vaughn L, Nell C, Waller EE, Brigham K, Wilson PWF, Quyyumi A, Le NA, Sperling LS.

- Progenitor cell counts in familial hypercholesterolemic patients compared to healthy controls. (accepted for presentation, AHA BCVS, 2013)
66. Weiss M, Eapen DJ, Veledar E, Kim J, Engberding N, BeDell P, Huey M, Williams BR, Lerakis S, **Sperling L**. Race independently predicts echocardiographic findings in NCAA Division I College Athletes. (accepted for presentation, AHA, 2013)
67. Ghasemzadeh N, Al Kassem H, Eapen D, Khayata M, Tahhan As, Manocha P, Alzaraneh B, Nanjundappa R, Thorball CW, Patel R, Lerakis S, **Sperling L**, Pielak T, Sikora S, Epstein S, Quyyumi AA. A composite risk score of biomarkers of inflammation, thrombosis, and cell stress pathways significantly predicts risk of adverse cardiovascular events. (accepted for presentation, AHA, 2013)
68. Khayata M, Ghasemzadeh N, Hritani A, Al Kassem H, Nguyen H, Eapen D, Alzaraneh B, Alanbari R, El-Khattabi M, Kaba AN, Manocha P, Patel R, Veledar A, Mavromatis K, **Sperling L**, Vaccarino V, Quyyumi AA. Prognostic Value of angina related health status in women with suspected coronary artery disease. (accepted for presentation, AHA, 2013).
69. Weiss M, Eapen DJ, Veledar E, Kim J, Engberding N, BeDell P, Huey M, Williams BR, Lerakis S, **Sperling L**. Type of sport independently predicts echocardiographic findings in NCAA Division I College Athletes. (accepted for presentation, 28th Annual AACVPR meeting, Nashville, TN 2013)
70. Kim JH, Gu D, Patton J, Binongo J, Shoop JL, Galante A, Williams BR, Quyyumi AA, **Sperling L**. Cardiac remodeling and Hypertension in elite NCAA Division I-American-style football players. (accepted for presentation, Georgia ACC meeting, 2013)
71. Patel S, Ghasemzadeh N, Patel R, Li Q, Eapen D, Khayata M, Malekzadegan M, Smith G, Barde R, Awad M, Reddy S, **Sperling L**, Waller E, Quyyumi A. Circulating progenitor cell levels are higher in patients with ST-segment elevation MI compared to other ACS presentations. (presented at 63rd ACC meeting, Washington, D.C., 2014)
72. Ghasemzadeh N, Kim J, Eapen D, Al Kassem H, Manocha P, Khayata M, Arafat D, Patel R, Kumar S, **Sperling L**, Gibson G, Quyyumi A. A distinct peripheral blood gene expression profile is associated with acute MI and predicts risk of cardiovascular death. (presented at 63rd ACC meeting, Washington, D.C., 2014)
73. Ghasemzadeh N, De Staercke C, Li Q, Eapen D, Khayata M, Malekzadegan M, Smith G, Alzaraneh B, Mekonnen G, Alanbari R, **Sperling L**, Hooper C, Waller EK, Quyyumi A. Stromal cell-derived factor-1 and circulating progenitor cell levels as predictors of adverse cardiovascular outcomes in patients with coronary artery disease. (presented at 63rd ACC meeting, Washington, D.C., 2014)
74. Kim J, Al Mheid I, Malekzadegan M, Sher S, Shoop J, Galanter A, Williams B, **Sperling L**, Weinter R, Baggish A, Quyyumi A. Arterial stiffness in NCAA Division I American-style football players. (presented at 63rd ACC meeting, Washington, D.C., 2014)
75. Ghasemzadeh N, Brooks M, Vlachos H, Sikora S, **Sperling L**, Quyyumi AA, Epstein SE. A validated, modifiable, and actionable pathway-specific

- aggregate biomarker risk score predicts risk of CV outcomes in patients with CAD: Findings from the BARI-2D Trial. (accepted for oral presentation, AHA 2014, Chicago)
76. Shen J, Morris A, Bidulescu A, Dunbar S, Vaccarino V, **Sperling L**, Gibbons G, Quyyumi A. Associations between neighborhood characteristics and inflammation: The Morehouse and Emory Team up to Eliminate Health Disparities (META-Health) Study. (accepted for presentation, AHA 2014, Chicago)
 77. Flueckiger P, Juraschek SP, Eades M, Khera A, Blaha M, **Sperling L**. Internal Medicine Housestaff perceptions of statins and ACC/ AHA Blood Cholesterol Guidelines. (accepted for presentation, AHA 2014, Chicago)
 78. Kim JH, Sher S, Wang F, Berkstresser B, Shoop JL, Galante A, Al Mheid I, Ghasemzadeh N, Hutter AM, Williams BR, **Sperling L**, Weinter RB, Quyyumi AA, Baggish AI. The Impact of American-style Football Participation on Vascular Function. Presented at the Sports Summit, Indianapolis, IN, 2014
 79. Shen J, Morris A, Hosny K, Vaccarino V, **Sperling L**, Gibbons G, Quyyumi A. Obesity affects circulating CD34+ cell number via the leptin pathway. (accepted for presentation, Europrevent 2015, Lisbon, Portugal).
 80. Sandesara P, Lambert C, Knapper J, Wilson P, **Sperling L**. Familial Hypercholesterolemia: Hidden in Plain Sight- An algorithm for closing the gaps in the diagnosis and treatment. (under consideration for International Academy of Cardiology Annual Scientific Sessions 2015, Vancouver, Canada).
 81. Shen J, Morris A, Al Mheid I, Vaccarino V, **Sperling L**, Gibbons G, Quyyumi A. Prediction of racial differences in subclinical vascular disease in African Americans and whites: Comparison of the Framingham and Atherosclerotic Risk scores (accepted for presentation at ACC 2015, San Diego)
 82. Mahlof E, Koren M, Emery M, Doshi S, Liu T, Somaratne R, Wasserman S, **Sperling L**. Relationship of body weight and dosing of Evolocumab (EVO) for the treatment of hypercholesterolemia (accepted to ESC meeting 2015, London, England)
 83. Sandesara PB, Eapen DJ, **Sperling L**, Salmon RD, Gordon NF. Multi-Center Study of ASCVD Risk Factor Status on entry to a Contemporary Phase 2 Cardiac Rehabilitation Program: Temporal Trends (accepted for presentation, AHA 2015)
 84. Sandesara P, Lambert C, **Sperling L**. Estimated prevalence of Familial Hypercholesterolemia in the United States: Data from the NHANES Study. (accepted for presentation at the Annual ASCP meeting, Boca Raton, FL, 2015)
 85. Schultz WM, Gordon N, Salmon R, Eapen DJ, **Sperling LS**. Statins do not attenuate improvements in fasting plasma glucose and multiple CHD risk factors during exercise-based cardiac rehabilitation (accepted for presentation at ACC 2016, Chicago)
 86. Kelli HM, Awad M, Hammadah M, Haider M, Ahmed H, Topel M, Hayek S, Patel K, Gray B, Mohammed K, Pemup P, Lewis T, Dunbar S, **Sperling**

- L**, Vaccarino V, Gibbons G, Quyyumi A. Education level is associated with cardiovascular risk factors, systemic inflammation, arterial stiffness and oxidative stress . (accepted for presentation at ACC 2016, Chicago)
87. Kelli HM, Ahmed H, Hammadah M, Topel M, Hayek S, Awad M, Patel K, Gray B, Mohammed K, Ko YA, **Sperling L**, Lewis TT, Martin G, Gibbons G, Quyyumi A. The association of living in food deserts with cardiovascular risk factors and subclinical vascular disease. (accepted for presentation at ACC 2016, Chicago)
88. Kelli HM, Haider MN, Hammadah M, Awad M, Dunbar S, Lewis T, **Sperling L**, Vaccarino V, Gibbons G, Quyyumi AA. Lower income is associated with cardiovascular risk factors, systemic inflammation, arterial stiffness and oxidative stress. (accepted for presentation at the World Congress of Cardiology 2016, Mexico City, Mexico)
89. Kim JH, Ko YA, Hedley J, MacNamara J, Awad M, Taylor W, Healy S, Aida H, Le NA, Wilson PW, White M, **Sperling L**, Wilson JS, Baggish AL.. The impact of age and completion of a moderate distance running race on cardiac function: results from the PEACH (Profiling the Effects of Aging on Exercise-induced Changes in cardiac mechanics) study. (accepted for presentation at ACC 2016, Chicago)
90. Arnold SV, Inzucchi SE, McGuire DK, **Sperling LS**, Wong ND, Kosiborod M. Quality of care in the initial patient cohort of the Diabetes Collaborative Registry. (submitted for consideration, ADA meeting 2016)
91. Arnold SV, Inzucchi SE, McGuire DK, **Sperling LS**, Wong ND, Kosiborod M. Baseline characteristics of the Diabetes Collaborative Registry. (submitted for consideration , ADA meeting 2016).
92. Arnold SV, Inzucchi SE, Maddox TM, Tang F, McGuire DK, Mehta SN, Goyal A, **Sperling LS**, Einhorn D, Wong ND, Kosiborod M. Defining the potential “real world” impact of EMPA-REG Outcomes trial on improving cardiovascular outcomes of patients in the Diabetes Collaborative Registry (DCR). (submitted for consideration to 2016 EASD meeting).
93. Kosiborod M, Arnold SV, McGuire DK, Tang F, Mehta SN, Goyal A, **Sperling LS**, Maddox TM, Einhorn D, Wong ND, Hammar N, Fenici P, Sheehan JJ, Inzucchi SE. Personalization of glycemic management among patients in the Diabetes Collaborative Registry (DCR). (submitted for consideration to 2016 EASD meeting).
94. Emmons A, Flueckiger P, **Sperling L**. Patient perceptions of the risks / benefits of statins. (submitted for consideration, AHA 2016)
95. Kelli HM, Corrigan FE, Heintz RE, Dhindsa DS, Hammadah M, Al Mheid I, Awad M, Patel K, Mohammed K, Gray B, Hayek SS, Ko YA, Vaccarino V, Ziegler TR, Alexander W, **Sperling LS**, Brigham K, Martin GS, Quyyumi. Body fat distribution is associated with oxidative stress. (submitted for consideration, AHA 2016)
96. Kelli HM, Hammadah M, Hayek SS, Awad M, Corrigan FE, Heintz RE, Dhindsa Ds, Patel K, Mohammed K, Gray B, Ko YA, Vaccarino V, **Sperling LS**, Quyyumi. Neighborhood income rather than food access is associated with adverse cardiovascular outcomes in food deserts. (submitted for consideration, AHA 2016)
97. Arnold SV, Inzucchi SE, McGuire DK, Tang F, Mehta SN, Goyal A,

- Sperling LS**, Maddox TM, Einhorn D, Wong ND, Hammar N, Fenici P, Sheehan JS, Kosiborod M. Assessing the personalization of glycemic management strategies through the Diabetes Collaborative Registry (DCR). (submitted for consideration, AHA 2016)
98. Gradidge P, Constaninou D, Salmon R, Schultz W, **Sperling L**, Franklin B, Gordon N. Gender differences in improvements in multiple cardiovascular disease risk factors during exercise-based cardiac rehabilitation in patients receiving statin therapy. (submitted for consideration, AHA 2016)
99. Kelli HM, Corrigan FE, Heintz RE, Dhindsa DS, Hammadah M, Tahhan AS, Sandesara P, Alghamdi T, Al Meid I, Ko Y, Ziegler T, **Sperling LS**, Brigham K, Jones D, Vaccarino V, Martin GS, Quyyumi AA. Changes in body fat distribution is associated with oxidative stress. (accepted for presentation, ACC 2017)
100. Tahhan AS, Sandesara P, Kelli HM, Allard-Ratick M, Kindya B, Hammadah M, Topel M, Almuwaqqat Z, Stahl E, Heintz R, Hesaroieih I, Naqui H, Mahar E, Waller EK, Vaccarino V, Ziegler TR, **Sperling LS**, Brigham K, Martin GS, Quyyumi AA. Association between progenitor cells and vascular function. (accepted for presentation, ACC 2017)
101. Almuwaqqat Z, Tahhan AS, Sandesara PB, Stahl E, Heintz R, Hayek SS, Kelli HM, Hammadah M, Topel M, Alkhoder A, Gafeer MM, Chivukula K, Aida H, Allard-Ratick M, Kindya B, Abdelhadi N, Hesaroieih I, Mahar E, Waller EK, **Sperling L**, Quyyumi A. Circulating progenitor cell levels and outcomes in acute myocardial infarction. (accepted for presentation, ACC 2017)
102. Khambhati J, Sandesara P, Tahhan AS, Topel M, Corrigan F, Kelli HM, Stahl E, Allard-ratick M, Alkhoder A, Aida H, Gafeer MM, Hesaroieih I, Mahar E, Waller E, Vaccarino V, Zeigler TR, **Sperling L**, Brigham K, Martin G, Quyyumi A. Central obesity predicts circulating progenitor cell levels. (accepted for presentation, ACC 2017)
103. Sandesara P, Tahhan AS, Khambhati J, Stahl E, Hayek S, Hammadah M, Kelli HM, Topel M, Alkhoder A, Chivkuka K, Aida H, Gafeer MM, Abdelhadi N, Hesaroieih I, Naqui H, Mahar E, Waller E, **Sperling L**, Quyyumi A. Association between circulating progenitor cells and outcomes in patients with coronary artery disease. (accepted for presentation, ACC 2017)
104. Shin E, Ochuko P, Bhatt K, Howard B, McGorisk G, Delaney L, Langdon K, Khosravanipour M, Nambi AA, Grahovec A, Morris DC, **Sperling LS**, Shaw LJ, Castellano PZ, Goyal A. Electronic health record-based overestimation of failure to prescribe statins in patients with coronary artery disease in a large academic multispecialty clinic practice. (accepted for oral presentation, AHA QCOR 2017)
105. Arnold S, Inzucchi S, Tang F, McGuire D, Mehta SN, Goyal A, Maddox T, **Sperling L**, Einhorn D, Wong N, Kosiborod M. Using the Diabetes Collaborative Registry to Estimate the potential real-world impact of the LEADER trial on improving CV Outcomes in patients with Diabetes at High CV Risk. (accepted for presentation, ACC 2017)
106. Sandesara P, Tahhan AS, Hajjari J, Khambhati J, Lee S, Hayek S,

- Hammadah M, Mohammad-Kelli H, Topel M, Alkhoder A, Chivukula K, Aida H, Gafeer M, **Sperling L**, Quyyumi A. Association between peripheral artery disease and measures of oxidative stress. (accepted for presentation, ESC 2017)
107. Lee S, Khambhati J, Sandesara P, O'Neal W, Tahhan S, Hayek S, Hammadah M, Mohammad-Kelli M, Topel M, Alkhoder A, Aida H, Chivukula K, **Sperling L**, Quyyumi A. High-sensitivity troponin I predicts the risk of adverse outcomes in patients with chronic kidney disease. (accepted for presentation, ESC 2017)
108. Sandesara P, Tahhan AS, Khambhati J, Lee S, Hayek S, Hammadah M, Mohammad-Kelli H, Topel M, Alkhoder A, Aida H, Hesaroieh I, Mahar E, Waller E, **Sperling L**, Quyyumi A. Association between progenitor cells and measures of vascular function. (accepted for presentation, ESC 2017)
109. Sandesara P, Tahhan AS, Ko Y, Hayek S, Khambhati J, Lee S, Alkhoder A, Aida H, **Sperling L**, Quyyumi A. Using a decision tree analysis to risk stratify patients with coronary artery disease. (accepted for presentation, ESC 2017)
110. Sandesara PB, O'Neal WT, **Sperling LS**. Diastolic blood pressure and adverse outcomes in patients with Heart Failure with Preserved Ejection Fraction: An Analysis from Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT), (submitted for consideration, ASCO Congress 2017)
111. Wong ND, Song Y, Arnold S, **Sperling L**, Cannon C, Inzucchi S, Kosiborod M. Composite Cardiovascular Risk Factor Target Achievement and its Indicators in US Adults with Diabetes; The Diabetes Collaborative Registry (accepted for presentation, ADA meeting 2018)
112. **Sperling L**, Raevschi E. Status of Cardiovascular Health in the Republic of Moldova. (submitted for consideration to CDC BRFSS Conference)
113. Sandesara P, O'Neal W, Kelli HM, Sathiyakumar V, Martin S, Blaha M, Blumenthal R, **Sperling L**. Prevalence of CV risk factors and prognostic significance of coronary artery calcium in individuals with LDL-C > 190 mg/dL: The MESA Study (presented at ACC 2018)
114. Arnold S, Seman L, Tang F, McGuire D, Mehta S, Goyal A, **Sperling L**, Kosiborod M. Real world opportunity of empagliflozin in CV risk factor modification: An NCDR Research to Practice project from the Diabetes Collaborative Registry. (presented at ACC 2018)
115. Sabbak N, Albadri A, Tahhan AS, Sandesara P, Alkhoder A, Hayek S, Kelli HM, Gafeer MM, Abdelhadi N, Kaseer B, Ko YA, Patel K, Choudhary F, Kumar S, Hajjari J, Patel A, Choudhary M, Hasnain L, Enigneer V, Qadir S, Sidoti A, **Sperling L**, Mehta P, Quyyumi A. Circulating Urokinase Plasminogen Activator Receptor levels predict mortality in subjects with obstructive coronary artery disease. (presented at ACC 2018)
116. Glovaci D, Bluemke DA, Budhoff M, **Sperling L**, Gaita D, Chaffin MM, Trejo ME, Allison M, Wong N. Metabolically healthy and unhealthy obesity and changes in LV mass, volume, and function by cardiac MRI: Results from the MESA study (presented at ACC 2018)
117. Hajjari J, Tahhan AS, Alkhoder A, Kaseer B, Naser A, Almuwaqqat Z,

- Gafeer MM, Choudhary F, Patel K, Patel A, Jafri M, Choudhary M, Hasnain L, Qadir S, Sidoti A, Lankford A, Bhimani R, Ko YA, Vaccarino V, **Sperling L**, Jones D, Quyyumi A. Markers of Oxidative stress and peripheral artery disease (presented at ACC 2018).
118. Kelli HM, Liu C, Samman-Tahhan A, Alghamdi T, Ko YA, Choudhary F, Engineer V, Hammadah M, Sandesara P, Al Mheid I, O'Neal W, Vaccarino V, Ziegler T, **Sperling L**, Lampl M, Brigham K, Martin G, Quyyumi A. Ideal Cardiovascular Health Score and Oxidative Stress. (presented at AHA Epi/ Lifestyle , 2018 New Orleans)
119. Allard-Ratick MP, Khambhati J, Topel M, Sandesara PB, **Sperling LS**, Quyyumi AA. Elevated HDL-C is associated with Adverse Cardiovascular Outcomes (accepted for oral presentation, ESC 2018, Munich, Germany)
120. Mehta A, Pandey A, Ayers CR, Khera A, **Sperling L**, Szklo M, Gottesman R, Nasir K, Budoff MJ, Blaha MJ, Blumenthal RS, Joshi PH. Predictive Value of Coronary Artery Calcium for Coronary Events versus Strokes. (submitted to Northwestern CV Young Investigator Forum (NCYIF) for consideration)
121. Mehta A, Pandey A, Ayers CR, Khera A, **Sperling L**, Szklo M, Gottesman R, Nasir K, Budoff MJ, Blaha MJ, Blumenthal RS, Joshi PH. Impact of Gender and Ethnicity on the Predictive Value of Coronary Artery Calcium for Coronary Events vs. Strokes. (submitted for consideration, ACC Young Investigator Competition, 2018)
122. Mehta A, Pandey A, Ayers CR, Khera A, **Sperling L**, Szklo M, Gottesman R, Nasir K, Budoff MJ, Blaha MJ, Blumenthal RS, Joshi PH. Impact of Gender and Ethnicity on the Predictive Value of Coronary Artery Calcium for Coronary Events vs. Strokes. (submitted for consideration, AHA Epi meeting, 2019)
123. Mehta A, Liu C, Dhindsa DS, Ko YA, Kim JH, Sandesara PB, Tahhan AS, Topel ML, Kelli HM, Moazzami K, Bakhtadze B, Alkhoder A, Martin S, **Sperling LS**, Reiser J, Hayek SS, Quyyumi AA. Sex-differences in circulating Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) levels and its impact on the Prognostic Value of suPAR among Patients with Coronary Artery Disease. (accepted for presentation at ACC 2019, New Orleans, LA)
124. Dhindsa D, Sandesara P, Mehta A, Topel M, Allard-Ratick M, O'Neal W, Khambhati J, Bakhtadze B, Tahhan AS, Hayek S, **Sperling LS**, Quyyumi A. Association of High HDL in Patients with CAD: Impact of Race and Sex (accepted for presentation at ACC 2019, New Orleans, LA)
125. Madan N, Sohal S, Parapid B, **Sperling L**, Januzzi JL, Lalic K, Lundberg G, Butler J, Kosiborod M, Volgman AS. Sex-based differences in cardioprotective effects of SGLT-2 inhibitors in patients with T2DM. (accepted for presentation at ESC 2019)
126. Volgman A, Madan N, Sohal S, **Sperling L**, Dembowski E, Lundberg G, Parapid B, Lalic K. SGLT2i Demonstrate Reduction in MACE and HF Admissions- An Up-to-Date Meta-analysis. (submitted for consideration to ESC 2019)
127. Dhindsa D, Sandesara PB, Liu C, Topel M, Mehta A, Allard-Ratick M, **Sperling L**, Quyyumi. HDL-C and All-cause mortality in a high-risk

- population: Impact of LDL-C. (presented at ESC meeting, Paris, France, 2019)
128. Mehta A, Ayers C, Blaha M, Blumenthal R, Hooda A, Khera A, Patel J, **Sperling LS**, Tsai M, Virani S, Shapiro MD, Vasquez N, Joshi P. Lp(a) and Coronary Artery Calcium Score Independently Predict CVD Risk in the MESA and Dallas Heart Study. (accepted for presentation, ACC 2020)
 129. Patel J, Mehta A, Al Rafai M, Blaha MJ, Nasir K, McEvoy JW, Pandey A, Kanaya A, Kandula N, Virani S, Abbate A, Hundley WG, **Sperling L**, Joshi PH. Hypertension Guidelines and Coronary Artery Calcification among S. Asians: Mediators of Atherosclerosis in S. Asians Living in America (MASALA) and MESA. (accepted for presentation, ACC 2020)
 130. Brown M, Mehta A, **Sperling L**. Skinny Fat: Metabolic Disease without the Metabolic Phenotype. (accepted for presentation, ACC 2020)
 131. Knijnik LM, Fernandes M, Rivera M, Blumer V, Cardoso R, Goyal A, McDaniel M, Lieberman H, **Sperling L**, Cohen M. Antiplatelet Duration Strategies after PCI with Stenting: systematic Review and Meta-Analysis. (accepted for presentation, ACC 2020, JACC 2020;75(11)).
 132. Ritchey MD, Maresh S, Jackson SL, McNeely J, Shaffer T, Keteyian SJ, Brawner CA, Whooley M, Stolp H, Wall HK, **Sperling LS**. Monitoring cardiac rehabilitation participation among eligible Medicare fee-for-service beneficiaries to track progress of a National Initiative, 2016-2018. (submitted for consideration, Academy Health Annual Research meeting and CMS Quality conference, 2020)
 133. Mehta A, Meng Q, Desai S, D'Souza MS, Ho AH, Islam SJ, Dhindsa DS, Nayak A, Alkhoder AA, Hooda A, Varughese A, Ahmad SF, Mokhtari A, Hesaroieh I, **Sperling LS**, Ko YA, Waller EK, Quyyumi AA. Vascular Regenerative Capacity: A Window Into the Pathobiology of Obesity Paradox. (submitted for consideration, AHA 2020)
 134. Okunrintemi V, Tibuakuu M, Virani SS, **Sperling LS**, Volgman AS, Gulati M, Cho L, Leuker TM, Blumenthal RS, Michos ED. Sex Differences in the Age of Diagnosis of Cardiovascular Disease and Risk Factors Among U.S. Adults: Trends from 2017-2018: The Medical Expenditure Panel Survey (MEPS). (accepted for presentation, AHA 2020)
 135. Ahmad MI, Mehta A, Almuuqaat Z, Vatsa N, Schwartz A, Islam SJ, Dhindsa D, Nayak A, Rogers S, Shah S, Alkhoder A, Liu C, ko YA, **Sperling L**, Quyyumi A. Association of B-type Natriuretic Peptide Levels with Obesity Paradox in Patients with Coronary artery Disease. (submitted for consideration, AHA 2020)
 136. Park S, Hong Y, Gillespie C, Merritt R, **Sperling L**. Temporal trends in non-invasive diagnostic tests for ischemic heart disease among U.S. adults, age 64 years or younger: results from the MarketScan Survey, 2010-2018. (accepted for presentation, AHA 2020)
 137. Hong Y, Park S, **Sperling L**, Gillespie C, Merritt R. Temporal trends in non-invasive diagnostic tests for ischemic heart disease among Medicare beneficiaries in the U.S., 2010-2017. (accepted for presentation, AHA 2020).
 138. Knijnik LM, Maza MR, Fernandes M, Cardoso R, Goyal A, McDaniel M,

- Liberman H, **Sperling L**, Cohen M. Dual Antiplatelet Therapy for 1 to 3 Months is Superior to 12 Months After Coronary Stenting (submitted for consideration, ACC 2021)
139. Yadalam A, Almuwaqqat Z, Desai S, Beydoun N, Alkhoder A, Alras Z, Ko YA, Lewis T, Kim J, Shah A, **Sperling L**, Quyyumi A. Living in Socially Vulnerable Neighborhoods Predicts Future Cardiovascular Events in Patients with Coronary Artery Disease. Accepted for presentation, ACC, 2022.
140. Razavi A, Iftekhhar Uddin SM, Dardari Z, Berman D, Budoff MJ, Miedema MD, Osei A, Obisesan AO, Nasir K, Rozanski A, Rumberger JA, Shaw LJ, **Sperling LS**, Whelton SP, Mortensen MB, Blaha M, Dzaye O. Coronary Artery Calcium for Risk Stratification of Sudden Cardiac Death: The Coronary Artery Calcium Consortium. accepted for presentation, ACC, 2022
141. Mehta A, Ahmad SF, Meng Q, Ho AH, Zuniga JV, Desai DR, Dindsa DS, Islam SJ, Almuwaqqat Z, Nayak A, Hooda A, Mokhtari A, **Sperling LS**, Ko YA, Waller EK, Quyyumi AA. Circulating Progenitor Cell Count: An Independent Biomarker of Adverse Outcomes in Coronary Artery Disease. accepted for presentation, ACC, 2022
142. Sekkarie A, Park S, Therrien N, Jackson S, Woodruff R, Attipoe-Dorcoo S, Yang P, **Sperling L**, Loustalot F, Thompson-Paul A. Trends of Lipid-Lowering Prescriptions by Statin Intensity-United States, Q3 2015-Q32021. Presented at the CDC EIS Conference, Chronic Disease and Emergency Preparedness Session, 2022.
143. Joy J, Haumschild R, **Sperling L**, Isiadinso I. Implementation of Specialty Clinical Pharmacist in a Preventive Cardiology Clinic. Accepted for presentation, American Society for Preventive Cardiology meeting, 2022).
144. Ford ND, DeSisto CL, Galang R, Kuklina E, **Sperling L**, Ko JY. Cardiac Arrest during Delivery Hospitalizations and Severe Hypertensive Disorders of Pregnancy, United States, 2017-2019. (accepted for presentation, AHA Hypertension meeting, 2022).
145. Razavi AC, Van Assen M, De Cecco CN, Dardari ZA, Berman DS, Budoff MJ, Miedema MD, Nasir K, Rozanaki A, Rumberger JA, Shaw LJ, **Sperling LS**, Whelton SP, Mortensen MB, Blaha MJ, Dzaye O. Discordance between Coronary Artery Calcium Area and Density Predicts Long-term Atherosclerotic Cardiovascular Disease Risk. (accepted for YIA presentation at SCCT meeting, 2022
146. Al-Kindi S, Motairek I, Nasir K, **Sperling L**, Farkouh M, Wright J, Dobre M, Rahman M, Rajagopalan S. Historical Neighborhood Redlining and Cardiovascular Risk in Patients with Chronic Kidney Disease: Results from Chronic Renal Insufficiency Cohort. (accepted to AHA 2022)
147. Sekkarie A, Park S, Therrien NL, Jackson SL, Woodruff RC, Attipoe-Dorcoo S, Yang P, **Sperling L**, Loustalot F, Thompson-Paul AM. Trends in Lipid –Lowering Prescriptions by Statin Intensity- United States, 2017-2022. (accepted to AHA 2022)
148. Cheung B, Block RC, Wong N, Eapen D, **Sperling LS**, McIntosh S. Accelerating the Diagnosis of Familial Hypercholesterolemia: A Mixed-

methods Analysis of Patient-Physician Communication Needs. Accepted for presentation, AHA 2022

149. Varghese MS, Beatty A, **Sperling LS**, Fonarow GC, Keteyian SJ, McConeghy KW, Penko J, Song Y, Yeh R, Figueroa JF, Wu WC, Xu J, Kazi DS. Cardiac Rehabilitation and COVID-19: Nationwide Decline in Access and Participation Among Medicare Beneficiaries. (accepted to AHA 2022)
150. Woodruff RC, Campbell Ap, Loustalot F, Oster M, **Sperling L**, Taylor CA, Whitaker M, Havers FP, for the COVID-19 Associated Hospital Surveillance Network team (COVID-NET) Myocarditis during COVID-19 Associated Hospitalizations-14 US States, March 2020-May 2022. (accepted to AHA as LBCT, Evolving Science COVID-19, 2022)
151. Razavi AC, Berman DS, Van Assen M, De Cecco C, **Sperling LS**, Quyyumi AA, Budoff MJ, Miedema MD, Nasir K, Rozanski A, Rumberger JA, Shaw LJ, Mortensen MB, Whelton SP, Blaha MJ, Dzaye O. Prognostic implication of thoracic aortic calcium area and density beyond coronary artery calcium for atherosclerotic cardiovascular disease mortality (accepted for presentation, ACC 2023)
152. Ford ND, Desisto C, Galang R, Kuklina E, **Sperling L**, Ko J. Cardiac Arrest During Delivery Hospitalization, U.S., 2017-2019. (submitted for consideration, ACOG National meeting, 2022)
153. Almuwaqqat Z, Martini A, Islam S, Nayak A, EjZ k, Mehta A, Yadalam A, Desai S, Alras Z, Alkhoder A, Ko Y, **Sperling L**, Quyyumi, A. Social Vulnerability, Inflammation and Cardiovascular Events (accepted for presentation at AHA 2022)
154. Minhas A, Jain V, Li M, Ariss R, Fudim M, Michos E, Virani S, **Sperling L**, Mehta A. Family Income and Cardiovascular Disease Risk in American Adults (accepted for presentation at AHA 2022)
155. Razavi A, Dzaye O, Michos E, Budoff M, Allen N, Lima J, Polak J, Post W, Nasir K, Blumenthal R, **Sperling L**, Blaha M, Whelton S. Non-Traditional Risk Markers for Incident Coronary Artery Calcium Among Persons > 65 Years Old: The Multi-Ethnic Study of Atherosclerosis. (accepted for presentation at AHA 2022)
156. Mohamed G, Daly D, Morales P, Alabyad D, Minja F, Lemuel-Clark M, Henriquez L, Navalkele D, **Sperling L**, Lundberg G, Mehta A, Nahab F. Lipoprotein(a) Levels in Patients with Embolic Stroke of Undetermined Source and its Association with Non-stenotic Atherosclerotic Disease. (accepted for presentation at the International Stroke Conference 2023).
157. He S, Park S, Kuklina E, Therrien NL, Lundeen EA, Wall HW, Lampley K, Kompaniyets L, Pierce SL, **Sperling L**, Jackson SL. Leveraging electronic health records to construct a phenotype for hypertension surveillance in the United States. Accepted for presentation, Academy Health Annual Research meeting (ARM), 2023.
158. Ye Z, Gilchrist S, Omeaku N, Shantharam S, Ritchey M, **Sperling L**, Holl J. Acute Stroke Care Coordination: Variation in State Laws for Emergency Medical Services and Hospitals. Accepted for presentation, Academy Health Annual Research meeting (ARM), 2023.
159. Razavi AC, Shaw LJ, Berman DS, Budoff MJ, Wong ND, Vaccarino V,

- van Assen M, De Cecco CN, Quyyumi AA, Mehta A, Muntner PM, Miedema MD, Rozanski A, Rumberger JA, Nasir K, Blumenthal RS, **Sperling LS**, Mortensen MB, Whelton SP, Blaha MJ, Dzaye O. Very-high risk ASCVD Status Among patients with CAC > 1000: Implications for Intensive Lipid-lowering therapies. Accepted for presentation, 1st Place Young Investigator Award, NLA meeting, 2023
160. Fueller D, Liu C, Ko YA, Alkhoder AA, Desai SR, Almuwaqqat Z, Patel SA, Ejaz K, Kauser T, Martini A, Alvi Z, Mehta PK, **Sperling LS**, Quyyumi AA. Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of low education in patients with coronary artery disease. Accepted for presentation, ESC meeting 2023
161. Asghar A, Talha KM, Waqar E, **Sperling LS**, DiNino EK, Sharafkhaneh A, Virani SS, Ballantyne CM, Nambi V, Minhas AMK. Trends in Sleep Apnea and Heart Failure-related Mortality in the United States from 1999 to 2019. (accepted, CHEST Annual meeting, 2023).
162. Woodruff RC, Melgar M, Pham H, Loustalot F, Kirley PD, Armistead I, Kim D, Openo K, Ryan PA, Brown C, Bye E, Davis SS, Barney G, Popham K, Thomas A, Talbot HK, Hill M, **Sperling LS**, Havers F. Acute Cardiac Events among Older Adults Hospitalized with Laboratory-Confirmed Respiratory Syncytial Virus. Accepted for presentation, AHA 2023).
163. Mehta A, Lee T, Liu C, Chew N, Ko YA, Siddiqui M, Gold ME, Gold DA, Vatsa, N, Desai SR, Fudim M, Pandey A, Arora P, Bugianesi E, **Sperling LS**, Sanyal A, Jain V, Quyyumi AA. N-terminal Prohormone of B-type Natriuretic Peptide levels Partly Mediate the Relationship of Advanced Hepatic Fibrosis with Mortality in Coronary Artery Disease. (accepted for presentation, AHA 2023).
164. Vatsa N, Bennett J, Desai SR, Gold DA, Gold ME, Jain V, Ejaz K, Rahbar A, Hartsfield J, Ko YA, **Sperling LS**, Mehta PK, Quyyumi AA. Persistent or Worsening Depression is Associated with Adverse Cardiovascular Outcomes in Patients with Coronary Artery Disease. (submitted for consideration, AHA 2023).
165. Gold ME, Jain V, Desai S, Ko YA, Chen X, Liu C, Gold DA, Vatsa N, Alkhoder A, Ejaz K, Hayek SS, Wilson P, **Sperling LS**, Quyyumi AA. An Externally Validated Proteomic Multi-Marker Risk Score Enhances Cardiovascular Risk Assessment in Patients with Coronary Heart Disease. (submitted for consideration, AHA 2023).
166. Varghese MS, Dahabreh IJ, Song Y, Xu J, Beatty AL, McConeghy KW, Yeh RW, **Sperling LS**, Fonarow GC, Keteyian SJ, Wu WC, Kazi DS. Target Trial Emulation: Evaluating Cardiac Rehabilitation after TAVR. (accepted for presentation, AHA 2023)
167. Razavi AC, Dzaye O, Cainzos-Achirica M, Dardari Z, van Assen M, Quyyumi AA, Nasir K, Carr JJ, Budoff MJ, Blumenthal RS, Raggi R, De Cecco CN, **Sperling LS**, Blaha MJ, Whelton SP. Association of Thoracic Aortic Calcium with Incident Cardiovascular Disease and All-Cause Mortality Across the Spectrum of Coronary Artery Calcium Burden. Presented at SCCT 2023.
168. Razavi AC, Mehta A, Budoff MJ, Gianos E, Wong ND, Vaccarino V, van

- Assen M, De Cecco CN, Rozanski A, Miedema MD, Rumberger JA, Mortensen MB, Shaw LJ, Nasir K, Blumenthal RS, Rohargi A, Quyyumi AA, **Sperling LS**, Whelton SP, Blaha MJ, Berman DS, Dzaye O. Coronary Artery Calcium for Risk Stratification among Persons with Very-High High-Density Lipoprotein Cholesterol. Accepted for presentation, AHA, 2023
169. Kim K, Faruque S, Kulp D, Lam S, **Sperling L**, Eapen D. Emory FIND FH (Flag, Identify, Network, and Deliver Patients with Hypercholesterolemia): Preliminary Chart Review and Baseline Awareness Survey. Presented at 8th FH Summit, 2023.
170. Kim K, Faruque S, Kulp D, Lam S, **Sperling L**, Eapen D. Emory FIND FH (Flag, Identify, Network, and Deliver Patients with Hypercholesterolemia): Patient / Provider Education and Outreach. Presented at 8th FH Summit, 2023.
171. Razavi AC, Vasani RV, van den Heuvel E, Whelton SP, Dzaye O, Mujahid M, Lewis T, Judd SE, Rotter J, Coronado F, Richardson L, van Assen M, De Cecco CN, Quyyumi AA, Blaha MJ, **Sperling LS**, Budoff MJ, Vaccarino V. Hypertension in Pregnancy and Coronary Artery Calcium in White and Black Women in Rural Alabama; The RURAL Cohort Study. (accepted for presentation, ACC, 2024)
172. Razavi AC, Vasani RV, van den Heuvel E, Whelton SP, Dzaye O, Mujahid M, Lewis T, Judd SE, Rotter J, Coronado F, Richardson L, van Assen M, De Cecco CN, Quyyumi AA, Blaha MJ, **Sperling LS**, Budoff MJ, Vaccarino V. Coronary Artery Calcium Burden According to Age, Sex, and Race in Rural Alabama: The RURAL Cohort Study. (accepted for presentation, AHA Epi, 2024)
173. Razavi AC, Richardson L, Dzaye O, Whelton SP, Mehta A, Quyyumi AA, Vaccarino V, Blaha M, Blumenthal RS, Coronado F, **Sperling LS**. Aspirin Use for Primary Prevention Among US Adults with and without Elevated Lipoprotein(a). (accepted for presentation, ACC, 2024)
174. Samaha H, Eisenberg S, Thompson K, Alam S, Kim P, Larson J, Lisko J, Babaliaros V, Attia T, **Sperling L**. The Clot Thickens: TAVR valve Thrombosis in a patient with von Willebrand Disease. (accepted for presentation, ACC, 2024)
175. Eisenberg S, Gold D, Sandesara P, Eapen D, **Sperling L**. Utilization of Cardiac Rehabilitation in Patients with Chronic Total Occlusion. (submitted for consideration, ACC, 2024).
176. Razavi AC, Richardson L, Dzaye O, Whelton SP, Mehta A, Quyyumi AA, Vaccarino V, Budoff MJ, Nasir K, Blaha MJ, Blumenthal RS, Coronado F, **Sperling LS**. Aspirin Use for Primary Prevention Among US Adults with and Without Elevated Lipoprotein (a). (accepted for presentation, ACC, 2024).
177. Faruque S, Kain K, Eapen D, **Sperling L**. Empowering Primary Care Clinicians to Identify and Deliver Care to Patients with Familial Hypercholesterolemia: A Systems-Based Approach. (submitted for consideration, SGIM, 2024).
178. Razavi AC, Bhatia HS, Dardari ZA, Mehta A, Nasir K, Blankstein R, Isadinso I, Quyyumi AA, Vaccarino V, Khoury MJ, Fialkow, Coronado F,

- Budoff MJ, Blumenthal RS, Whelton SP, Mortensen MB, **Sperling LS**, Matsushita K, Blaha MJ, Dzaye O. Detailed Family History of Premature Atherosclerotic Cardiovascular Disease to Guide Lipoprotein (a) Testing: The Multi-Ethnic Study of Atherosclerosis. (submitted for consideration, NLA meeting, 2024).
179. Kim K, Faruque SC, Kulp D, Lam S, **Sperling LS**, Eapen DJ. The Name of the Game: Implications of Diagnosis through Machine Learning for Patients with Familial Hypercholesterolemia. (accepted for presentation, ACC 2024).
180. Kim K, Faruque SC, Kulp D, Lam S, **Sperling LS**, Eapen DJ. Primary Care Physician Engagement in Implementing a Machine-Learning Algorithm for Targeting Screening of Familial Hypercholesterolemia. (accepted for presentation, ACC 2024).
181. Shah R, Joy J, Dickert N, **Sperling L**, Isiadinso I. Heartfelt Decisions: Incorporating Patient Decision Aids in a Preventive Cardiology Clinic. (to be presented at Emory Quality Conference, 2024)
182. Joy J, Shah R, Dickert N, **Sperling L**, Isiadinso I. Development of Patient Decision Aids for an Academic Preventive Cardiology Clinic. (submitted to ASCP Congress for consideration, 2024)
183. Razavi AC, Zhang AMC, Dardari ZA, Nasir K, Khorsandi M, Mortensen MB, Al-Mallah MH, Shapiro MD, Daubert MA, Blumenthal RB, **Sperling LS**, Whelton SP, Blaha MJ, Dzaye O. Modelling Allocation of Semaglutide According to Coronary Artery Calcium and Body Mass Index in Persons without Clinical ASCVD and Diabetes: The Multi-Ethnic Study of Atherosclerosis. (selected as finalist for Canon Young Investigator Award at SCCT meeting, 2024).
184. McLean P, Chandrasekhar S, **Sperling L**, Vengoechea J, Mitchell A. Fish Eye Disease: The Depths of HDL- Phenotype of Fish Eye-Disease with Heterozygosity for LCAT-Deficiency. (submitted to ACC for consideration, 2025)
185. Fuller D, Liu C, Boten DN, Ritter O, Dorr G, Jain V, Desai SR, **Sperling LS**, Sun YV, Quyyumi AA. Comparative Effects of Socioeconomic Factors and Cardiovascular Risk Factors for the Risk of Incident Ischemic Heart Disease, Ischemic Stroke, Peripheral Arterial Disease and Mortality in the United Kingdom Biobank. (accepted for presentation AHA,2024)
186. Razavi AC, Reyes MP, Wilkins JT, Szklo MS, Tsai MY, Whelton SP, **Sperling LS**, Tsimikas S, Bhatia HS. Traditional Risk Factors, Cardiovascular Health, and Elevated Lp(a): The Multi-Ethnic Study of Atherosclerosis. (accepted for presentation, AHA 2024)
187. Guynn N, Regis K, Eckert A, D'Spuza M, Westerman S, Lloyd M, **Sperling L**. Ticking Time Bomb: A Case of Wide Complex Tachycardia. (submitted for consideration, ACC, 2025).
188. Peng AW, Razavi AC, Bimal T, Rubin M, Allen NB, Wilkins JT, **Sperling LS**, Rana JS, Whelton SP, Blaha MJ, Blumenthal RS, Gianos E. Long-term Cumulative LDL Exposure and ASCVD Events in Young Adults with CAC=0: Insights from the CARDIA Study. (accepted for presentation, AHA 2024)
189. Alebna PL, Amborsio M, Akakpo DS, Bolden G, Razavi AC, Chew N,

- Hundley WG, Salloum FN, **Sperling LS**, Shapiro MD, Bhatia H, Mehta A. Association of Lipoprotein (a) with Cardiovascular Outcomes Across the Spectrum of HbA1C Levels. (accepted for presentation, AHA 2024)
190. Shrikhande S, Taylor S, Liprandi AS, Banerjee A, Razavi AC, **Sperling LS**, Perel P. The Role of Healthcare Professionals in patient knowledge and communication on influenza vaccines in cardiac patients. (accepted for presentation, Options XII meeting, Brisbane, AU, 2024).
191. Shrikhande S, Taylor S, Liprandi AS, Banerjee A, Razavi AC, **Sperling LS**, Perel P. Influenza Vaccinations in cardiac patients across five countries: Findings and Implications from a World Heart Federation Study. (accepted for presentation, Options XII meeting, Brisbane, AU, 2024).
192. Gershon G, Razavi AC, Yang Y, Dzaye O, Whelton SP, Blaha MJ, Blumenthal RS, **Sperling LS**, De Cecco C, van Assen M. Prevalence and Burden of Coronary Artery Calcium Across the Pooled Cohort Equation versus the American Heart Association PREVENT Risk Calculator. (accepted for presentation, AHA, 2024).
193. Razavi AC, Bhatia HS, Marrero N, Dzaye O, Post WS, Nasir K, Tsai M, Vaccarino V, Vasan RS, Thanassoulis G, Tsimikas S, **Sperling LS**, Budoff MJ, Blumenthal RS, Blaha MJ, Whelton SP. Regular Aspiring Use, Lipoprotein (a), LDL-Cholesterol and Incident Aortic Valve Calcium: The Multi-Ethnic Study of Atherosclerosis. (honorable mention, YIA, ACC 2025).
194. Bhatia HS, Ambrosio M, Razavi AC, Alebna PL, Yeang C, Spitz JA, Patel J, Tsai M, **Sperling L**, Shapiro MD, Tsimikas S, Mehta A. Evaluation of the AHA PREVENT Equations in Individuals with Elevated Lipoprotein(a): Insights from MESA and the UK Biobank. (accepted for presentation, ACC 2025).
195. Yadam AK, Liu C, Razavi AC, **Sperling LS**, Sun YV, Quyyumi AA. Large-Scale Proteomics-Based Protein Risk Scores for the Prediction of Incident Cardio-Kidney-Metabolic-Disease. (accepted for presentation, ACC 2025).
196. Gershon G, Yang Y, Razavi AC, Dzaye O, Whelton SP, Blaha MJ, Blumenthal RS, **Sperling LS**, De Ceco C, van Assen M. Comparative Analysis of Coronary Artery Calcium Prevalence and Burden: Pooled Cohort Equation versus AHA PREVENT 10-year Risk Calculator. (accepted for presentation, ACC 2025).
197. Gershon G, Razavi Ac, Dzaye O, Whelton SP, Blaha MJ, Blumenthal RS, **Sperling LS**, Rapaka S, De Cecco C, van Assen M. AI-Derived Cohort Analysis of Sex and Race Differences in Coronary Artery Calcium Area and Density. (accepted for presentation, ACC 2025).
198. McLean P, Chandrasekhar S, **Sperling L**, Vengoechea J, Mitchell A. Genetic Analysis to Diagnose Fish Eye-Disease: The Depths of HDL-Cholesterol. (accepted for presentation, ACC 2025).
199. Guynn N, Regis K, Eckert A, D'Souza M, Annakie D, Westerman S, **Sperling LS**, Lloyd MS. Ticking Time Bomb: A Case of Wide Complex Tachycardia on a Smartwatch. (submitted for consideration, ACC 2025).
200. Harris K, Alkhoder A, Ko YA, **Sperling L**, Mehta PK, Quyyumi A.

- Assessing Cardiometabolic Burden and Cardiovascular Risk in Women with Polycystic Ovary Syndrome: Insights from the Emory Cardiovascular Biobank Study. (submitted for consideration, ACC 2025).
201. Vogel B, Eisenberg S, Sakr S, Yadalam A, Gold M, Chuckaree I, Agusala V, Jain V, Vatsa N, Gold D, Eapen D, Vaccarino V, Mehta P, Hayek S, Raavi A, **Sperling L**, Quyyumi A. Lipoprotein (a), Soluble Urokinase Plasminogen Activator Receptor, and Cardiovascular Disease Risk. (accepted for presentation, ACC 2025).
 202. Essa M, Da RosaDecker SR, Liang L, Song Y, Figueroa J, **Sperling LS**, Beatty AL, Kazi D. Social Determinants of Health and Use of Cardiac Rehabilitation in Patients with Myocardial Infarction and Cardiogenic Shock. (accepted for presentation, ACC 2025).
 203. Essa M, da Rosa Decker SR, Song Y, Liang L, **Sperling LS**, Beatty AL, Dahabreh I, Kazi D. Real-World Effectiveness of Cardiac Rehabilitation after ST-elevation Myocardial Infarction in Medicare Beneficiaries: A Target Trial Emulation. (accepted for presentation, ACC 2025).
 204. DapamedeT, Urooj A, Gershon G, Van Assen M, Ayoub C, **Sperling LS**, Arsanjani R, Gichoya J, O' NeillC, Banerjee I, Trivedi H. Risk Stratification of Adverse CV Events and Mortality in Women using AI-basedQuantification of Vascular Calcifications. (accepted for presentation, ACC 2025).
 205. Pollack LM, Kompaniyets L, Chang A, Thompson MP, Keteyian SJ, Stolp H, Wall HK, **Sperling LS**, Jackson SL. Cardiac Rehabilitation Metrics Among Commercially Insured Individuals in the United States, 2017-2022. (submitted for consideration, Academy Health, 2025).
 206. Koumas A, Sriprada TS, Tripathi S, Dixit H, Amer A, Gladders B, **Sperling L**, Sanchez R, Gu J. Patient-level Simulation of LDL-C Goal Attainment in a Population with Homozygous Familial Hypercholesterolemia following Evinacumab Treatment Intensification (submitted for consideration, NLA meeting, 2025).
 207. Beveridge E, Medina Inojosa JR, Philipsborn R, Martin ZT, Goel R, **Sperling L**. Enhancing CDC and EPA HeatRisk and Air Quality Risk Recommendations: A Narrative Review and Action Algorithm for Cardiac Patients. (accepted for presentation, ASPC Congress, 2025)
 208. Kulp D, Furman B, Lam S, Kim K, Bardach S, **Sperling LS**, Eapen D. Catching Cholesterol Culprits: Machine-Learning Algorithm (MLA)-based Approach to Detection of Familial Hypercholesterolemia (FH). (accepted for presentation, ASPC Congress, 2025)
 209. Bardach S, Chernichky-Karcher S, Hawke A, Wilemon K, MacDougall D, **Sperling L**. Examining Barriers and Facilitators to Testing Lipoprotein(a): Understanding At-risk Individual and Clinician Perspectives through the Lens of the Integrated Screening Action Model. (accepted for presentation, ASPC Congress, 2025).
 210. Razavi AC, Mehta A, Dzaye O, Post WS, McGuire DK, Nasir K, Vaccarino V, Dardari ZA, Quyyumi AA, Bancks MP, Blumenthal RS, **Sperling LS**, Blaha MJ, Budoff MJ, Whelton SP. Intensive Blood Pressure Control and SGLT2 Inhibitors for the PREVENTion of Heart Failure: The Multi-Ethnic Study of Atherosclerosis. (accepted for

- presentation, AHA 2025)
211. Decker SRR, Essa M, Song Y, Liang L, McConeghy KW, Wu WC, Varghese MS, Thompson MP, Inoue K, Rosa RG, Yeh RW, **Sperling LS**, Fonarow GC, Keteyian SJ, Beatty AL, Dahabreh I, Kazi D. Comparative Effectiveness of Cardiac Rehabilitation after Surgical Aortic Valve Replacement- A Target Trial Emulation. (submitted for consideration, AHA 2025).
212. Alebna PL, Ambrosio M, Dod R, Campbell M, Carbone S, Chew N, Pagidipati N, Quyyumi AA, **Sperling L**, Salloum FN, Shapiro MD, Mehta A. Evaluation of the AHA PREVENT Equations and Visceral Adiposity: Insights from the UK Biobank. (accepted for presentation, AHA 2025).
213. Eldaidamouni AA, Alkhoder A, Razavi AC, Harris KA, Medina Inojosa JR, Mehta PK, **Sperling LS**, Quyyumi AA. Very High HDL Cholesterol and Risk of Heart Failure Hospitalization. (submitted for consideration AHA 2025).
214. Patel SA, Eisenberg S, Lateef A, Deng N, Hayes D, Campbell M, Westerman S, **Sperling LS**. Way too Long: An Atypical Presentation of Takotsubo Cardiomyopathy Recrudescence. (submitted for consideration, AHA, 2025).
215. Paige H, Hartsuff B, Wilemon K, Bardach SH, MacDougall D, Baum S, **Sperling LS**. Payer Analysis of Cholesterol Management in US Individuals with ASCVD in 2023: A Study from the Family Heart Database. (accepted for presentation, American Managed Care Pharmacy, 2025)
216. MacDougall D, Hartsuff, Wilemon K, Paige H, Baum SJ, Ferdinand K, **Sperling LS**, Nissen SE. Cholesterol Management in US Individuals with ASCVD during 2022/2023: Gaps in Care and Opportunity for Improvement- A Study from the Family Heart Database. (accepted for presentation, AHA 2025)
217. Gershon G, Barr JR, Hacek M, Yang Y, Razavi AC, Dzaye O, Whelton SP, Blaha MJ, Blumenthal RS, **Sperling LS**, De Cecco C, van Assen M. Comparative Performance of PCE, PREVENT, and CAC for MACE Prediction in Asymptomatic Patients. (accepted for presentation, AHA 2025).
218. Gershon G, Zhou K, Yang Y, Yan X, Barr J, Razavi AC, Rapaka S, Dzaye O, Whelton SP, Blaha MJ, Blumenthal RS, **Sperling LS**, De Cecco C, van Assen M. Coronary Calcium Volume and Density Percentiles by Age, Sex, and Race (submitted for consideration, AHA 2025).
219. Osei J, **Sperling LS**, Khoury MJ, Sun YV. Trends in Adoption of the Familial Hypercholesterolemia Diagnostic Code E78.01 in U.S. Healthcare Settings from 2016 to 2024. (accepted for presentation, AHA

- 2025).
220. Harris K, Shamsa E, Liang D, Chang H, Ko YA, Medina-Inojosa JR, Ahmed T, Huang J, Alkhoder A, Haroun N, Kaied D, Eldaidamouni A, Mehta PK, **Sperling LS**, Quyyumi AA. Air Pollution, Social Vulnerability, and Cardiovascular Outcomes in Individuals with Coronary Artery Disease. (submitted for consideration, AHA 2025).
221. Brugger C, Tricou E, Dodge A, Sullivan A, Schartz M, Farnell J, Bardach SH, Paige H, Wilemon K, MacDougall D, **Sperling LS**. Care Navigation as a Valued Partner to Reducing Gaps in Healthcare Delivery for People Living with Familial Hypercholesterolemia and Lipoprotein (a): Data from the Family Heart Foundation. (submitted for consideration, AHA 2025).
222. Bardach SH, Brugger C, Hawke A, Tricou E, Wilemon K, MacDougall D, Farnell J, **Sperling LS**. The Family Heart Foundation Cholesterol Connect Program: Reducing Gaps in Cardiovascular Risk Factor Awareness through Free At-Home LDL-C and Lipoprotein (a) Screening and Support. (submitted for consideration, AHA 2025).
223. MacDougall D, Ferdinand KC, Baum SJ, **Sperling L**, Hartsuff BK, Wilemon KA, Nissen SE. Cholesterol Management in US Individuals with ASCVD during 2022/2023: Gaps in Care and Opportunity for Improvement- A Study from the Family Heart Database. (accepted for presentation, AHA 2025).
224. Rashid Z, Haghioo A, Dave EK, Chen Y, Evenhuis B, Rubin J, Harris K, Thakker V, Rashid F, Shah A, Vaccarino V, **Sperling L**, Quyyumi AA, Mehta PK. Functional Capacity, Step Count and Angina among Women with Coronary Microvascular Dysfunction Compared to Obstructive Coronary Artery Disease and Healthy Controls (accepted for presentation, AHA 2025).
225. Furman B, Kulp D, Kim K, Lam S, **Sperling L**, Eapen DJ. AI-Driven Identification and Outreach for Familial Hypercholesterolemia: Early Results from the FIND-FH Initiative at Single Academic Center. (accepted for presentation, AHA 2025).
226. Medina Inojosa JR, Gold M, Ko YA, Gold D, Razavi A, Ismail A, Vasbinder A, Hunang Y, SakrS, Haroun N, Shah A, Vaccarino V, **Sperling L**, Hayek SS, Quyyumi A. A 4-protein biomarker risk score enhances cardiovascular risk assessment: Insights from the Multi-ethnic study of Atherosclerosis. (presented at ESC/ WCC. Madrid, 2025)
227. Alabi O, Romain G, Quyyumi A, **Sperling L**, Smolderen K, Mena-Hurtado C. Premature peripheral arterial disease (PAD) is Associated with worse Outcome after endovascular peripheral vascular intervention. (accepted for oral presentation, Southern Association for Vascular Surgery meeting, 2025).
228. Bardach SH, Brugger C, Hawke A, Wilemon K, MacDougall D, **Sperling**

- LS.** The Family Heart Foundation Cholesterol Connect Program: Reducing Gaps in Cardiovascular Risk Factor Awareness through Free At-Home LDL-C and Lipoprotein(a) Screening and Support. (accepted for presentation, WCIRDC, 2025).
229. Razavi AC, Bhatia HS, Dzaye O, Post WS, Shapiro MD, Pibarot P, Clavel MA, Arsenault B, Nasir K, Tsai M, Lindman B, O’Gara P, Dardari Z, Banach M, Aikawa E, Otto C, Thanassoulis G, Budoff MJ, Blumenthal RS, Blaha MJ, **Sperling LS**, Tsimikas S, Whelton SP. Oxidized Phospholipids, Aspirin Therapy, and Calcific Aortic Valve Disease: The Multi-Ethnic Study of Atherosclerosis. (accepted for presentation, ACC 2026).
230. Bardach SH, Brugger C, Hawke A, Wilemon K, MacDougall D, **Sperling LS.** The Family Heart Foundation Cholesterol Connect Program: Reducing Gaps in Cardiovascular Risk Factor Awareness through Free At-Home LDL-C and Lipoprotein (a) Screening and Support (accepted for presentation, WCIRDC meeting, 2025).
231. MacDougall D, Baum SJ, Ferdinand K, **Sperling LS**, Hartsuff BK, Wilemon K, Nissen S. Prescribing Patterns of LDL-C Lowering Therapies by US Clinicians Regularly Treating Adults with ASCVD During 2023/24. (submitted for consideration, ACC 2026).
232. Bennett J, Harris K, Medina Inojosa J, Ahmed T, Al Kasem M, Ko YA, Chen Y, Shah AJ, Mehta PK, **Sperling LS**, Vaccarino V, Quyyumi AA. Impact of Depression and Social Vulnerability on Cardiovascular Outcomes in Patients with Coronary Artery Disease. (accepted for presentation, ACC 2026).
233. Bardach SH, MacDougall D, Paige H, Hartsuff B, Wilemon K, Baum S, **Sperling LS.** Payer Analysis of Cholesterol Management in US Individuals with ASCVD in 2023: A Study from the Family Heart Database. (accepted for presentation, NLA meeting, 2026)
234. MacDougall D, Ferdinand KC, Baum SJ, **Sperling L**, Hartsuff BK, Wilemon KA, Nissen SE. Cholesterol Management in US Individuals with ASCVD within the Family Heart Database during 2022/2023: State of Care and Opportunity for Improvement. (accepted for presentation, NLA meeting, 2026).
235. MacDougall D, Baum SJ, **Sperling L**, Hartsuff BK, Wilemon KA. Prevalence and Associated Determinants of Lipoprotein (a) Testing in a Contemporary Cohort of US Adults from the Family Heart Database. (accepted for presentation, EAS 2026)
236. Bardach SH, Blike G, Gladders B, Hawke A, Wilemon K, Clary JM, Helm BM, Martin SS, Knowles W, Cornier MA, Liotta MA, Almedia SO, Isiadinso I, Razavi AC, **Sperling LS.** Report from the FIND (Flag, Identify, Network, Deliver) Lipoprotein (a) Multi-Center Collaborative:

- Implementation Insights from the Deployment of a Machine Learning Model to Flag Individuals with ASCVD Likely to Have Elevated Lp(a) for Targeted Screening. (accepted for presentation, ASPC Congress, 2026).
237. Bardach SH, Blike G, Gladders B, Hawke A, Wilemon K, Clary JM, Helm BM, Martin SS, Knowles W, Cornier MA, Liotta MA, Almedia SO, Isiadinso I, Razavi AC, **Sperling LS**. Report from the FIND (Flag, Identify, Network, Deliver) Lipoprotein (a) Multi-Center Collaborative: A Mixed Methods Approach to Characterizing Factors Promoting Screening for Elevated Lp(a) in ASCVD Populations. (accepted for presentation, ASPC Congress, 2026).
238. Bennett J, Eisenberg S, Najjar RS, Razavi AC, Sakr SM, Inojosa JM, Eldaidamouni AA, Hasan M, Al Kasem M, Thakore K, Kaushik N, Mandal S, Radha V, Mohan V, Mohan D, Anjana RM, Tandon N, Chang HH, Wei J, Ko YA, Jagannathan R, Sun YV, Gupta R, Patel SA, Ali MK, Gupta P, Mohan S, Narayan KMV, Wilson PWF, Mehta PK, **Sperling LS**, Mehta A, Vaccarino V, Prabhakaran D, Quyyumi AA. Prevalence and Cardiovascular Outcomes of Familial Hypercholesterolemia in South Asians. (accepted for early career research award session, ASPC Congress, 2026).
239. Ayirebi-Acquah E, Shapiro M, Whelton S, Gulati M, Bhatia H, Razavi A, Gianos E, Mehta A, **Sperling L**. Association of Incretin Therapy with Cardiovascular Events in Adults with Elevated Lipoprotein (a): A Multicenter Propensity-Matched Study. (submitted for consideration, ASPC Congress, 2026).
240. Hasan M, Eldaidamouni AA, Alkhoder A, Ghazzal B, Ko YA, Bennett J, Sakr SM, Maisuradze N, Medina Inojosa J, Taha A, Al Kasem M, Hritani W, Barghout M, Thakore K, Biswas S, Jones DP, Mehta PK, **Sperling LS**, Mehta A, Quyyumi AA. Oxidative Stress Modifies the Association Between Lipoprotein(a) and Major Adverse Cardiovascular Events. (submitted for consideration, AHA 2026).
241. MacDougall D, Baum S, **Sperling L**, Hartsuff B, Paige H, Wilemon K. Prevalence and Associated Determinants of Lipoprotein (a) Testing in a Contemporary Cohort of US Adults from the Family Heart Database. (accepted for presentation, Heart in Diabetes, 2026).
242. Razavi AC, Dzaye O, Post WS, Gianos E, Bhatia HS, Shapiro MD, Nasir K, Tiosano S, Budoff MJ, **Sperling LS**, Blumenthal RS, Matsushita K, Blaha MJ, Whelton SP. Assessing Net Clinical Benefit of Primary Prevention Aspiring Therapy in Older Adults According to Coronary Artery Calcium Burden: The Multi-Ethnic Study of Atherosclerosis. (submitted for consideration, AHA 2026).
243. Medina-Inojosa BJ, Medina-Inojosa JR, Ortega-Aviles L, Esmaeili Z, Gomez-Aviles P, LeBrasseur NK, Noseworthy PA, **Sperling L**, Friedman

- PA, Attia ZI, Lopez-Jimenez F. Performance of the Estimated Predicting Risk of Cardiovascular Disease EVENTS (PREVENT) Age and Artificial Intelligence-Enabled Electrocardiogram Predicted Age to Predict Incident Atherosclerotic Cardiovascular Events in the Community. (submitted for consideration, AHA 2026).
244. Bennett J, Eldaidamouni A, Hasan M, Shamsa E, Almas T, Hritani W, Evenhuis B, Sakr SM, Eisenberg S, Najjar R, Ko YA, Al Kasem M, Thakore K, King J, Biswas S, Moiz A, Ksahlan A, Alkhoder A, Shah A, Mehta A, Mehta PK, Vaccarino V, **Sperling L**, Quyyumi AA. Prognostic Value of Neighborhood Deprivation for Cardiovascular Events and its Mediation by Inflammation. (submitted for consideration, AHA 2026).
245. Eldaidamouni A, Hasan M, Bennett J, Alkhoder A, Medina-Inojosa J, Maisuradze N, Ko YA, Liu C, Evenhuis B, Eisenberg S, Sakr SM, Barghout MY, Hritani W, Eldaboush A, Najjar R, Kashlan A, Haroun N, Al Kasem M, Kaied D, Thakore K, Mehta PK, Mehta A, **Sperling L**, Quyyumi AA. Apolipoprotein A-1, Not HDL-Cholesterol, Captures the Protective Signals in Coronary Artery Disease. (submitted for consideration, AHA 2026).
246. Mouawad C, Bhattacharya A, Eisenberg S, Mallipeddi T, Gangadharan A, **Sperling L**. From Silent Ischemia to Septal Rupture: A Delayed Mechanical Complication (submitted for consideration, AHA 2026).
247. Eisenberg SD, Evenhuis B, Medina-Inojosa J, Ko YA, Ahmed T, Bennett J, Sakr S, Eldaidamouni A, Alkhoder A, Al-Mir M, Thakore K, Biswas S, Moiz A, Al Kasem M, Hasan M, Haroun N, Tanveer F, **Sperling L**, Quyyumi A. Elevated Lp(a) Level is not Associated with Adverse Outcomes in Patients with Coronary Heart Disease with Low LDL-C Levels. (submitted for consideration, AHA 2026).
248. Thaker V, Beveridge E, Agrawal A, Dave AK, Rana HY, Lu A, Evenhuis B, Najjar RS, Rashid FA, Feresin RG, Quyyumi AA, **Sperling LS**, Mehta PK. Dietary Patterns and Angina Frequency in Postmenopausal Women with Ischemic Heart Disease. (submitted for consideration, AHA 2026).
249. Hasan M, Eldaidamouni AA, Medina-Inojosa J, Alkhoder A, Razavi A, Hritani W, Bennett J, Sakr SM, Ko YA, Al Kasem M, Thakore K, Kaied D, Jones DP, Mehta PK, **Sperling LS**, Mehta A, Quyyumi AA. Lipoprotein (a) and Arterial Stiffness in a Community-based Cohort: Modification by Oxidative Stress. (submitted for consideration, AHA 2026).
250. Stresemann S, Bennett J, **Sperling LS**, Bhatt KN. Transthyretin Amyloid Cardiomyopathy: Extracardiac Red Flags and Opportunities for Earlier Recognition in a Cohort of Predominantly Black Individuals. (submitted for consideration, AHA 2026).

